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 1 SUMMARY 
 
Every cell needs to ensure the maintenance and faithful propagation of genetic 
information in order to prevent the development of life-threatening diseases such as 
cancer. However, cells are constantly exposed to various types of genotoxic agents 
e.g. free oxygen radicals or UV radiation. To counteract these threats, cells have 
developed specialized mechanisms to detect and repair DNA damage, and to initiate 
signaling cascades that delay or arrest cell cycle progression, induce certain 
transcriptional programs or trigger apoptosis. This complex signaling network is 
collectively denoted as the DNA damage response (DDR).  
Double strand breaks (DSBs) are one of the most hazardous forms of DNA 
damage because they can cause chromosomal instability or cell death if not repaired 
correctly. This type of DNA lesion can arise from the exposure to ionizing radiation 
or radiomimetic drugs, both frequently used in cancer treatment. DSBs lead to the 
activation of the ATM kinase and to the phosphorylation of the histone variant 
H2AX. Phosphorylated H2AX (γH2AX) is directly recognized by mediator of DNA 
damage checkpoint protein 1 (MDC1), a large mediator/adaptor protein that regulates 
the accumulation of DDR factors in chromatin regions flanking DSBs. MDC1 
contains a forkhead associated (FHA) domain at its N-terminus. Even though it is 
known that FHA domains act as phosphopeptide recognition motifs, the function of 
the MDC1 FHA domain has remained enigmatic.  
In this study, we identified a novel phosphorylation-specific binding partner of the 
MDC1 FHA domain, namely MDC1 itself. We show that ATM phosphorylates 
MDC1 at the conserved N-terminal Thr4 residue in a DNA damage-dependent 
manner and that this induces the interaction with the FHA domain of other MDC1 
molecules. Biochemical, biophysical and X-ray structural analysis revealed that the 
presence of a Thr4-phosphopeptide stabilizes the formation of a tight FHA dimer in a 
head-to-tail-oriented manner. We furthermore demonstrate that the isolated FHA 
domain is capable of localizing to sites of DNA damage in a phosphorylation-induced 
and dimerization-dependent manner. The elucidation of this mechanism contributes to 
our understanding of how MDC1 functions in the mammalian DDR and supports the 
notion that dimerization/oligomerization is a common theme of DDR mediator 
proteins. 
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2 ZUSAMMENFASSUNG 
 
Der Erhalt und die getreue Weitergabe der genetischen Information ist wichtig 
für jede Zelle, um der Entwicklung von Krankheiten wie Krebs vorzubeugen. Zellen 
sind jedoch ständig verschiedenen Substanzen ausgesetzt, welche die DNA 
beschädigen (z.B. freie Sauerstoffradikale und UV-Strahlung). Um diese Gefahren 
abzuwenden, besitzen Zellen spezialisierte Mechanismen zur Erkennung und 
Reparatur von DNA Schäden sowie zur Aktivierung von Signalkaskaden, die das 
Fortschreiten des Zellzyklus hemmen, bestimmte Transkriptionsprogramme einleiten 
oder programmierten Zelltod (Apoptose) auslösen. 
Doppelstrangbrüche (DSBs) stellen dabei eine der gefährlichsten Formen von 
DNA Schäden dar, da sie bei nicht ausreichender Reparatur chromosomale Instabilität 
oder Zelltod zu verursachen vermögen. DSBs können durch die Einwirkung 
ionisierender Strahlung oder ähnlich wirkender Zytostatika, die beide häufig in der 
Krebstherapie ihre Anwendung finden, entstehen. DSBs führen zur Aktivierung der 
ATM-Kinase und Phosphorylierung der Histon-Variante H2AX. Phosphoryliertes 
H2AX wird direkt von MDC1, einem grossen Adapter-Protein, gebunden, das die 
Ansammlung von weiteren Proteinen in den Doppelstrangbruch umgebenden 
Chromatinregionen reguliert. MDC1 besitzt eine N-terminale FHA Domäne. Obwohl 
bekannt ist, dass FHA Domänen als Phosphopeptid-Erkennungsmotive fungieren, 
konnte die Funktion der MDC1 FHA Domäne bisher noch nicht entschlüsselt werden. 
In dieser Arbeit haben wir MDC1 selbst als einen neuen phosphospezifischen 
Interaktionspartner der MDC1 FHA Domäne identifiziert. Wir zeigen, dass MDC1 an 
der konservierten Aminosäure Thr4 infolge von DNA Schäden von der Kinase ATM 
phosphoryliert wird und dass dies für die Interaktion mit der FHA Domäne eines 
anderen MDC1 Moleküls verantwortlich ist. Biochemische, biophysikalische und 
Röntgenstruktur-Analysen legen offen, dass das T4-Phosphopeptid die Ausbildung 
eines FHA-Dimers in umgekehrter Orientierung stabilisiert. Des Weiteren kann die 
isolierte FHA Domäne an DNA geschädigte Regionen in Abhängigkeit vom 
Phosphorylierungs- und Dimerisierungsstatus binden. Die Aufklärung dieses 
Mechanismus trägt zu unserem Verständnis der Funktion von MDC1 in der Antwort 
auf DNA Schäden in Säugetierzellen bei und unterstützt die Auffassung von 
Dimerisierung (Oligomerisierung) als allgemeines Leitmotiv in Adapterproteinen.
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 3 ABBREVIATIONS 
 
ATM   Ataxia telangiectasia mutated  
ATR   Ataxia telangiectasia and Rad3 related  
BRCA1   Breast cancer 1  
BRCT   BRCA1 C-terminal  
CHK1/2   Checkpoint protein 1/2  
DDR   DNA damage response  
DNA-PKcs  DNA-dependent protein kinase catalytic subunit  
DSB   Double strand break  
EYFP  Enhanced yellow fluorescent protein 
FHA   Forkhead-associated  
GFP   Green fluorescent protein  
HNE  HeLa nuclear extract 
HR   Homologous recombination  
IR   Ionizing radiation  
IRIF   Ionizing radiation induced foci   
LOH   Loss of heterozygosity 
MDC1   Mediator of DNA damage checkpoint 1  
MEF   Mouse embryonic fibroblast  
MRN   MRE11-RAD50-NBS1  
MS  Mass spectrometry 
NBS   Nijmegen breakage syndrome  
NHEJ   Non homologous end joining  
NMR   Nuclear magnetic resonance  
PIKK   Phosphoinositide-3-kinase-related protein kinase  
PNK   Polynucleotide kinase  
PST   Pro-Ser-Thr  
RDS  Radioresistant DNA synthesis 
RNF8   Ring finger protein 8  
SCD   SQ-TQ cluster domain  
SDT   Ser-Asp-Thr  
9
 10
  INTRODUCTION 
 
4 INTRODUCTION 
4.1 General introduction 
4.1.1 The importance of genome maintenance 
 
Preservation of genomic integrity is an essential condition for all living 
organisms in order to faithfully propagate the genetic information. However, cells are 
constantly threatened by genotoxic stress arising from various endogenous or 
exogenous sources. In particular, DNA double-strand breaks (DSBs) display one of 
the most deleterious forms of DNA damage in mammalian cells. This type of lesion 
can occur as product of collapsed or stalled replication forks that originate from single 
strand breaks (SSB) or base damages. DSBs are further generated as programmed 
events during antigen-receptor rearrangement in lymphocytes or during meiotic 
recombination and the cells also recognize dysfunctional telomeres as DSBs. 
Moreover, DSBs can arise from exposure to ionizing radiation (IR) or radiomimetic 
drugs, which are widely used for clinical treatment of cancer diseases. Improper 
functioning of mechanisms that deal with DSBs can lead to chromosomal 
rearrangements that on a broader scale cause chromosomal instability, which is a 
prominent feature of most human malignant cancer types. Correspondingly, various 
genetic diseases such as Ataxia-telangiectasia (A-T) or Fanconi Anemia (FA) that are 
caused by a defective protein in the DNA damage response machinery often show a 
cancer-prone phenotype. A deeper understanding of the mechanisms that are involved 
in the recognition of DSBs and regulation of DNA repair processes may therefore 
form the basis for a rational design of new therapies for treatment of genetic diseases 
or to selectively kill cancer cells. Since defects in these pathways are often specific to 
cancer cells and do not occur in normal cells, they can be therapeutically exploited 
with only very limited side effects, which makes them a much more attractive target 
compared to conventional cancer targeting strategies that are usually accompanied by 
high toxicity for normal cells.  
Chromosomal instability has recently been classified as an early event during 
tumorigenesis forming a prerequisite for the accumulation of mutations required for 
transition of precancerous lesions into cancer cells (Beckman & Loeb, 2006). 
Mechanisms that have been suggested to contribute to chromosomal instability 
11
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include defects in the regulation of genome caretakers, including DNA repair and cell 
cycle checkpoint genes. Genome caretaker genes are main players in the DNA 
damage response and mutations of some of them have been shown to be involved in 
tumorigenesis by enhancing chromosomal instability (Cahill et al, 1998; Wang et al, 
2004). However, up to now, only few mutations in classical caretaker genes have 
been reported in sporadic cancers (Greenman et al, 2007; Sjoblom et al, 2006; Wood 
et al, 2007). Telomere shortening is also widely accepted to contribute to genomic 
instability, although it is not yet completely clear whether it constitutes a mechanism 
that can specifically initiate chromosomal instability during tumorigenesis (Feldser et 
al, 2003). A relatively new concept as underlying mechanism of chromosomal 
instability in human precancerous lesions is oncogene-induced replication stress that 
includes stalling and collapse of replication forks resulting in the formation of DSBs. 
Common fragile sites turned out to be at particularly high risk for breakage during 
replication stress (Bartkova et al, 2005; Gorgoulis et al, 2005; Halazonetis et al, 
2008). These events have been shown to activate the DDR machinery, thus resulting 
in either apoptosis or senescence and thereby forming a barrier to tumorigenesis and 
cancer invasiveness (Bartkova et al, 2006; Di Micco et al, 2006). However, the 
suppressive effect of active DDR signaling is released upon mutation and inactivation 
of the p53 gene, which strongly correlates with cancer progression (Gorgoulis et al, 
2005). In addition, inhibition of another checkpoint protein, the ATM kinase, was 
shown to inhibit senescence and to increase tumor invasiveness in tumor mouse 
models. However, p53 inactivation seems to be the major cause of compromised 
checkpoint signaling (Bartkova et al, 2006). 
 
4.1.2 The DNA damage response  
 
Mammalian cells have evolved sophisticated mechanisms to sense DNA damage 
and to activate signal transduction cascades that result in different cellular responses 
involving delay of cell cycle progression and activation of DNA repair in order to 
ensure the faithful propagation of the genetic information. Cells can also reach a 
senescent state or even enter apoptosis if the damage is too severe and difficult to 
repair. Moreover, a certain subset of genes can be subjected to transcriptional 
activation or repression. This interactive signaling network is usually referred to as
12
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the DNA damage response (DDR) (Figure 4.1) (reviewed in (Harper & Elledge, 2007; 
Zhou & Elledge, 2000)).  
 
 
Figure 4.1 
The DNA damage response. 
An interactive signaling 
network, depicted here as linear 
pathway, converts the signal of 
damaged DNA into specific 
cellular responses mediated by 
the action of sensors, 
transducers and effectors. 
(Zhou & Elledge, 2000) 
 
 
 
 
 
Proteins that participate in the DDR have initially been categorized as sensors, 
transducers and effectors, although in some cases, multiple functions can be assigned 
to the same protein. Sensors monitor the genomic integrity by recognizing damaged 
DNA either directly or indirectly as part of a protein complex and initiate a signaling 
cascade by recruiting transducers to sites of DNA damage. Transducers are typically 
protein kinases that propagate and amplify the signal to downstream effectors. 
Finally, effector proteins, which are mainly regulated through posttranslational 
modification such as phosphorylation and ubiquitylation, convert the signal of 
transducers into a specific cellular response such as transient or permanent cell cycle 
arrest, DNA repair or transcriptional regulation (Nyberg et al, 2002). Recently, a 
fourth class of proteins has been introduced to the concept of the DDR. These so-
called mediators or adaptors often do not possess any enzymatic activity. However, 
they generally act as a recruiting platform for other proteins and thus might bring 
transducers’ activities in close proximity to their substrates and facilitate protein 
complex formation, thereby providing signal transduction specificity and 
amplification (Sancar et al, 2004). 
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4.2 Responses to DNA Double Strand Breaks  
 
4.2.1 Double Strand Break Signaling 
 
The response to DSBs is coordinated in space and time and involves numerous 
proteins that become recruited and activated at sites of DNA damage in a hierarchical 
order. In mammalian cells, DSBs are directly sensed by the MRN complex, which 
consists of the proteins MRE11, RAD50 and NBS1. The MRN complex has been 
described to tether and process broken DNA ends. Moreover, it is required to recruit 
the ATM kinase via an interaction with NBS1 (Falck et al, 2005). MRN is also 
involved in ATM activation by as yet poorly understood mechanisms. ATM is the 
major kinase responsible for signaling from DSBs that are not associated with 
replication forks. It belongs to the conserved family of phosphoinositide 3-kinase-like 
kinases (PIKKs), which mainly possesses Ser/Thr kinase activity and further includes 
the members ATR and DNA-PKc. Activation of ATM in human cells is mediated by 
autophosphorylation on Ser1981, which results in dissociation of the inactive dimer 
into active monomers (Bakkenist & Kastan, 2003). Several other proteins have been 
suggested to contribute to regulation of ATM activity including the MRN complex, 
53BP1, histone acetyltransferase Tip60 and protein phosphatases PP2A and PP5 
(reviewed in (Lee & Paull, 2007)). However, how these cofactors specifically regulate 
ATM activity remains largely unclear, but mechanisms likely involve modulation of 
ATM substrate-specificity, or response to different cell stimuli. Activated ATM 
phosphorylates a large number of proteins that participate in cell cycle checkpoint 
regulation, DNA repair, senescence, apoptosis and other cellular processes (Figure 
4.2) (Matsuoka et al, 2007).  
One key target of the ATM kinase is the histone variant H2AX that becomes 
phosphorylated at a conserved Ser residue (Ser139) in DSB-flanking chromatin 
regions (Rogakou et al, 1998), indicating that modification of chromatin components 
plays an important role in the DNA damage response. Phosphorylated H2AX 
(γH2AX) forms a direct recognition motif for binding to MDC1 (mediator of DNA 
damage checkpoint protein 1), which initiates a whole cascade of events that have an 
impact on checkpoint activation, DNA repair and survival (reviewed in detail below: 
Jungmichel and Stucki, 2010).  
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ATR and DNA-PKc have also been shown to become activated in response to 
DSBs and to target H2AX, although ATR signaling is effectively initiated by the 
presence of single stranded lesions that occur in response to UV and lead to stalling of 
replication forks. However, following DSB induction, ATR activity is triggered in an 
ATM-dependent manner in S and G2 phase of the cell cycle (Jazayeri et al, 2006; 
Myers & Cortez, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 
Early DNA damage signaling. A DSB is 
directly recognized by sensor complex 
MRN, which recruits and activates ATM 
(yeast homologue Tel1). ATM kinase in 
turn phosphorylates various downstream 
effectors, among them the histone variant 
H2AX in order to elicit a checkpoint 
response and to promote DNArepair. 
Broken DNA ends can become resected by 
nucleases and the generated ssDNA is 
subsequently bound by RPA, which 
recruits a complex containing ATR kinase 
(yeast homologue Mec1), which further 
contributes to cell cycle arrest (Pardo et al, 
2009). 
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Recently, Shiotani and Zou demonstrated that this ATM-dependent ATR activation is 
dependent on resection of DSBs. In this process, ATM becomes first activated at 
blunt ends or short single stranded overhangs in an MRN-dependent manner. Ongoing 
resection then leads to formation of single stranded tails that can be coated by RPA 
and subsequently recruits ATR through its binding partner ATRIP to sites of DNA 
damage resulting in ATR activation followed by ATM inactivation (Shiotani & Zou, 
2009) (Figure 4.2). DNA-PKc with its major function during DSB repair via NHEJ 
seems to act redundantly with ATM, as it can, for instance, take over IR-induced 
H2AX phosphorylation in ATM-deficient cells (Stiff et al, 2004). The lack of 
embryonic lethality of ATM null cells, but synthetic lethality between mutations of 
both ATM and DNA-PKc during murine embryogenesis, further points to DNA-PKc 
acting as a backup kinase for ATM (Gurley & Kemp, 2001). 
The prevalent function of ATM/ATR signaling is initiation of cell-cycle arrest at 
G1/S, intra-S-phase and G2/M checkpoints. Among the various protein substrates, the 
checkpoint kinases CHK2/CHK1 are major targets of ATM/ATR. They transduce the 
signal to further downstream effectors including the key targets CDC25 phosphatases 
and transcription factor p53, which can also become directly phosphorylated by ATM 
at Ser15, eventually resulting in inhibition of cyclin-dependent kinases (CDKs) at 
various stages of the cell cycle. The elicited cell cycle arrest is generally thought to 
leave time for repair before replication or meiosis can occur.  
The critical role of the aforementioned players within the DDR is underlined by 
congenital deficiencies that give rise to a genomic instability syndrome. Mutations in 
ATM are associated with Ataxia telangiectasia (AT) and mutations in MRE11 with 
Ataxia telangiectasia-like disorder (ATLD). The Nijmegen breakage syndrome (NBS) 
is caused by mutations in NBS1, whereas the Seckel syndrome results from 
hypomorphic mutations in ATR. In contrast to ATM, ATR is an essential gene since 
ATR knockout in mice leads to early embryonic lethality, which might be explained 
by the essential role of ATR signaling required in the stabilization and recovery of 
stalled replication forks (Kerzendorfer & O'Driscoll, 2009).  
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4.2.2 DSB Repair 
 
DSB repair occurs primarily by two mechanisms in eukaryotic cells: non-
homologous end-joining (NHEJ) and homologous recombination (HR), whose 
preferential choice seems to be dependent on cell cycle regulations at the level of 
DSB-end resection and protein protein interactions (reviewed in (Hartlerode & Scully, 
2009; Pardo et al, 2009)). 
 
4.2.2.1 Non-homologous end-joining 
 
The underlying principle of NHEJ involves efficient re-ligation of broken DNA 
ends without the requirement of a homologous sequence as a template. Since this may 
cause loss or gain of DNA bases it is referred to as an error-prone mechanism. It 
occurs throughout the cell cycle but is 
mainly active during G0, G1 and early S-
phase. The pathway is initiated by direct 
binding of the KU70/KU80 heterodimer to 
free double-stranded DNA ends, which 
recruits and activates the catalytic subunit 
of DNA-PK (Gottlieb & Jackson, 1993; 
Walker et al, 2001; Yaneva et al, 1997) 
(Figure 4.3). 
 
 
 
Figure 4.3 
NHEJ in mammalian cells. The KU70/80 
heterodimer directly binds and tethers DNA ends 
through the recruitment of DNA-PKcs, which 
becomes activated and autophosphorylated. 
Activated DNA-PKcs facilitates recruitment of end-
processing factors Artemis and DNA polymerases 
of the X family that generate ligatable DNA ends. 
Finally, the Ligase IV/XRCC4/XLF complex 
completes repair by ligating the DNA ends. 
(adapted from (Hartlerode & Scully, 2009)) 
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The various phosphorylation targets of DNA-PKcs include XRCC4, Artemis and 
DNA-PK itself. This autophosphorylation reaction seems to cause a conformational 
change in DNA-PKcs thereby regulating the accessibility of further factors to DNA 
ends (Weterings et al, 2003). However, prior to ligation, IR-induced DSB might 
require some DNA end processing in order to generate ligatable 5’-phosphorylated 
and 3’-dephosphorylated ends. Polynucleotide kinase (PNK) and the nuclease 
Artemis together with the activity of DNA-PKcs were shown to stimulate processing 
of DNA for efficient NHEJ (Chappell et al, 2002; Ma et al, 2002). Remaining single-
stranded gaps after pairing of partially complementary strands are filled by DNA 
polymerases, which might also randomly add nucleotides to DNA ends to generate 
regions of microhomology for base pairing. The X family DNA polymerases Polλ, 
Polµ and terminal deoxynucleotidyl transferase (TdT) have been implicated in these 
processes (Nick McElhinny & Ramsden, 2004). Finally, DNA ends are ligated by the 
NHEJ ligase complex essentially comprising DNA ligase IV, XRCC4 and XLF 
(Ahnesorg et al, 2006; Grawunder et al, 1997). Core members of the NHEJ pathway 
have also function during V(D)J recombination to generate B- and T-cell receptor 
diversity in vertebrate immune cells, explaining, for example, the radiosensitive 
severe combined immunodeficiency (RS-SCID) phenotype of patients with defective 
Artemis (Moshous et al, 2001). 
 
4.2.2.2 Homologous recombination 
 
Homologous recombination requires the presence of identical or highly similar 
DNA sequences as a template and is considered to be an error-free mechanism of 
DSB repair in contrast to NHEJ. Due to the availability of a homologous sister 
chromatid HR is the main DSB repair pathway during late S and G2 phase of the cell 
cycle. An important component of the HR machinery is the MRN complex that binds 
to broken ends and is involved in the initiation of resection (Figure 4.4). Nucleolytic 
degradation of the 5’-stranded end of DSBs has been shown to be a prerequisite for 
HR. Much of the information on the resection process has been derived from studies 
in yeast (Huertas). However, it is unlikely that the MRE11 nuclease carries out the 5’ 
to 3’ resection directly because MRE11 is a 3’ to 5’ exonuclease, at least in vitro. 
Therefore, ExoI and another, yet undefined, exonuclease were suggested to provide 
18
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the activity for resection of 5’-stranded DNA. In vertebrate cells, MRE11, RAD50 
and CtIP (Sae2 homologue) were sufficient for resection even though it is believed 
that efficient HR in vivo requires additional factors such as the tumor suppressor 
BRCA1 (Sartori et al, 2007; Yun & Hiom, 2009). The arising single stranded 3’-
overhang is then rapidly coated by RPA to avoid formation of secondary structures. 
Further accumulation of multimers of the RAD51 recombinase in dependency of 
BRCA1/BARD1 and BRCA2 entails formation of a nucleoprotein filament that is 
able to perform homology search in duplex DNA (Hartlerode & Scully, 2009). 
Following strand invasion into a homologous DNA template, which involves pairing 
with the complementary strand and displacement of the other, a so-called D-loop 
(displacement loop) structure is formed. After that, several pathways can complete 
HR with different outcomes, whose detailed mechanisms, regulations and 
participating factors remain to be elucidated. In principle, SDSA (synthesis-dependent 
strand annealing) or DSBR (double strand break repair) have been described to occur 
in case of two-ended DSBs. During SDSA the elongated invading strand pairs again 
with the second DSB end (Figure 4.4A). Since this process does only produce non-
crossovers, SDSA is the preferred recombination-mediated DSB repair in somatic 
cells in order to prevent loss of heterozygosity (LOH) or other genetic 
rearrangements. Alternatively, during DSBR, the extended D-loop captures the 
second DSB end and creates a double Holliday junction (HJ) between the four strands 
that can undergo branch migration catalyzed by members of the RecQ helicase family 
(Bohr, 2008). Resolution of these recombination structure intermediates finally occurs 
in different ways resulting either in non-crossovers or crossovers, which 
predominantly occur during meiotic recombination (Figure 4.4B). The enzyme 
complexes BLM/TopoIIIa, MUS81/EME and GEN1 have been suggested to 
contribute to separation of the two repaired strands (Chen et al, 2001; Ip et al, 2008; 
Wu & Hickson, 2003). The resulting nicks are finally sealed by DNA ligases. In the 
absence of homology, SSA (single-strand annealing) might be initiated. This involves 
resection of both 5’-strands until repetitive sequences are uncovered that can be 
annealed (Figure 4.4C). Non-homologous terminal DNA is then removed by 
nucleases followed by DNA synthesis and ligation of the nicks. Due to deletion of the 
intervening sequences, SSA is considered a mutagenic repair pathway. One-ended 
DSBs, which can arise through uncapping telomeres or collapse of the replication fork 
upon encountering a single stranded break (SSB), are repaired by BIR (break-induced 
19
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repair) (Figure 4.4D). In this event invasion of the 3’-stranded end into homologous 
duplex DNA generates a replication fork that replicates the template to the 
chromosome end. This process is potentially leading to LOH. 
Mutation or deletion of HR components often results in cancer development, thus 
reflecting the critical role of HR in suppressing genome instability. For example, 
inherited mutations in BRCA1 and BRCA2 are frequently associated with 
development of breast and ovarian cancer. The genomic instability disorders Werner, 
Bloom and Rothmund-Thomson syndrome have been linked to mutations in the RecQ 
helicases WRN, BLM and RECQL4, respectively (Bohr, 2008). Strikingly, deletion 
of the RAD51, BRCA1 or BRCA2 gene causes early embryonic lethality in mice, 
thus underlining the essential nature of this repair pathway. 
20
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Figure 4.4 
Homologous Recombination. The DSB is directly recognized by the MRN complex, which tethers 
the DNA ends and participates in end processing. The CtIP/BRCA1/BARD1 complex co-operates 
with MRN to assist in end resection. RPA binds the resulting ssDNA to prevent formation of 
secondary structures. BRCA1/BARD1 promote accumulation of BRCA2, which catalyses the 
assembly of Rad51 nucleoprotein filaments. The Rad51 filament is assembled captures duplex DNA 
and searches for homology. Different repair pathways can be initiated: (A) During SDSA the extended 
invading strand is displaced and anneals to the resected second DNA end. (B) In the DSB repair 
pathway both DNA ends are captured by annealing to the extended D loop, forming a double HJ, 
which is resolved to yield either crossover or non-crossover products. (C) SSA occurs when direct 
repeat sequences are revealed by resection on complementary strands that can be annealed whereby 
intervening sequences are deleted. (D) During BIR the 3’-end of the invading strand leads to formation 
of a replication fork that copies long tracts of the donor DNA strand. (adapted from (Hartlerode & 
Scully, 2009)) 
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4.3 Mediators 
 
Mediator/adaptor proteins form a distinct category of DDR components and have 
functionally been placed directly downstream of ATM and ATR. They often do not 
possess any enzymatic activity, but rather act as recruiting factors and as scaffold for 
the efficient assembly of protein complexes (reviewed in (Harper & Elledge, 2007)). 
This way, mediators can relay and amplify the DNA damage signal. Recent years of 
research have revealed their regulatory functions within the DDR, although detailed 
mechanisms are not yet completely understood. Mediators that have so far been 
described in mammalian cells include MDC1, 53BP1, MRN, TopBP1, Claspin, 
Mcph1/Brit1, PTIP and BRCA1. A typical feature of mediator proteins is the 
presence of protein-protein interaction motifs in their sequence that are often 
regulated by the phosphorylation activity of cellular kinases. The best-characterized 
phosphopeptide-binding motifs constitute the BRCT (BRCA1 C-terminus) and the 
FHA (Forkhead-associated) domains that recognize short amino acid sequences 
surrounding a phosphorylated serine or threonine. BRCT- and FHA domain 
containing proteins mainly regulate the formation of so-called ionizing radiation-
induced DNA damage foci (IRIF), distinct nuclear structures that can be 
microscopically visualized upon treatment with DSB-inducing agents. Early events 
during the DDR involve activation of ATM kinase, which mediates phosphorylation 
of H2AX (γH2AX) and the subsequent recruitment of MDC1 to the DSB-flanking 
chromatin (Stucki et al, 2005). MDC1 is a key player in the process of foci formation 
since recruitment and retention of MRN, RNF8, 53BP1, BRCA1 and other 
downstream factors depend on MDC1 and its ability to bind to γH2AX. However, 
even though H2AX or MDC1 deletion abrogates relocalization of most DDR proteins 
into nuclear foci, these cells exert comparatively mild defects in radiation sensitivity 
and checkpoint activation. Hence, the role of mediators and IRIF formation in the 
DNA damage response remains to be established. However, foci formation can denote 
the presence of DNA damage in pre-cancerous lesions and therefore may have the 
potential to be used as markers to visualize genomic instability in early neoplastic 
lesions (Bartkova et al, 2005; Gorgoulis et al, 2005). 
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4.3.1 Phosphopeptide interaction motifs  
 
4.3.1.1 BRCT domains 
 
BRCT repeats were first identified in the breast-cancer associated protein 
BRCA1 and since then have been shown to exist in a large number of proteins 
involved in the response to DNA damage (Bork et al, 1997). The BRCT domain 
encompasses 90-100 amino acids in length and can fold independently, despite its 
frequent appearance as tandem pairs, which are separated by regions of different size. 
BRCA1, MDC1, NBS1, 53BP1, DNA ligase IV and MCPH1 were shown to contain 
tandem BRCT repeats. MCPH1 carries a third BRCT domain at its N-terminus, PTIP 
was characterized with 6 BRCT domains and TopBP1 contains even 8 BRCT 
domains, while some proteins such as XRCC1, PARP1 and Polλ were shown to 
contain only a single domain (Mohammad & Yaffe, 2009). 
The perception of BRCT domains as phosphopeptide-binding modules emerged 
only in 2003 and provided a basis for its molecular function during the DDR (Manke 
et al, 2003; Yu et al, 2003). The phosphopeptide-binding activity of BRCT domains is 
limited to tandem BRCT repeats and is generally much stronger for phosphoserine 
than for phosphothreonine. Furthermore, several BRCT domains were shown to 
strongly select for an aromatic residue in the pSer+3 position. In case of the 
interaction between BRCA1 and a phosphopeptide derived from BACH1, the 
phosphoserine binds to a pocket in the N-terminal BRCT domain, whereas the Phe at 
the pSer+3 position is bound to a deep groove at the interface between the two 
domains explaining the structural requirement of this BRCT tandem fold (Clapperton 
et al, 2004; Shiozaki et al, 2004). Similarly, a γH2AX peptide was shown to bind to a 
groove at the interface between the two BRCT domains of MDC1 with a strong 
preference for a C-terminal Tyr in the pSer+3 position (Stucki et al, 2005). However, 
not all BRCT domains act as phosphopeptide binding modules. Phospho-independent 
interactions have been described between 53BP1 and p53 as well as DNA ligase IV 
and XRCC4 (Derbyshire et al, 2002; Joo et al, 2002; Sibanda et al, 2001). 
The critical role of BRCT domains in the DDR is corroborated by the observation 
that truncation and missense mutations of the essential BRCA1 BRCT repeats are 
frequently associated with human breast and ovarian cancers (Williams et al, 2003). 
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4.3.1.2 FHA domains 
The FHA domain was first described for forkhead family transcription factors 
(Hofmann & Bucher, 1995). Since then, more than 2000 FHA-containing proteins 
have been identified in prokaryotes and eukaryotes (http://pfam.sanger.ac.uk/family/ 
PF00498). The FHA domain can be found in many regulatory proteins, kinases, 
phosphatases and transcription factors and it is involved in various biological 
processes such as cell cycle control, cell growth, signal transduction and transcription 
and in the DNA damage signaling (reviewed in (Mahajan et al, 2008)). All 
characterized FHA domains differ greatly from BRCT domains or other 
phosphopeptide interaction motifs such as 14-3-3 proteins or WW-domains in that 
they specifically recognize phosphothreonine and not phosphoserine residues. 
Up to now, the structures of 19 FHA domains, either free or in complex with 
their phosphopeptide ligands, have been solved by NMR or X-ray crystallography. 
Although the known FHA domains share rather low sequence homology, they all 
adapt a similar fold. The domain spans approximately 80-120 amino acid residues 
consisting of 11 β-strands. These strands form two large twisted anti-parallel β-sheets, 
which are folded into a β-sandwich structure. The specificity in binding to 
phosphopeptides is determined by the loops and turns that connect the β-strands and 
can vary in length and α-helical insertions between the different FHA domains 
(Figure 4.5). 
 
Figure 4.5 
Structure of the Rad53 FHA1 domain. Left: The 11 β-strands of the FHA1 domain associate to form 
a β-sandwich fold. Right: Binding of in vitro selected phosphothreonine-containing peptides to the 
FHA1 domain mediated by interactions with loops and turns in between the β-strands. (Yaffe & 
Smerdon, 2004) 
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Combinatorial peptide library screening recently helped to identify ligand 
specificities for the different FHA domains (Durocher et al, 2000). In this approach 
peptides with a central phospho-threonine flanked by up to four random amino acid 
residues on either side were tested. The key finding of this analysis was that the 
highly conserved pThr and the following pThr+3 residue form the primary and 
secondary recognition site for binding to FHA domains. On the basis of their pThr+3 
specificity, the FHA domains can be categorized into two major groups selecting for 
either Asp or Ile/Leu at the +3 position. For example, the Cds1-FHA and the Rad53-
FHA1 domain showed a particular peptide binding preference for Asp in the pThr+3 
position, whereas the Rad53-FHA2 domain selected for Ile or Leu. Some exceptions 
have also been identified including the proteins KAPP (kinase-associated protein 
phosphatase) with a preference for Ser or Ala and RNF8 with a preference for Tyr or 
Phe in the pThr+3 position (Durocher et al, 2000; Huen et al, 2007). Although most of 
the predicted ligand specificities could be confirmed by biological approaches, some 
FHA domains showed differences to the results obtained by the chemical library 
approach. For example, in an in vivo approach for Rad9p, which contains 5 potential 
TXXD motifs, pThr192 instead of the predicted pThr390 was determined as binding site 
for Rad53-FHA1 (Schwartz et al, 2002; Yuan et al, 2001). 
In addition to the typical binding specificities of FHA domains for pTXXD or 
pTXX(I/L/V) sequences, three different types of recognition specificities were 
identified (reviewed in (Mahajan et al, 2008)). One group of FHA domains can 
additionally recognize residues N-terminal to pThr, as it was shown for murine PNK-
FHA (Polynucleotide kinase) in complex with a peptide derived from XRCC4 
(Bernstein et al, 2005). Another unique FHA domain is formed by Dun1, which 
specifically binds to the SQ-TQ cluster domain (SCD1) of Rad53 only when it is 
dually phosphorylated at Thr5 and Thr8. This finding could be confirmed in vivo, 
showing that dual phosphorylation of Rad53 is essential for full activation of Dun1 
(Lee et al, 2008). The FHA domain of Ki67 constitutes another exception, as it rather 
recognizes an extended binding surface of a long peptide (43 amino acids) derived 
from hNIFK instead of a short phosphopeptide. In addition to pThr, this interaction 
requires the stacking of the β-strand of the peptide with the β-sheet of the Ki67 FHA 
domain (Byeon et al, 2005; Li et al, 2004; Mahajan et al, 2008).  
Interestingly, in many cases FHA domains have been shown to be involved in 
kinase activation and oligomerization processes in response to DNA damage. A well-
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studied example is the CHK2 kinase, which plays an important role in cell cycle 
regulation and apoptosis (Bartek et al, 2001). Following DNA damage, ATM 
phosphorylates CHK2 on Thr68 within an N-terminal SQ/TQ-rich cluster, which 
promotes the binding of this region to the FHA domain of another CHK2 molecule, 
resulting in dimerization or oligomerization. Eventually, dimerization triggers trans-
autophosphorylation of CHK2 in the kinase activation loop, necessary for full CHK2 
activation (Ahn et al, 2002; Xu et al, 2002). It has further been demonstrated that 
dimerization is a rather transient process since autophosphorylation, in particular of 
Ser140, destabilizes the dimer leading to its dissociation (Ahn et al, 2002; Li et al, 
2008). Recently, the group of Pavletich succeeded in resolving the crystal structure of 
dimeric CHK2 involving the FHA and kinase-inactive domain but lacking the SCD 
domain (Cai et al, 2009). The dimer forms through mutual FHA-KD (kinase domain) 
and FHA-FHA interactions, whereby the FHA-KD interaction involves Ile157, a 
residue whose mutation gives rise to the cancer-predisposition Li-Fraumeni 
syndrome. However, the observation of an SCD-independent dimerization seems to 
be rather weak and is thought that the phospho-Thr68-FHA interaction might further 
stabilize the dimer in vivo. This hypothesis is supported by an approach that uses 
expressed protein ligation to generate the N-terminal regulatory region of CHK2 (Li 
et al, 2008). In this case phosphorylation at Thr68 stabilized the weak FHA-FHA 
interactions that occur in the non-phosphorylated form. It is proposed that thereby the 
dimerization not only activates CHK2, but also modulates potential phospho-
dependent interactions with effector proteins and their substrates.  
Similar FHA-dependent dimerization and autophosphorylation mechanisms have 
been described for the CHK2 homologues Cds1 in S. pombe and Rad53 in S. 
cerevisae, albeit the FHA domain structures are not identical and molecular 
mechanism may vary (Mahajan et al, 2008). The transactivation mechanism of Rad53 
is complicated by the presence of two sets of SCD-FHA domains and molecular 
details of this process have not yet been completely understood. 
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Abstract The chromatin structure is important for recog-
nition and repair of DNA damage. Many DNA damage
response proteins accumulate in large chromatin domains
flanking sites of DNA double-strand breaks. The assembly
of these structures—usually termed DNA damage foci—is
primarily regulated by MDC1, a large nuclear mediator/
adaptor protein that is composed of several distinct
structural and functional domains. Here, we are summariz-
ing the latest discoveries about the mechanisms by which
MDC1 mediates DNA damage foci formation, and we are
reviewing the considerable efforts taken to understand the
functional implication of these structures.
Introduction
The DNA, the genetic material of our cells, is constantly
exposed to DNA-damaging agents such as the sun’s
radiation or free oxygen radicals that arise as a consequence
of natural cellular metabolism. Alternatively, cells may
become transiently exposed to external sources of DNA
damage such as cigarette smoke or various toxic chemical
compounds. DNA double-strand breaks (DSBs), which are
a particularly deleterious form of DNA damage, are formed
upon treatment of the cells with ionizing radiation (IR) or
chemical clastogens. They are also formed in a programmed
manner during meiosis and development of the immune
system. Since DSBs are highly toxic lesions that can lead to
genomic rearrangements if they are not efficiently and
accurately repaired, it is not surprising that cells have
evolved highly sophisticated mechanisms to counteract
those threats. Based on a seminal Nature review article by
Zhou and Elledge in 2000, these mechanisms are often
referred to as the DNA damage response (DDR; Zhou and
Elledge 2000).
The DDR is a conglomerate of signaling transduction
pathways consisting of sensors, transducers, and effectors.
Although it is often delineated as a linear pathway, it is
more accurately described as a network of interacting
pathways that together execute the cellular response.
Components of the DDR in mammalian cells include the
phospho-inositide-like kinases (PIKKs) ATM, ATR, and
DNA-PKcs, the transducer kinases CHK1 and CHK2, and
the various effector proteins that are either targeted directly
by the PIKKs or by one or both of the transducer kinases.
Additional proteins have emerged as essential components
of the DDR eukaryotes. For example, there is a group of
proteins that contain phosphorylation-specific protein–pro-
tein interaction modules such as BRCA1 carboxy-terminal
(BRCT) domains and/or forkhead-associated (FHA)
domains. This protein family is usually referred to as
mediators/adaptors of the DDR because most of these
proteins lack enzymatic activity but may predominantly act
as “molecular matchmakers” through their ability to
mediate the efficient interaction of proteins that would
otherwise not bind to each other.
A major hallmark of the mammalian DDR is the rapid
deploying of a host of proteins to the sites of DNA damage
within the nuclei of affected cells. Some of these proteins
engage in the repair of the lesions, while others trigger
kinase-dependent signaling cascades that induce events not
only confined to the region where the damage has occurred,
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but involving the entire cellular system. Some of the DDR
factors that are rapidly recruited to sites of DNA damage
have intrinsic affinity to aberrant DNA structures. For
example, the MRE11/RAD50/NBS1 (MRN) complex, a
conserved DDR sensor and repair factor, has been shown to
bind preferentially to free DNA ends that arise at the sites
of DSBs (de Jager et al. 2001). Other factors do not just
bind to the DNA lesions per se, but accumulate in large
nuclear aggregates surrounding the lesion site. These
structures, which can be visualized by standard immuno-
fluorescence microscopy, are usually referred to as nuclear
foci, DNA damage foci, or ionizing radiation-induced foci
(IRIF). The key regulators of IRIF formation are histone
proteins that form the core of the nucleosome, the
organizational unit of eukaryotic genomes. In mammalian
cells, the histone H2A variant H2AX, a component of the
nucleosome core structure that comprises 10–15% of total
cellular H2A in higher organisms, is rapidly phosphorylated
by PIKKs on a conserved Ser residue at its C-terminus in
chromatin regions bearing DSBs. Phosphorylation of the
H2AX C-terminus (termed γH2AX) “spreads” over large
chromatin domains but is strictly confined to the damaged
chromosome and does not involve neighboring chromo-
somes that are not affected by DNA damage (Rogakou et
al. 1999). We are henceforth referring to these γH2AX
modified chromatin regions as γH2AX chromatin domains.
The phosphorylated H2AX C-terminus serves as an
epigenetic chromatin mark that flags regions in the genome
that contain DNA breaks. Mediator of the DNA damage
checkpoint 1 (MDC1; sometimes also referred to as
NFBD1), a large protein that belongs to the mediator/
adaptor group of DDR factors, specifically binds to the
phosphorylated H2AX C-terminus and appears to be the
predominant γH2AX recognition factor in mammalian
cells. MDC1 knockout mice display a very similar
phenotype as H2AX knockout mice, thus corroborating
the close functional relationship between these two DDR
factors (Table 1). Moreover, MDC1 is an emerging tumor
suppressor because loss of MDC1 is associated with
increased tumor frequency in mice (Minter-Dykhouse et
al. 2008), and reduction or lack of MDC1 is observed in a
significant proportion of carcinomas (Bartkova et al. 2007).
MDC1 is composed of several distinct domains and
regions. Each of these domains or regions seems to be
tailored to recognize one or several specific protein
interaction partners that are recruited to the damaged
chromatin regions.
In the past 5 years, we have seen much progress in the
exploration of the molecular mechanisms by which MDC1
recognizes the γH2AX chromatin mark and mediates the
interaction of several DDR factors with damaged chromatin
regions. Phosphorylation-dependent protein–protein inter-
actions that are dependent upon FHA and BRCT domains
appear to be the central theme of these processes. In this
article, we will review these latest findings. For the sake of
clarity, we decided to follow a structural delineation rather
than a chronological account by starting from the MDC1 C-
terminus and subsequently working our way up to the N-
terminus. We will briefly describe each of MDC1’s
structural and functional domains and regions and specify
the proteins that are binding to these domains and regions.
Moreover, we will summarize the functional implications of
each of these domains and regions, as far as they are
known. Finally, we will point out where our current
knowledge about MDC1 is still incomplete and we will
also highlight some of the major discrepancies in the
literature.
The C-terminal tandem BRCT domain: assembly
and maintenance of the γH2AX chromatin domain,
regulation of mitotic progression, and control
of the decatenation checkpoint
The tandem BRCT domain of MDC1 is located at the very
C-terminus of the protein, between amino acid 1891 and
2082 (Fig. 1). X-ray structural analysis revealed that this
region of MDC1 retains the typical tandem BRCT fold in
which each BRCT repeat adopts a compact α/β fold and is
connected by a linker region to form an extended structure
about 70 Å long and 35 Å in diameter (Lee et al. 2005;
Stucki et al. 2005). The first indication that the MDC1
tandem BRCT domain was involved in the regulation of the
assembly of the γH2AX chromatin domain came from the
observation that a green fluorescent protein (GFP) tagged
version of the protein lacking the C-terminal BRCT region
did not accumulate in IRIF in response to IR treatment.
Moreover, the same study showed that overexpression of
the BRCT region abrogated MDC1 and γH2AX IRIF
(Shang et al. 2003).
Since BRCT repeats can act as phosphopeptide-binding
domains, oriented phosphopeptide library screening was
used to define the optimal phosphopeptide binding motif
for the MDC1 BRCT tandem domain (Rodriguez et al.
2003; Stucki et al. 2005). These screens revealed that the
MDC1 tandem BRCT domain bound selectively to peptides
containing a phosphorylated Ser residue, and furthermore,
selected for Glu at the +2 position and Tyr at the +3
position after the phosphorylated serine. These binding
preferences closely match the sequence of the phosphory-
lated H2AX C-terminus (pS-Q-E-Y-COOH), suggesting
that γH2AX is one of the binding partners of the MDC1
tandem BRCT domain. Indeed, biochemical, X-ray struc-
tural, and cell biological approaches clearly demonstrated
that MDC1 directly interacts with γH2AX via its C-
terminal BRCT region (Lee et al. 2005; Lou et al. 2006;
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Stucki et al. 2005) (reviewed in Stucki and Jackson 2006).
The structural data revealed that the phospho-peptide
binding cleft of the MDC1 tandem BRCT domain is
exquisitely tailored to recognize the γH2AX motif (Lee et
al. 2005; Stucki et al. 2005). Point mutations in the
phosphopeptide binding cleft of the MDC1 BRCT tandem
domain, as well as in the H2AX C-terminus, abrogated the
MDC1–γH2AX interaction in vitro; disrupted IRIF forma-
tion by several DDR factors including MDC1 itself, the
MRN complex, phosphorylated ATM, 53BP1, and BRCA1;
and rendered cells radio-sensitive (Stucki and Jackson
2006). These findings strongly indicate that one of the
major biological functions of the MDC1 C-terminal BRCT
region is the initial recognition of the γH2AX chromatin
mark and the mediation of the recruitment and retention of
DDR factors in chromatin regions flanking DSBs.
MDC1 does not only recognize the γH2AX chromatin
mark, but it is also involved in its regulation. It was shown
that MDC1 loss or experimental disruption of the
MDC1–γH2AX interaction leads to reduced H2AX phos-
phorylation and small γH2AX IRIF (Lou et al. 2006;
Stewart et al. 2003; Stucki et al. 2005). This indicates that
MDC1 somehow positively regulates H2AX phosphoryla-
tion and that this regulation is dependent on the direct
interaction between MDC1 and γH2AX. Since H2AX
phosphorylation in response to DSBs does not spread in
three dimensions throughout the cell nucleus, but is
confined to chromatin regions flanking the break site on
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Fig. 1 Schematic representation of the domain architecture of MDC1
and its interaction partners. MDC1 is composed of several distinct
domains and regions that either interact with phosphorylated proteins
or are themselves phosphorylated and serve as docking sites for other
proteins that contain phospho-specific interaction modules such as
FHA and BRCT domains. Each of these domains and regions appears
to be functionally relevant for the DDR and/or for control of the cell
cycle. See text for details
Table 1 Phenotypes associated with MDC1 loss. MDC1 loss induces a multitude of phenotypes both on the cellular level and also on the level of
the whole organism
KO organism (mouse) KO cellular (mouse) siRNA cellular (human)
Small size Radiosensitivity Radiosensitivity
Male infertility Intra-S phase checkpoint Intra-S phase checkpoint
Radiosensitivity G2/M checkpoint G2/M checkpoint
Tumor-prone IRIF IRIF
Phosphorylation (CHK1, CHK2, ATM) Phosphorylation (CHK1, CHK2, ATM, SMC1)
DSB repair by HR DSB repair by HR
NHEJ of dysfunctional telomeres Random plasmid integration
Chromosomal instability Apoptosis
Reduced proliferation Slow mitosis
Class switch recombination
In this table we summarized the most important phenotypes associated with MDC1 loss
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the damaged chromosome (i.e. “spreads” only in two
dimensions), it was proposed that MDC1 may be required
for γH2AX spreading along the damaged chromatin fiber
(Lou et al. 2006; Stucki and Jackson 2006). According to
this model, MDC1 is recruited to γH2AX proximal to the
lesion and either directly or indirectly mediates the
recruitment and retention of activated ATM in the damaged
chromatin compartment. ATM could then phosphorylate
more H2AX molecules that are located more distal to the
initiating lesion. As a consequence, the γH2AX chromatin
mark would spread further and further away from the initial
break. However, the model of MDC1-fuelled self-reinforcing
H2AX phosphorylation cycles to spread the γH2AX chro-
matin mark along the chromosome axis has recently been
challenged. One of the major caveats in assessing the
mechanism of γH2AX formation was the lack of “resolu-
tion.” Up until recently, researchers have relied on micro-
scopic techniques to study the dynamic assembly of the
γH2AX chromatin domain. While these microscopic techni-
ques have been very useful to measure the kinetics of protein
recruitment to sites of DNA damage and to assess the
dynamics of the assembly and disassembly of the γH2AX
chromatin domain, they have not been capable of delivering
any information about the density of H2AX phosphorylation
and the distance of γH2AX spreading along the axis of the
damaged chromosome. However, there exists a very power-
ful technique that can yield this kind of data: chromatin
immunoprecipitation (ChIP). While ChIP has been widely
and successfully used to study the assembly of protein
complexes on chromatin, as well as the dynamic changes of
epigenetic states (e.g., in transcriptional control), its success-
ful application in the mammalian DDR field has long been
impeded by the challenge to efficiently induce DNA breaks at
specific loci in the genome. To circumvent this problem, one
group studied the spreading of γH2AX on shortened
telomeres in senescent primary cells (Meier et al. 2007).
Shortened telomeres in senescent cells have been shown to
trigger a DDR similar to the one that is activated by DSBs.
In this study, it was shown that the γH2AX chromatin mark
spreads up to about 570 kb into the subtelomeric regions.
Furthermore, the spreading pattern of MDC1 was very
similar to that of γH2AX, confirming the functional and
structural link between these two factors. Importantly, this
study also revealed that γH2AX density is not uniform
along the chromosome axis (Meier et al. 2007). Another
study recently used primary mouse lymphocytes to study
γH2AX density and spreading during V(D)J recombination
in G1 (Savic et al. 2009). The major advantage of this
experimental system is the efficiency by which the RAG1/
RAG2 (RAG) endonucleases induce DSBs between the
variable (V), diversity (D), and joining (J) gene segments
and their flanking RAG recognition sequences. Since the
genomic locations of the RAG-initiated DSBs are known,
γH2AX density and spreading could readily be measured
by ChIP at this specific locus. Surprisingly, these data
revealed that MDC1 is not required for the spreading of the
γH2AX chromatin mark but, instead, for keeping up a high
γH2AX density proximal to the break site (Savic et al.
2009). Thus, it is possible that the previously proposed
MDC1-dependent γH2AX self-reinforcing mechanism only
applies to chromatin regions close to the lesion, while other
mechanisms may regulate γH2AX spreading into more
distal regions of the damaged chromatin fiber. It remains to
be determined whether these observations only apply to
RAG-initiated DSBs or if they are a general characteristic of
the cellular response to DSBs.
It has been proposed that MDC1 may control H2AX
phosphorylation through another mechanism that is not
related to its ability to mediate the accumulation of active
ATM in damaged chromatin compartments. This model
suggests that MDC1 may control the dephosphorylation of
H2AX through its direct binding to the phospho-epitope
located at C-terminus of H2AX. This interpretation was
based on the observation that the purified MDC1 BRCT
domains could efficiently shield γH2AX phosphopeptides
from phosphatase activity in vitro. Moreover, overexpres-
sion of the isolated MDC1 BRCT region in mammalian
cells resulted in H2AX hyperphosphorylation (Stucki et al.
2005). It was recently discovered that the phosphatases
PP2A and PP4 are involved in the removal of γH2AX from
chromatin in mammalian cells (Nakada et al. 2008). Thus,
it will be interesting to see if MDC1 can limit the access of
these phosphatases to γH2AX in vivo.
The recent discovery of yet another phosphorylation
event at the H2AX C-terminus has added an additional
layer of complexity to the regulation of the γH2AX
chromatin domain. In two recent Nature articles, the Allis
and Rosenfeld laboratories described the phosphorylation
of Tyr142 (the very C-terminal amino acid of H2AX) by
the WICH complex and its dephosphorylation by the
EYA1/3 phosphatases (Cook et al. 2009; Xiao et al.
2009). As these findings and their implications for the
DDR have recently been reviewed in detail elsewhere
(Stucki 2009), we will just briefly summarize the main
issues here: while H2AX Ser139 is targeted by DNA
damage-activated PIKKs, Tyr142 is phosphorylated by the
constitutive kinase WSTF, a subunit of the WICH chroma-
tin remodeling complex. However, upon induction of DNA
damage, Tyr142 becomes dephosphorylated by the EYA1/3
phosphatases. How exactly this dephosphorylation is
regulated remains elusive, but Tyr142 dephosphorylation
is necessary for the assembly of the γH2AX chromatin
domain because MDC1 is not capable of efficiently binding
to γH2AX as long as Tyr142 is phosphorylated.
But what is the physiological role of H2AX Tyr142
phosphorylation? One attractive possibility is that the
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Tyr142 phosphorylation/dephosphorylation equilibrium
may determine cell fate in response to genotoxic stress.
As mentioned above, Tyr142 phosphorylation attenuates
MDC1 recruitment and the establishment of the γH2AX
chromatin domain. However, it was proposed that the
Tyr142 modification may promote the recruitment of the
pro-apoptotic factor JNK1 to sites of DNA damage (Cook
et al. 2009). Thus, if repair is possible, Tyr142 is
dephosphorylated and the DDR machinery is recruited to
sites of DNA damage to promote repair. However, if the
damage is too severe to be repaired in time, tyrosine
phosphorylation remains and apoptosis is favored through
the association of JNK1 with γH2AX. This is still a rather
simplified model, and our understanding of the regulation
of the γH2AX chromatin domain is still incomplete. Thus,
more work is needed to understand this important process
in detail.
Recently, two additional phosphorylation-specific inter-
action partners for the MDC1 BRCT domains have been
discovered. CDC27, a subunit of the anaphase promoting
complex APC/C was shown to interact directly with MDC1
via its phosphorylated C-terminal region (Coster et al.
2007). The APC/C is a multi-subunit E3 ubiquitin ligase
that controls mitotic progression mainly through ubiquitin-
dependent destruction of mitotic cyclins and other sub-
strates in a coordinated manner. Interestingly, the sequence
of the phosphorylated MDC1 binding site in CDC27 is
located at the very C-terminus of the protein and is very
similar to the MDC1 binding site in H2AX: the phospho-
acceptor Ser residue is also followed by a Glu at the +2
position and a Phe at the +3 position (pS-D-E-F-COOH).
Phosphopeptide screening has indicated that the MDC1
BRCT domains strongly select for Glu at +2, and Tyr, but
not Phe, at the +3 position (Rodriguez et al. 2003; Stucki et
al. 2005). Thus, it appears that CDC27 binding to MDC1 is
effectively produced by the strong selection of Glu at +2.
Moreover, the relative localization of the C-terminal
carboxylate in respect to the phosphorylated Ser residue is
identical in CDC27 and γH2AX. The kinase that targets the
CDC27 C-terminus is currently unknown, but considering
that the MDC1 CDC27 interaction is increased after DNA
damage (Coster et al. 2007), CDC27 phosphorylation may
be somehow modulated by DNA damage. An interesting
possibility would be that MDC1 is involved in the
regulation of mitotic progression in response to DNA
damage through its interaction with the APC/C. However,
no experimental evidence for such a function has yet been
produced. Instead, it was recently demonstrated that MDC1
is regulating mitotic progression independently of DNA
damage. Grant Stewart and colleagues showed that MDC1-
deficient human cells have defects in mitotic progression at
the metaphase/anaphase transition (Townsend et al. 2009).
Moreover, the activity of the APC/C ubiquitin ligase is
compromised in the absence of MDC1. However, mecha-
nistically, MDC1 appears to modulate the APC/C activity
rather through its interaction with CDC20 (an activator
protein that regulates the substrate specificity of the APC/C
ubiquitin ligase) and not through its interaction with the
APC/C subunit CDC27 (Townsend et al. 2009). Thus, it
remains elusive as to how the phospho-dependent MDC1–
CDC27 interaction contributes to the control of mitotic
progression.
Another phospho-specific MDC1 BRCT-interacting fac-
tor was recently discovered by Lou and colleagues: DNA
topoisomerase IIα (Topo IIα; (Luo et al. 2009)). MDC1-
Topo IIα interaction seems to regulate the decatenation
checkpoint, a checkpoint that controls the entanglement
(“catenation”) of chromosomes at the end of DNA
replication. This checkpoint arrests cells in G2 and delays
onset of mitosis until sister chromatids are fully separated.
A phosphorylation site close to the C-terminus of Topo IIα
appears to mediate the interaction with the MDC1 C-
terminal BRCT repeat. Surprisingly though, this phosphor-
ylation site presents only limited sequence similarity to the
H2AX and CDC27 C-terminal MDC1-binding epitopes,
suggesting a different mode of binding, or perhaps an
indirect interaction. Quantitative phosphopeptide-binding
studies and/or structural approaches will be required to
resolve this issue.
The PST repeat region: regulation of DSB repair
and mitotic progression?
The region in human MDC1 between amino acids 1141 and
1662 is generally referred to as the proline–serine–threo-
nine (PST)-rich repeat (Fig. 1). In humans, this region
consists of 13 consecutive imperfect repeats of 41 amino
acids. The PST repeat is one of the least conserved regions
in MDC1 and does not appear to exist at all in MDC1
orthologues of non-vertebrates (e.g.,Drosophila (Dronamraju
and Mason 2009)). However, in most vertebrate species, the
PST repeat is present and conserved, even though the
number of repeats varies greatly from 13 consecutive repeats
in human MDC1 to seven repeats in mouse MDC1. Primary
sequence analysis did not reveal any known structural and
functional motifs, and sequence comparison and database
searches did not retrieve significant homology to any other
known protein.
To this day, little is known about the functional
implication of the PST repeat region. However, it is clear
that the PST repeat is neither required for MDC1
accumulation at sites of DSBs (Shang et al. 2003), nor for
MDC1’s function to mediate the accumulation of 53BP1,
BRCA1, and the MRN complex in damaged chromatin
compartments (Lou et al. 2004; Xie et al. 2007) (see also
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next sections). In an early study by the Chen laboratory, it
was proposed that the PST repeat region constitutes a
binding site for DNA-PK. Moreover, in this work, it was
shown that deletion of the PST repeat triggers a partial non-
homologous end joining (NHEJ) defect (Lou et al. 2004).
However, the mechanism by which the MDC1 PST repeat
would regulate NHEJ remained elusive because MDC1 is
not required for DNA-PK recruitment to sites of DSBs
(Gottlieb and Jackson 1993). It was proposed that MDC1
may mediate the accumulation of DNA-PK in chromatin
regions flanking DSBs in similar manner as it mediates the
accumulation of the MRN complex (Lou et al. 2004).
However, DNA-PK does not seem to accumulate in IRIF in
response to DSBs (Bekker-Jensen et al. 2006). Thus, a
functional implication of the observed interaction between
the MDC1 PST region and DNA-PK remains elusive.
Interestingly, the PST repeat region does not only appear
to be important for DSB repair by NHEJ, but also for
homologous recombination (HR). In a genetic HR reporter
system, a mutant MDC1 version lacking the PST repeat
region was defective for HR, while this mutant was still
proficient in accumulating at sites of DSBs and in
mediating the accumulation of other DDR proteins such
as 53BP1, BRCA1 at sites of DSBs (Xie et al. 2007). It thus
appears that the MDC1 PST repeat region is implicated in
DSB repair by both NHEJ and HR, although the mecha-
nism of action of this unusual repeat motif in DSB repair
remains to be elucidated.
According to a recent report, the PST repeat region is
also implicated in mitotic progression. As outlined in the
last section, MDC1 deficient cells have defects in mitotic
progression at the metaphase/anaphase transition, which is
associated with an increased number of mitotic cells in a
population of MDC1 deficient cells as compared to control
cells that express normal amounts of MDC1 (Townsend et
al. 2009). Expression of a mutant MDC1 version lacking
the PST repeat region could not restore this mitotic defect
while expression of wild-type MDC1 rescued the pheno-
type. Interestingly, there seems to be an interaction between
several subunits of the APC/C and the MDC1 PST repeat
region, which may mechanistically explain the mitotic
defect observed in cells expressing a MDC1 version lacking
the PST repeat (Townsend et al. 2009).
The TQXF cluster: Regulation of chromatin
ubiquitylation
N-terminal of the PST repeat resides a region in MDC1 that
is characterized by a noticeable abundance of PIKK
consensus phosphorylation Ser/Thr-Gln (S/TQ) sites. Par-
ticularly striking is a cluster of four nearby TQ motifs that
are all followed by the Phe at the +3 position (located
between amino acid 699–768 in human MDC1). We will
henceforth refer to this region as the TQXF cluster. Early
studies on human MDC1 suggested that the protein is
targeted by ATM in response to IR treatment, but the exact
location of the phosphorylation sites were not determined
(reviewed in Stucki and Jackson 2004). However, at least a
subset of the TQXF motifs in MDC1 have recently been
identified to represent bona fide ATM targets in response to
IR (Kolas et al. 2007; Mailand et al. 2007; Matsuoka et al.
2007). Phosphorylation of these sites mediates the recruit-
ment of the E3 ubiquitin ligase RNF8 through direct
interaction of its FHA domain with the MDC1 phosphor-
ylated TQXF region (Huen et al. 2007; Kolas et al. 2007;
Mailand et al. 2007) (see Fig. 2). FHA domains, like BRCT
tandem domains, recognize amino acid sequences around a
central phosphorylation site. However, while BRCT tandem
domains recognize both pSer and pThr-containing sequen-
ces, FHA domains appear to only recognize pThr-containing
motifs (Durocher and Jackson 2002). Intriguingly, the RNF8
FHA domain showed strong selection for Phe and Tyr at
the +3 position (Huen et al. 2007). Such a selection for
aromatic amino acids at the +3 position closely resembles
the optimal phosphopeptide motifs recognized by the
tandem BRCT domains of MDC1 and BRCA1 (reviewed
in Mohammad and Yaffe 2009; see also above).
Immunofluorescence microscopy showed that deletion
of these TQXF motifs in MDC1 or depletion of RNF8 led
to impaired IRIF formation for conjugated ubiquitin, 53BP1
and BRCA1, whereas γH2AX, MDC1, and NBS1 IRIF
were not affected. Furthermore, 53BP1 and BRCA1
accumulation was dependent on the E3 ubiquitin ligase
domain (a RING domain) of RNF8, indicating that IRIF
formation of these proteins is controlled by local ubiquity-
lation of substrates in chromatin regions flanking DSBs.
Although the identity of these substrates has currently not
yet been addressed in vivo, several lines of in vitro
evidence suggest that the major RNF8 substrates that
mediate 53BP1 and BRCA1 accumulation at sites of DSBs
may be the histone proteins H2A and H2AX (Huen et al.
2007; Mailand et al. 2007).
What is the physiological role of local chromatin
ubiquitylation and how exactly does this posttranslational
modification influence the accumulation of DDR proteins
such as 53BP1 and BRCA1 in damaged chromatin regions?
Downregulation of RNF8 by small interfering RNAs
(siRNAs) yields a G2/M checkpoint defect and renders
cells radiosensitive, implicating MDC1-dependent local
chromatin ubiquitylation in DNA damage signaling and
perhaps also DSB repair in mammalian cells. The mecha-
nism, by which MDC1-dependent RNF8 recruitment
ensues the chromatin ubiquitylation cascade and mediates
IRIF formation by 53BP1 and BRCA1 appears to be rather
complicated and has yet to be resolved in detail. However,
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it is clear that at least one additional ubiquitin ligase and
ubiquitin-dependent adaptor proteins are involved in these
processes. As these downstream events are not directly
controlled by MDC1 and have been recently reviewed in
detail elsewhere (Panier and Durocher 2009; Van Attikum
and Gasser 2009), we will just briefly summarize the most
important findings here and outline the current model (see
Fig. 2).
While it was shown that the ubiquitin ligase activity of
RNF8 is required to trigger DSB-associated ubiquitylation,
it is not sufficient to sustain the conjugated ubiquitin in the
damaged chromatin regions. Several groups identified
RNF168 as a novel chromatin-associated ubiquitin ligase
that acts in concert with UBC13 to catalyze formation of
K63-linked ubiquitin conjugates and ubiquitylates family
members of the H2A family in regions surrounding the
DSB as efficiently as RNF8. In addition, RNF168 pos-
sesses the ability to bind ubiquitylated H2A in an RNF8-
dependent manner (Doil et al. 2009; Stewart et al. 2009).
This suggests that, while RNF8 acts as initiating ubiquitin
ligase in DSB-flanking chromatin, RNF168 activity stabil-
izes and/or amplifies the signal in order to reach a threshold
level that mediates the recruitment of downstream factors
53BP1 and BRCA1 and thereby allows the completion of
the DSB-induced chromatin response. Significantly,
RNF168 is mutated in RIDDLE syndrome patients that
Fig. 2 Model of the assembly of the γH2AX chromatin domain. 1 In
response to DSB-causing genotoxic agents MRN directly binds to free
DNA ends and facilitates the recruitment and activation of the ATM
kinase, which is autophosphorylated and, thus, converted from an
inactive dimer into active monomers. ATM phosphorylates H2AX in
the nearby DSB-flanking chromatin. 2 MDC1 recognizes the γH2AX
chromatin mark and mediates the sustained interaction of the MRN
complex with damaged chromatin through direct phosphorylation-
dependent interaction. 3 Phosphorylated MDC1 recruits the ubiquitin
ligase RNF8 and additional DDR factors, thereby triggering a
signaling cascade that is dependent on ubiquitylation of histones and
results in checkpoint activation and DNA repair. See text for details
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suffer from immunodeficiency and radiosensitivity (Stewart
et al. 2007, 2009). These phenotypes may arise mainly
from defective chromatin ubiquitylation and dysfunctional
53BP1 and BRCA1 retention, a process that may be
particularly important for the proper repair of programmed
DSBs during the development the immune system in
humans (recently reviewed in Stewart 2009).
The ubiquitylated histones likewise form a direct
recognition motif for the ubiquitin-interacting motif
(UIM)-containing receptor-associated protein 80 (RAP80),
leading to its accumulation in IRIF with a preference for
K63- and K6-linked ubiquitin polymers (Kim et al. 2007;
Sobhian et al. 2007; Wang et al. 2007). RAP80 accumulates
in IRIF and facilitates the recruitment of BRCA1, which is
mediated by Abraxas that directly interacts with the BRCT
domain of BRCA1 in a DNA damage-induced phospho-
dependent manner (Wang et al. 2007) (Fig. 2). Taken
together, the sequential recruitment of the three ubiquitin
ligases RNF8, RNF168, and BRCA1 and the resulting
ubiquitylation of chromatin components (perhaps mainly
H2A-type histones) imply that this type of posttranslational
modification represents a crucial novel regulatory process
in the response to genotoxic lesions.
While the MDC1/RNF8-dependent retention of BRCA1
can be mechanistically explained with a model that
involves direct protein–protein interactions, the MDC1/
RNF8-dependent accumulation of 53BP1 is less well
understood. No ubiquitin-binding domains have yet been
identified in 53BP1 that could explain its recruitment to
DSB-associated ubiquitylated chromatin components. Thus,
MDC1 may exert its function also more indirectly, e.g.,
through initiation of chromatin reorganization events that
would eventually increase the accessibility of proteins to
newly exposed histone marks that are buried in higher-
order chromatin structure. In this regard, the 53BP1 Tudor
domain was shown to be required for 53BP1 accumulation
at sites of DSBs (Huyen et al. 2004). These domains may
bind to methylated histone marks that are masked in
unperturbed chromatin, but may become locally exposed in
a ubiquitin-dependent manner in response to DNA damage
(Botuyan et al. 2006; Huyen et al. 2004). In any case, the
vast majority of data presently available promote the idea
that MDC1-mediated chromatin modifications and/or higher-
order chromatin rearrangements might facilitate the accumu-
lation and sustained retention of 53BP1 at sites of DSBs.
What is the functional implication of MDC1/RNF8-
mediated BRCA1 and 53BP1 accumulation at sites of
DSBs? While this is still not yet resolved in detail, an
interesting clue recently came from the telomere field. It
has been known for quite some time that chromosomes that
have lost their protective telomeric “cap” undergo chromo-
some end-to-end fusions in a process that is dependent on
the NHEJ machinery. MDC1-deficient cells show a
significant reduction in NHEJ of dysfunctional telomeres
(Dimitrova and de Lange 2006). This is most likely due to
the inefficient accumulation of 53BP1 at dysfunctional
telomeres in the absence of MDC1. 53BP1 is thought to
promote chromosome end-to-end fusions by altering the
dynamic behavior of chromatin at dysfunctional telomeres
(Dimitrova and de Lange 2008). However, it is not yet
known if this effect is specific for NHEJ of dysfunctional
telomeres or if it also applies to NHEJ in general.
The SDT repeat region: constitutive interaction
with the MRN complex
Upstream of the TQXF cluster, MDC1 features a second
repeat region that is characterized by conserved patches of
8–10 amino acids comprising Ser and Thr residues typically
separated by an aspartate and further embedded in an acidic
sequence environment. This so called SDT region (in some
papers also referred to as SDTD region) interacts with the
MRN complex in a phosphorylation-dependent manner
(Chapman and Jackson 2008; Melander et al. 2008;
Spycher et al. 2008; Wu et al. 2008) (Fig. 2). The MRN
complex is an essential component of the DNA damage
signaling machinery. Due to its ability to recognize free
DNA ends, the MRN complex is capable of acting as a
sensor of DSB. It further exhibits DNA-end processing
activity, tethers DNA ends, and is required for efficient
ATM kinase activation (reviewed in Williams et al. 2007).
Accomplishing the aforementioned functions does not seem
to require the presence of MDC1. However, similar to
53BP1 and BRCA1 (see above), accumulation and reten-
tion of MRN complex in DSB-flanking chromatin regions
strictly depends on MDC1 (Bekker-Jensen et al. 2006;
Goldberg et al. 2003; Lukas et al. 2004).
In human MDC1, six SDT motifs were identified, and
deletion of at least five of them leads to complete
abrogation of MRN IRIF formation (Melander et al. 2008;
Spycher et al. 2008). Analysis of NBS1 recruitment to sites
of DSBs revealed that, upon expression of an MDC1
version lacking the SDT regions, NBS1 only accumulates
in micro-IRIF but is not found in the broader chromatin
compartments usually covered by γH2AX and MDC1
(Chapman and Jackson 2008). This indicates that the
MRN complex is recruited to DSBs in a MDC1-
independent manner, but its sustained interaction with the
DSB-flanking chromatin requires MDC1.
Interestingly, MDC1 and MRN exist in a complex even
in undamaged cells. This interaction is dependent on the
activity of the acidophilic caseine kinase 2 (CK2) for which
the SDT motifs form consensus phosphorylation sites
(Spycher et al. 2008; Wu et al. 2008). Both Ser and Thr
residues in each SDT motif are phosphorylated by CK2 in
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vivo, and only doubly phosphorylated pSDpT motifs are
capable of mediating the interaction with NBS1 (Melander
et al. 2008; Spycher et al. 2008).
Two recent X-ray structural studies revealed that NBS1
contains a compact module at its N-terminus formed by an
FHA and a tandem BRCT domain (Lloyd et al. 2009;
Williams et al. 2009). Phosphopeptide-binding studies
revealed that both the FHA domain of NBS1 and its BRCT
domains preferentially bind to SDT-like motifs that are
phosphorylated on both Ser and Thr residues (Lloyd et al.
2009). These motifs are found in MDC1 (see above), and
also in fission yeast Ctp1 (the yeast orthologue of
mammalian CtIP that is involved in DSB resection and
HR) and budding yeast Lif1 (the yeast orthologue of
mammalian XRCC4 that is involved in NHEJ). Both Ctp1
and Lif1 have been shown to interact with the N-terminal
region of yeast NBS1 (Lloyd et al. 2009; Matsuzaki et al.
2008; Williams et al. 2009). MDC1 orthologues have so far
not been detected in yeast. It is currently also not known if
human NBS1 is capable of interacting with the human
orthologues of yeast Ctp1 and Lif1 (CtIP and XRCC4,
respectively) in a CK2-dependent manner.
Doubly phosphorylated pSDpTD peptides interact with
both FHA and BRCT domains of human NBS1 since only
mutations in both domains effectively abolished the
interaction (Lloyd et al. 2009). Mutation of key residues
in the FHA and the tandem BRCT domain similarly reduce
the interaction between CK2-phosphorylated MDC1 pro-
tein and the MRN complex, thus indicating the requirement
of an intact domain structure at the N-terminus of NBS1 for
optimal binding (Chapman and Jackson 2008; Lloyd et al.
2009). Moreover, alterations in either FHA or BRCT
domains impair relocalization of the MRN complex to
IRIF (Cerosaletti and Concannon 2003; Spycher et al.
2008; Wu et al. 2008; Xu et al. 2008). These data point to a
dual phospho-dependent interaction mode between MDC1
and the FHA/BRCT region of NBS1.
Functionally, the NBS1 FHA/BRCT region is required
for the activation of the intra-S-phase and the G2/M DNA
damage checkpoints and is likely also participating in DSB
repair. However, the molecular mechanisms underlying
these functional implications remain largely elusive. De-
fective checkpoint activation has been observed in NBS1
FHA and BRCT phospho-binding mutants (Difilippantonio
et al. 2007; Wu et al. 2008; Zhao et al. 2002), strongly
suggesting that the interaction with MDC1 may be required
for ensuing an efficient DNA damage checkpoint response.
However, it is not yet clear how exactly MDC1–NBS1
complex formation is implicated in DNA damage signaling.
One possibility is that accumulation and retention of the
MRN complex in chromatin regions flanking DSBs may
help to amplify the checkpoint response in the presence of
low numbers of DNA breaks (Spycher et al. 2008; Stucki
and Jackson 2006). In addition, MDC1-dependent chroma-
tin retention of NBS1 may also be necessary to efficiently
recruit the ATM kinase to the damaged chromatin compart-
ments (Falck et al. 2005), even though this issue is
currently still a matter of controversy (see also below).
The N-terminal FHA domain: an enigma at the end
Perhaps with the exception of the PST repeat region, the N-
terminal FHA domain of MDC1 is still the most enigmatic
element of this large and versatile mediator protein. This is
surprising given that FHA domains are well-characterized
phospho-specific interaction modules that occur rather
frequently in DDR proteins. It has also been clear for a
while that the N-terminal FHA domain is important for
MDC1’s functions in the DDR: deletion of this domain
leads to multiple DDR defects, including a defective G2/M
DNA damage checkpoint, inefficient DSB repair by sister
chromatid recombination, and reduced apoptosis in re-
sponse to IR (Lou et al. 2003, 2006; Xie et al. 2007; Zhang
et al. 2005). Even though several interaction partners for the
FHA domain have been identified in the past years, none of
them seems to quite “fit in.”
As a first candidate, phosphorylated CHK2 was de-
scribed as putative MDC1–FHA interacting factor (Lou et
al. 2003). Immunoprecipitation and peptide-binding studies
suggested that CHK2, phosphorlyated on Thr68, could
form a stable complex with MDC1 in vitro and in cell
extracts. Moreover, the MDC1 FHA domain was required
for this interaction. In support of this finding, oriented
phosphopeptide library screening revealed that the MDC1
FHA domain bound selectively to peptides containing a
phosphorylated Thr residue, and furthermore, selected for
Gln at the +1 position and Leu/Ile at the +3 position after
the phosphorylated Thr (Durocher et al. 2000). These
binding preferences closely match the sequence surround-
ing the Thr68 of CHK2 (pT-Q-E-L), thus corroborating the
interpretation that CHK2 phosphorylated on Thr68 is a
bona fide binding partner of the MDC1 FHA domain.
However, CHK2 and MDC1 do not co-localize in cells that
have been treated by DSB-inducing agents. While MDC1
accumulates in IRIF, CHK2 remains dispersed throughout
the nucleus (Lukas et al. 2003). This implies that the
interaction between MDC1 and phosphorylated CHK2 is
very transient in nature (at least in vivo) and, thus, does not
compare, for example, to the stable interaction between the
phosphorylated MDC1 TQXF cluster and the RNF8 FHA
domain, even though this latter interaction is also based on
a phosphorylated TQ motif and an FHA domain. Further-
more, it was recently shown that a tight pThr68-dependent
head-to-tail dimerization of CHK2 results in effective
occlusion of the phospho-epitope and would prevent
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interaction of the phospho-Thr68 motif with the MDC1
FHA domain (Li et al. 2008). However, autophosphoryla-
tion of CHK2 releases monomeric CHK2 (Ahn and Prives
2002; Li et al. 2008), which would expose the phospho-
Thr68 motif and, potentially, allow binding to the MDC1
FHA domain. This mechanism could cause a very rapid
switching of the phosphorylated CHK2 between MDC1-
bound state and MDC1-free dimeric state and may account
for the observation that, in response to DNA damage,
CHK2 remains dispersed throughout the nucleus and does
not accumulate in IRIF (Lukas et al. 2003).
MDC1 was also reported to interact with the ATM
kinase through its N-terminal FHA domain (Lou et al.
2006). Immunoprecipitation experiments showed that ATM
and MDC1 exist in a complex (Stewart et al. 2003).
Moreover, ATM seems to weakly associate with the
isolated FHA domain of MDC1 in vitro (Lou et al. 2006).
Immunofluorescence microscopy revealed that, in the
absence of MDC1 (or in the presence of an MDC1 version
lacking the N-terminal FHA domain), antibodies raised
against the autophosphorylated ATM kinase could not
anymore detect phospho-ATM IRIF accumulation, indicat-
ing that MDC1 may recruit phosphorylated ATM into
damaged chromatin compartments via direct interaction
with its FHA domain. However, it should be pointed out
that a correct interpretation of these data is difficult because
it is currently very difficult to control the specificity of
phospho-specific ATM antibodies in indirect immunofluo-
rescence. Phospho-specific antibodies raised against pTQ/
pSQ peptides are notoriously promiscuous and usually
cross-react with many PIKK target proteins (Matsuoka et
al. 2007). It is therefore likely that phospho-specific ATM
antibodies are no exception and may be recognizing other
proteins besides ATM in immunofluorescence. Thus, it is
not yet clear if ATM IRIF formation is really dependent on
the MDC1 FHA domain. To complicate matters further, it
has also been suggested that ATM accumulation at sites of
DSBs is mediated by the C-terminal region of NBS1. ATM
IRIF formation was defective in cells expressing a NBS1
version lacking a C-terminal ATM-interacting peptide
(Falck et al. 2005). Since NBS1 IRIF formation is also
dependent on MDC1, it is possible that ATM accumulation
is not mediated by direct interaction with MDC1, but
indirectly, through its association with the NBS1 C-
terminus. To resolve this matter in an unbiased manner,
ATM IRIF formation needs to be analyzed with antibodies
raised against the non-phosphorylated protein, whose
specificity can be properly controlled in ATM-deficient
cells. Alternatively, GFP-tagged recombinant ATM may be
used to test if IRIF accumulation is dependent upon the
SDT region of MDC1 (that mediates the accumulation of
the MRN complex, see above), or upon the FHA domain of
MDC1 that may directly interact with ATM.
The MDC1 FHA domain has also been implicated in
DSB repair via sister chromatid recombination (Xie et al.
2007; Zhang et al. 2005). It was proposed that this is
brought about through a specific interaction between the
FHA domain of MDC1 and the recombinase RAD51
(Zhang et al. 2005). However, this is difficult to compre-
hend because, at early time points after irradiation, RAD51
foci and MDC1 IRIF do not co-localize (Goldberg et al.
2003). Moreover, RAD51 and MDC1 do not occupy the
same compartments at sites of DSBs: while RAD51 binds
to single-stranded DNA stretches that are the result of DSB
resection in S and G2 phases of the cell cycle, MDC1
accumulates in the chromatin compartment flanking sites of
DSBs, independently of the cell cycle state (Bekker-Jensen
et al. 2006). Thus, whether and how interaction between the
MDC1 FHA domain and RAD51 contributes to DSB repair
by HR remains elusive.
Concluding remarks
In the past few years, MDC1 has emerged as a prototype
mediator, acting mainly as a “molecular matchmaker” in the
mammalian response to DNA damage. The entire protein
appears to be composed of regions and domains that are
involved in protein–protein interactions; most of them
occur as phosphorylation-specific interactions.
Recent key findings have also significantly contributed
to our understanding as to how MDC1 functions in the
DDR. The best-characterized functional role of this protein
is that it acts as a bridging element to dynamically tether
various DDR factors to damaged chromatin regions that
contain phosphorylated H2AX molecules. Mechanistically,
this function is based upon a very specific interaction
between the MDC1 C-terminal tandem BRCT domain and
the phosphorylated H2AX C-terminus. Moreover, several
domains and regions within the central and N-terminal
sections of MDC1 feature repeated sequence motifs that are
shaped by post-translational modifications, mostly phos-
phorylations. These regions are then recognized by proteins
that contain domains capable of specifically binding to the
modified amino acid stretches such as FHA and BRCT
tandem domains. These factors subsequently accumulate at
sites of DSBs and, thus, the γH2AX chromatin domain is
efficiently established.
While the mechanism of accumulation of DDR factors in
damaged chromatin and the role of MDC1 in this process is
now relatively well understood, it is much more difficult to
implicate these processes to the physiological roles of
MDC1. While we do know that MDC1 is important for the
activation of the intra-S phase and G2/M DNA damage
checkpoint and for DSB repair, it is not clear yet how
exactly these physiological roles are connected to MDC1’s
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major task to control the assembly of the γH2AX
chromatin domain. This is especially true for checkpoint
activation. To make this point clear, we touch on just one
example: As outlined above, MDC1 is implicated in the
G2/M DNA damage checkpoint. Theoretically, this func-
tion could be mediated by 53BP1 or BRCA1 accumulation
because both 53BP1 and BRCA1 are implicated in the G2/
M checkpoint response and mutation of the TQXF cluster
of MDC1 that is essential for 53BP1 and BRCA1
accumulation triggers a G2/M checkpoint defect. However,
deletion of the MDC1 FHA domain also triggers a G2/M
checkpoint defect, which might be related to the ability of
the FHA domain to interact with ATM and CHK2, factors
that are also critical to induce a proper G2/M checkpoint
response. To complicate matters further, MDC1 also
mediates the accumulation of the MRN complex via direct
interaction of its phosphorylated SDT repeats with the
FHA/BRCT region of NBS1. Mutation in the FHA domain
of NBS1 also results in a G2/M checkpoint defect,
indicating that MDC1-mediated accumulation of NBS1 in
damaged chromatin regions may be required for proper G2/
M checkpoint activation. The relative contribution of these
protein–protein interactions is not yet clear and no firm
mechanistic explanation is yet available as to how MDC1-
mediated accumulation of DDR factors at sites of DSBs
brings about an efficient G2/M checkpoint response.
Thus, while MDC1 has clearly emerged as the major
organizer of the assembly and maintenance of the γH2AX
chromatin domain, we still need to learn a lot more about
how these events translate into a timely and efficient DDR
that protects cells from the deleterious and dangerous
effects of DNA damage and chromosomal instability.
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Abstract 
Mdc1 is a large modular phosphoprotein scaffold that maintains signaling and 
repair complexes at double-stranded DNA break sites. Mdc1 is anchored to 
damaged chromatin through interaction of its C-terminal BRCT-repeat domain with 
the tail of γH2AX following DNA damage, but the role of the N-terminal forkhead-
associated (FHA) domain remains unclear. We show that a major binding target of 
the Mdc1 FHA domain is a previously unidentified DNA-damage and ATM–
dependent phosphorylation site near the N-terminus of Mdc1 itself. Binding to this 
motif in vitro and in human cells stabilizes a weak self-association of the FHA 
domain to form a tight dimer. X-ray structures of free and complexed Mdc1 FHA 
domain reveal a ‘head-to-tail’ dimerization related to that seen in dimeric forms of 
the Chk2 DNA-damage kinase. Together, our data highlight dimerization as an 
unsuspected regulator of Mdc1 activity and show how this may further modulate 
interactions with other DNA-damage response components. 
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Introduction 
Genomic integrity is constantly challenged by the effects of DNA-damaging agents. 
Double-stranded DNA breaks (DSBs) are considered to be the most genotoxic lesions since 
incorrect repair can lead to chromosome breaks and other aberrations that are characteristic of 
and which may lead to cancer. DSBs initiate a program of cellular responses involving activation 
of cell-cycle checkpoints and deployment of the repair machinery. Central to DNA-damage 
response (DDR) regulation is a protein kinase cascade involving ataxia telangiectasia-mutated 
kinase (ATM) which acts as sensor of DSBs, initiating damage signals that are propogated 
through phosphorylation of checkpoint kinases and other diverse downstream targets 1. Many of 
these phosphorylation events are now known to initiate protein-protein interactions mediated by 
phosphoserine/threonine-specific binding domains, most commonly forkhead-associated (FHA) 
and Brca1 C-terminal (BRCT) modules 2, providing for highly regulated, physical links between 
DDR components.  
Mediator of the DNA-damage Checkpoint-1 (Mdc1) is a modular, 2089 amino-acid 
protein originally identified as an essential factor for establishment of the S-phase checkpoint 3-6. 
It functions as an assembly platform for the localization and maintenance of signaling and repair 
factors at and around DSB sites 7. As such, Mdc1 is a founding member of a class of large 
scaffolding/adaptor proteins known as 'mediators' that includes proteins such as human Brca1, 
53BP1 and yeast Rad9 and Crb2. While all of these molecules contain two or more copies of 
BRCT-repeat motifs, Mdc1 also contains an additional FHA domain at its N-terminus.  
Functionally, the C-terminal BRCT-repeats tether Mdc1 to regions of DNA-damage by 
virtue of their specific binding to ATM-phosphorylated H2AX (known as γH2AX), a variant 
histone H2A which acts as the primary marker of damaged chromatin in all eukaryotic cells 8. In 
contrast, the function of the FHA domain is less clear but has been suggested to include 
interaction with ATM itself 9, Chk2 3, components of the Mre11/Rad50/Nbs1 (MRN) complex 
5,10 and other repair proteins such as Rad51 11. In addition, although self-association has been 
shown to be a functional feature of 53BP112, Rad9 13 and Crb2 14, the oligomeric status of Mdc1 
in DNA-damaged cells has not, to our knowledge, been investigated. We now show that the 
Mdc1 FHA domain mediates an inter-molecular interaction with a previously uncharacterized, 
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ATM phosphorylation site located within its own N-terminal region, revealing a role for DNA-
damage inducible Mdc1 dimerization in the cellular response to double-stranded DNA breaks. 
 
Results 
Mdc1 Thr-4 is a novel site of ATM phosphorylation in vitro and in vivo.  
Mdc1 contains many potential PI3 kinase-like protein kinase (PIKK) target sites (S/TQ-
motives) throughout its open reading frame and early studies have shown that upon genotoxic 
stress, Mdc1 is rapidly phosphorylated in a PIKK-dependent manner 3-5. However, only few of 
these potential PIKK target sites are conserved and the extent and physiological relevance of 
PIKK-dependent Mdc1 phosphorylation are largely unknown. In order to identify bona fide 
PIKK target sites in Mdc1, we generated eight overlapping fragments of the human Mdc1 cDNA 
and expressed them in E. coli as GST-fusion proteins as described previously (Fig. 1a; 15). All 
but one fragment, M-6 comprising the Mdc1 PST repeat region, expressed well and could be 
purified (Fig. 1a, upper panel). These fragments were then subjected to an in vitro kinase assay 
using immunoprecipitated human ATM 16. Surprisingly, ATM only phosphorylated fragment M-
1 (amino acids 1-124) and fragment M-4 (amino acids 531-770), (Fig. 1a, lower panel). 
Fragment M-4 features a cluster of four conserved 'T-Q-X-F' motifs that constitute binding sites 
for the FHA domain of the ubiquitin ligase RNF8 following phosphorylation by ATM 17-19. 
Fragment M-1 contains two conserved TQ motifs: one at the very N-terminus of Mdc1 (Thr-
4/Gln-5) and one within the FHA domain (Thr-98/Gln-99). Thr-4 appears to be the major site of 
ATM phosphorylation since a deletion mutant of M-1 lacking the first 18 amino acids was not 
phosphorylated by ATM in vitro (Supplementary Fig. 1) while a point mutation altering Thr-4 
to Ala (T4A) resulted in a protein that could no longer be phosphorylated by ATM in vitro (Fig. 
1b). 
In order to investigate Thr-4 phosphorylation in vivo, we raised a phosphospecific 
antibody (pT4) directed against a pThr-4 peptide derived from the Mdc1 N-terminus. The 
antibody recognized the in vitro phosphorylated M-1 fragment and cross-reacted only minimally 
with the unphosphorylated form of M-1 (Fig. 1b, third panel). Moreover, the antibody did not 
recognize the T4A mutant M-1 fragment, nor did it recognize the repeating TQxF motifs within 
fragment M-4 (Supplementary Fig. 2) either before or after ATM phosphorylation, indicating 
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clear specificity for the pThr-4 site. We then exposed U2OS cells to various doses of IR and 
analyzed total cell extracts by immunoblotting with the pT4 antibody. The antibody cross-reacted 
with several proteins in total cell extracts, but one band (migrating at approximately 250 kDa) 
only emerged in extracts derived from cells that had been treated with IR. The intensity of this 
band increased with increasing dose of IR (Fig. 1c - left). Stripping and re-probing the blot with 
an antibody against human Mdc1 revealed that the protein recognized by the pT4 antisera 
overlapped with at least one of the Mdc1 size variants. Time course analysis showed that 1 h post 
irradiation, phosphorylation levels were maximal and then slowly decreased to background levels 
after 21 hours (Fig. 1c - right panels). 
To exclude the possibility that the pT4 antibody cross-reacted with another protein 
phosphorylated in response to IR, we subjected Mdc1–/– mouse embryonic fibroblasts and control 
(Mdc1+/+) cells to various doses of IR and analyzed total cell extracts by immunoblotting using 
the pT4 antibody. In extracts prepared from irradiated Mdc1+/+ MEFs, a clear signal appeared on 
polyacrylamide gels at the position where mouse Mdc1 would be expected. No such signal was 
detected in extracts derived from irradiated Mdc1–/– cells, indicating that the protein recognized 
by the pT4 antibody indeed corresponds to Mdc1 (Fig. 1d). 
Mdc1 phosphorylation in response to IR is ATM-dependent 3-5. Consistent with this, no 
Mdc1 signal was detected by the pT4 antibody in extracts from irradiated cells that had been pre-
treated with a specific ATM inhibitor or with a combination of ATM and DNA-PKcs inhibitors, 
while the signal was still present, albeit weaker, when the cells had been pre-treated with the 
DNA-PKcs inhibitor alone (Fig. 1e). Together, these data suggest that Mdc1 contains a 
conserved PIKK target site at its very N-terminus and that, in response to IR, this is mainly 
targeted by ATM in vivo.  
 
The phosphorylated N-terminus of Mdc1 binds to its own FHA domain.  
To understand the functional implication of Mdc1 Thr-4 phosphorylation, we carefully 
analyzed the amino acid sequence surrounding the PIKK target site. Besides the TQ motif, 
several additional amino acids are conserved, most notably an isoleucine three residues C-
terminal to the phosphoacceptor threonine (Fig. 1b). This is intriguing since pT-X-X-I was 
previously shown to constitute a favoured motif for certain classes of FHA domains 20. Indeed the 
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entire N-terminal motif (M-E-D-pT-Q-A-I) resembles that derived for the Mdc1 FHA domain by 
oriented library screening in these earlier studies (Fig. 2a). In order to test whether the 
phosphorylated N-terminus of Mdc1 could serve as a binding site for an FHA domain-containing 
protein, we designed a phosphopeptide comprising the first 12 N-terminal residues of human 
Mdc1 phosphorylated on Thr-4. The phosphopeptide and its unphosphorylated derivative were 
coupled to magnetic beads and used to pull down proteins from Hela nuclear extracts. Both 
peptides retrieved several proteins that appeared as clear bands on a SDS polyacrylamide gel 
(Supplementary Fig. 3). At least three proteins were pulled down by the phosphopeptide only, 
but not by its unphosphorylated counterpart (Supplementary Fig. 3). Most prominent were two 
bands of ~250kDa identified as Mdc1 itself by Western blot analysis with an antibody against 
human Mdc1 (Fig. 2b). The other two bands at ~150 kDa and ~80 kDa were RAD50 and 
MRE11, respectively. Together with our previous finding that Mdc1 exists in a complex with 
MRN in Hela nuclear extracts 8,15, these results indicate that Mdc1 may be the predominant 
interaction partner of its own phosphorylated N-terminus.  
Of the two phosphospecific protein binding domains within Mdc1 (Fig. 1a), 
phosphopeptide pull-down experiments with bacterially expressed GST fusion proteins of these 
regions showed that only the FHA domain bound tightly and specifically to the Mdc1 N-terminal 
phosphopeptide, with no significant interaction detectable for the C-terminal BRCT-repeat region 
(Fig. 2c). Furthermore, we were able to demonstrate high affinity binding of purified Mdc1 FHA 
to a synthetic phosphopeptide encompassing the Thr-4 motif by isothermal titration calorimetry 
(ITC). Interestingly, these data could only be satisfactorily fit using a model incorporating two 
independent phosphopeptide binding sites (Fig. 2d; see below). Thus, these results establish that 
Mdc1 interacts directly with its own phosphorylated N-terminus via the N-terminal FHA domain 
and, additionally suggest that it does so in a manner that differs somewhat from pThr-dependent 
FHA interactions described previously. 
 
The Mdc1 FHA domain forms a dimer  
In order to characterize the Mdc1 FHA-pThr 4 interactions further, we determined the 
structures of both free and phosphopeptide-bound forms at high resolution by X-ray 
crystallography. The pThr-4 phosphopeptide complex was solved using the single wavelength 
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anomalous diffraction method with crystals grown from selenomethionine-substituted Mdc1 
FHA domain, and a synthetic peptide in which Ala-6 was also replaced by selenomethionine, an 
approach we have described previously 21. The refined coordinates of the complex were then used 
to solve the structure of the peptide-free form by molecular replacement. Data collection and 
refinement statistics are shown in Table 1 along with representative electron density for residues 
at the edge of the FHA dimer interface (Fig. 3a). 
As expected, the Mdc1 FHA domain adopts an 11-stranded β-sandwich fold that is 
characteristic of these signaling modules (Supplementary Fig. 4). Strikingly, we observed two 
FHA domains in the crystallographic asymmetric unit in both peptide-free and bound forms, each 
similarly arranged around a pseudo 2-fold non-crystallographic symmetry axis (Fig. 3b; 
Supplementary Fig. 5). Although other FHA-FHA lattice interactions are observed in the two 
crystal forms, the non-crystallographic interaction surface is the most extensive burying a total of 
~900Å2/dimer in each case. Of these, ~600Å2 are contributed by non-polar atoms from the side-
chains of Phe 37, Leu 101, Leu 120, Leu 122 and Leu 127 (Fig 3c), all highly conserved in 
available sequences of Mdc1 orthologues (Fig. 3d). Together these residues form a hydrophobic 
cluster on one face of each FHA β-sandwich that is tightly packed with high surface 
complementarity at the FHA-FHA interface.  
In the light of these observations, we examined the solution behaviour of the isolated 
FHA by size-exclusion chromatography and multi-angle laser light scattering (SEC-MALLS) that 
is able to conveniently measure shape-independent and accurate molecular weights. This showed 
significant self-association of the Mdc1 FHA domain with an apparent molecular weight of 18.3 
+/- 0.06 kDa, some 40% greater than the calculated monomer mass of 12.8 kDa (Fig. 3e). 
Moreover, a double mutation, L120E/L127E, resulted in a significant reduction in apparent 
molecular weight (14.3 kDa; Fig. 3e) presumably due to juxtaposition of repulsive charges at the 
interface. Thus, we conclude that the dimeric arrangement observed in the crystal structures is 
likely to be representative of the dimer we observe in solution.  
 
Thr-4 phosphorylation stabilizes Mdc1 FHA domain dimerization 
 The structure of the Mdc1 FHA/phosphopeptide complex (Fig. 4a) shows a binding mode 
for the pThr-4 motif resembling that seen in several previously reported FHA domain complexes. 
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The phosphothreonine is held by a network of hydrogen-bonds with the highly conserved Arg-58 
and Ser-72 side-chains along with accessory interactions with the less-well conserved Lys-73 
(Fig. 4b). Ile-7 occupies the pThr +3 position that has been shown to represent a major 
determinant of FHA specificity 20 and interacts with the FHA domain through a shallow pocket 
formed by side-chains of residues 70, 96, 124 and 125. Most interestingly, Trp-9 that is present in 
all available sequences of Mdc1 orthologues, is the last peptide residue visible in electron density 
maps and packs into a cleft formed at the edge of the FHA-FHA interface. Here, the Trp-9 indole 
side-chain packs against Pro-103 and the aliphatic portion of Arg-102 from the second protomer. 
Due to the fact that the local 2-fold symmetry is imperfect, the FHA domain interactions of the 
Trp-9 side-chain from non-crystallographic symmetry-related peptide are still significant but less 
extensive, potentially explaining the two binding sites observed in ITC measurements. 
Regardless, the structural data strongly suggest that pThr motif binding might contribute to the 
overall stability of the dimeric complex and further SEC-MALLS analysis (Fig. 4c) clearly 
showed that addition of the pThr-4 peptide substantially increases the apparent weight-averaged 
molecular weight to within ~90% of that calculated for a fully dimeric, peptide-bound complex. 
Consistent with the structural location of Trp-9 at the FHA-FHA interface, a peptide variant 
containing a W9A substitution results in no significant dimer stabilization. Thus, accessory 
interactions mediated by Trp-9 of the bound phosphopeptide seem to directly contribute to Mdc1 
FHA domain dimerization. 
These structural and hydrodynamic data reveal an unusual dimeric FHA domain 
architecture that is stabilized through binding of each FHA domain in trans to a motif 
representing the ATM-phosphorylated Mdc1 N-terminal region. Such a head-to-tail model is 
attractive since we note that the conserved and highly acidic region (residues 10-18) C-terminal 
to Thr-4 could potentially interact with an equally conserved basic patch adjacent to the pThr-4 
binding site but located on the adjacent protomer of the Mdc1 dimer (Fig. 4d). Nonetheless, we 
realized that other arrangements are possible in the normal context where the N-terminal motif is 
physically attached to the FHA through the intervening linker region (Fig. 4e). In particular the 
peptide-binding data did not eliminate the possibility of polymerization of the intact molecule, 
nor did they exclude intra-molecular binding of the pThr-4 motif to its own FHA domain, which 
could potentially disrupt the weakly associated un-phosphorylated dimer. This latter idea is 
particularly relevant since we have observed just such an intra-molecular regulatory association 
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in the Rv1827 FHA-domain protein from M. tuberculosis 22. In order to distinguish between these 
possibilities, we used expressed protein ligation technology to generate a specifically and 
stoichiometrically Thr-4-phosphorylated sample (Fig. 4f - left panel). In doing so we noticed that 
Cys-26, which could potentially act as an N-terminal nucleophile, is located immediately C-
terminal to Arg-25. Thus by limited tryptic cleavage of Mdc1 (residues 1-138), we were able 
generate a C-terminal FHA-containing fragment with an N-terminal Cys-26 which could be 
efficiently ligated to a pThr-4 phosphopeptide (residues 1-25) synthesized with a protected C-
terminal thioester 23. SEC-MALLS analysis of this material reported an apparent molecular 
weight of 31.2 kDa, essentially identical to the formula mass of the fully dimeric phosphorylated 
fragment (31,110 Da) (Fig. 4f - right panel). Thus, we conclude that pThr-4 phosphorylation 
results in tight Mdc1 dimerization through a head-to-tail mechanism. 
 
Mdc1 self-association occurs in human cells and is pThr-4-dependent 
We next asked whether the homodimeric, head-to-tail dimer also occurs in cells. First, we 
used differentially tagged Mdc1 fragments to detect homotypic interaction by co-
immunoprecipitation. As shown in Fig. 5a, a Flag-tagged Mdc1 fragment (1-800) efficiently 
interacted with an identical Myc-tagged fragment. An N-terminal Mdc1 fragment lacking the 
BRCT domains was used to avoid avid association of Mdc1 with DNA damage-induced 
chromatin. Surprisingly, interaction between the two fragments was not completely dependent on 
IR treatment. However, when we probed the membranes with the pT4 antibody, we noticed that 
transiently expressed Mdc1 (1-800) fragment was constitutively phosphorylated on Thr-4 even 
without prior irradiation of the transfected cells (data not shown). Since Thr-4 phosphorylation of 
endogenous Mdc1 is clearly DNA-damage dependent (Fig. 1) we assume that this effect is a 
result of the transfection procedure 24. Indeed, this effect may have been responsible for earlier 
observations of pThr-68-dependent oligomerisation of transiently transfected Chk2 in the absence 
of DNA-damage 25.  Nevertheless, mutation of either the FHA domain (R58A) or the phospho-
epitope (T4A) led to a significant reduction of the interaction between Flag-tagged and Myc-
tagged Mdc1 (1-800) and concomitant mutation of both the FHA domain and Thr-4 resulted in a 
complete loss of binding. 
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On the basis of the foregoing, we reasoned that if DNA damage-induced Mdc1 
dimerization occurs via the FHA domain, we should detect partial recruitment of the FHA 
domain to sites of DSBs through association with endogenous Mdc1. Moreover, this recruitment 
should be diminished by mutations in either the FHA domain or at the pThr-4 site. To circumvent 
limitations of the static assessment of IRIF formation in fixed cells, we used an integrated 
imaging unit that combines microlaser-assisted generation of spatially defined DSB areas in 
mammalian cells with rapid, continuous and interactive image acquisition 26,27. Since we and 
others have previously observed that overexpression of the Mdc1 FHA domain interferes with 
accumulation of DDR proteins (including Mdc1 and the Mre11/Rad50/Nbs1 complex) at sites of 
DSBs 5,10,28, we also generated a panel of cell lines derived from checkpoint-proficient U2OS 
cells carrying stably integrated, tetracycline-regulated expression cassettes directing the 
expression of the Mdc1 FHA domain fused to enhanced yellow fluorescent protein (EYFP). 
Significantly, when expressed at low levels, the Mdc1 FHA domain is recruited to microlaser-
induced DNA damage (Fig. 5b). The real-time measurements revealed a rapid accumulation of 
the fusion protein around the laser-generated, DSB-containing, subnuclear tracts (Fig. 5c), with a 
detectable increase in fluorescence in the damaged nuclear compartments within 20-30 seconds 
(Fig. 5c, first panel). Subsequently, the fusion protein underwent a rapid accumulation in the 
DSB regions, and reached a steady-state by 8-10 minutes after laser exposure. Importantly, no 
increase in fluorescence was observed in DSB-containing laser tracks in Mdc1-depleted cells, 
indicating that EYFP-FHA domain accumulation is strictly Mdc1-dependent (Fig. 5d). 
Moreover, no accumulation was detectable in cells that express T4A or the R58A and L120/127E 
mutant derivatives of the FHA domain (Fig. 5d). Thus, these data reveal that FHA accumulation 
to microlaser-induced DNA damage in living human cells mirrors the in vitro requirements for 
Mdc1 dimerization. We therefore conclude that Mdc1 dimerization in response to DNA damage 
occurs in vivo in a manner that is consonant with our structural data. 
 
Discussion 
Mediator proteins perform a variety of crucial roles in many, if not all aspects of the 
response to DNA-damage. Although these molecules are essentially unrelated, oligomerisation 
now appears to be core feature of their activities and 53BP1, along with budding yeast Rad9 and 
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fission yeast Crb2 have all been shown to self-associate albeit through different mechanisms. 
Rad9 oligomerises via BRCT interactions with phosphosites generated by the ATR orthologue, 
Mec1, in a process that promotes activation of the Rad53 checkpoint kinase 13,29. In contrast Crb2 
and 53BP1 dimerization appear to be independent of any post-translational modification 12,14,30,31. 
To date, the oligomeric status of Mdc1 has not been examined. Here, we have presented a 
molecular description of FHA-mediated Mdc1 dimerization in response to ATM phosphorylation 
following DNA damage.  
Our observation of phospho-independent FHA dimerization is intriguing. Previous 
sequence comparisons have identified a patch of low-level conservation associated with β-strands 
9 and 10 and the connecting loop of a subset of FHA domains, leading to the suggestion that this 
may act as a self-interaction surface 32. Our structure now shows that this putative surface 
substantially overlaps with the Mdc1 dimer-forming region (Supplementary Fig. 6) and we also 
show that mutations within this region disrupt FHA-FHA interactions in vitro (Fig. 3d) and in 
living human cells (Fig. 5e).  Similarly, weak self-association of the isolated FHA domain of the 
Chk2 kinase 23 has recently been shown to arise from a dimeric FHA domain architecture 33 that 
appears to be related to but distinct from that of Mdc1 consistent with substantial divergence at 
the sequence level. Although the structural basis for Chk2 dimer stabilization by ATM 
phosphorylation remains elusive, these data, together with our recent observation that a similar 
region of a mycobacterial FHA domain mediates phospho-independent intermolecular 
interactions with several physiological targets 22, support a more expansive role for the β-
sandwich architecture in FHA-mediated interactions than has previously been assumed. 
Functionally, our observation that a major binding partner for the Mdc1 FHA domain is 
Mdc1 itself is of major significance and suggests several ways in which FHA binding activity 
may be both positively and negatively regulated (Fig. 6a-c). Firstly, pThr-4 mediated 
dimerization would be expected to occlude the canonical FHA domain phospho-binding surface 
and restrict the availability of pThr-4 itself (Fig. 6a). Such a 'bind and release' mechanism could, 
in principle, operate for any Mdc1 binding partner containing a suitable pThr-containing motif. 
However, it does potentially resolve the paradoxical observations that Chk2 is highly mobile in 
DNA-damaged nuclei prior to and following its activation at dsDNA break sites 26 in spite of a 
direct interaction of Chk2 pThr-68 with the Mdc1 FHA domain 3 that would otherwise retain 
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monomeric, pThr-68 forms of Chk2 within regions of damage. Similarly, formation of the tight 
pThr-4 Mdc1 dimer would also occlude the FHA-FHA interfacial region that could function as a 
phospho-independent binding surface in the weakly self-interacting Mdc1 FHA prior to Thr-4 
phosphorylation (Fig. 6b). Consistent with this idea, and as mentioned above, we have recently 
shown that part of this FHA domain surface can function in just such a fashion in other signaling 
contexts 22. Finally, we surmise that Mdc1 dimerization might create new composite phospho-
independent surfaces spanning both FHA domains (Fig. 6c) and note that such an extensive, 
negatively charged surface is evident in our crystal structures (Supplementary Fig. 7). Indeed a 
role for phospho-independent interactions implied by the latter two models likely may have 
significance for the previously described in vitro interaction of the Mdc1 FHA produced as a 
GST-fusion with bacterially expressed, and thus un-phosphorylated Rad51 11. 
Finally, from a more macroscopic viewpoint, a major effect of Mdc1 Thr-4 
phosphorylation is to stabilize formation of a ~4000 residue dimeric super-scaffold. Although the 
major means by which broken DNA ends are maintained in proximity for efficient repair is 
through the bridging function of the MRN complex 34, it may be that Mdc1 dimers play a 
contributing role in stabilizing more global structure within chromatin loops containing damage 
sites 35-37. Such a 'velcro' model may also contribute to an overall modulation of local chromatin 
compaction, thereby facilitating retention of downstream repair factors in this compartment. This 
model is particularly attractive since Mdc1 has long been known to occupy large areas of 
chromatin flanking double-stranded DNA break sites.  
In conclusion, the last ten years or so have seen a considerable expansion in our 
appreciation of the fundamental importance of post-translational modifications, particularly 
serine/threonine phosphorylation, in pathways of DNA-damage dependent checkpoint 
establishment and assembly of repair and signaling complexes. Mdc1 has emerged as a focal 
point for many of these processes, functioning as a scaffold and adaptor in various contexts. We 
now reveal an additional and unsuspected level of Mdc1 regulation through DNA-damage and 
phosphorylation-dependent FHA domain dimerization, suggesting a number of ways in which 
this phenomenon might contribute to Mdc1 activities in these pathways. Thus, our observations 
not only emphasise and extend the significance of mediator self-association, but also provide the 
first insights into how this can occur at a structural level.  
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Methods 
Plasmids 
Human Mdc1-GST constructs were previously described 15 Human Mdc1 (aa 1-800) was 
generated by PCR and C-terminally tagged with HA/FLAG and Myc, respectively, and cloned 
into pcDNA3.1 (+) mammalian expression vector (Invitrogen). The Mdc1 FHA domain-
containing fragment (aa 1-154) was amplified by PCR and cloned into a modified pEYFP-nuc 
vector (Clontech), in which two tetracycline-repressor binding elements were inserted between 
promotor and coding sequences to generate an inducible expression cassette 8. Point mutations 
were introduced by PCR-based methods or using the QuikChange Site-Directed Mutagenesis kit 
(Stratagene).  
Protein expression and purification 
DNA fragments encoding human Mdc1 residues 1-138, 19-138 or 27-138 were amplified from a 
Mdc1 cDNA clone and ligated into BamH1/Xho1 digested pGEX-6P1. GST fusion proteins were 
affinity purified on glutathione-4B resin (Amersham) and cleaved from the affinity resin with 
rhinovirus 3C protease overnight at 4°C. Cleaved Mdc1 fragments were further purified by gel-
filtration chromatography on Superdex 75.  
Crystallisation and X-ray data collection 
Crystals of peptide-free Mdc1 (27-138) were grown by microbatch methods under Al's oil 
at 18°C at a protein concentration of 10 mg/ml mixed with an equal volume of 1.32 M 
ammonium sulphate, 50 mM sodium acetate pH 4.6 and 5% v/v methyl-pentanediol. Complex 
crystals were grown from 1:1 complexes of selenomethionine substituted Mdc1 (19-138) with 
pThr-4 peptide containing a selenomethionine substituent at the pT+2 position, at a concentration 
of 15 mg/ml, mixed with an equal volume of 25% v/v ethanol, 0.1 M sodium acetate pH 5.5. 
Crystals were cryo-protected in mother liquor supplemented with 25 % v/v glycerol (peptide-
free) or 17.5 % v/v ethylene glycol/10 % v/v ethanol prior to data collection.  
Structure solution and refinement 
The structure of the selenomethionine peptide complex was solved by the single-wavelength 
anomalous diffraction (SAD) method using data collected on beamline 10.1 at the SRS 
Daresbury, UK. Four selenium sites were located and phases refined by SOLVE/RESOLVE 38. 
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The resulting map was readily interpretable allowing an essentially complete model for the two 
complexes in the asymmetric unit. The resulting FHA domain structure was then used to solve 
the non-complexed crystal form by molecular replacement using PHASER 39. Model-building 
was carried out with 'Coot' 40 and both structures were refined using REFMAC5 41. 
Cell culture and gene transfer 
Mdc1-/- and Mdc1+/+ MEFs were gifts from J. Chen (Yale University, New Haven, CT). U2OS, 
HEK 293T and MEFs were grown in D-MEM (Invitrogen) supplemented with 10% FCS (Gibco) 
and streptomycin/penicillin (100 U/ml, Gibco). Transfection of plasmids was done using either 
FuGene 6 (Roche) or calcium phosphate. U2OS-TetOn cells stably expressing the tetracycline 
repressor were generated by transfection of EYFP-tagged Mdc1-FHA domain following selection 
in G418-containing medium (Calbiochem). The siRNA oligonucleotides against endogenous 
human Mdc1 were purchased from Ambion (siRNA ID: 21738) containing the following 
sequence: sense 5’-GGAUCACACAAAGAUUAGAtt and antisense 5’-
UCUAAUCUUUGUGUGAUCCtt. SiRNA transfections were performed using Lipofectamine 
RNAiMAX (Invitrogen) according the manufacturer’s protocol. DNA damage was induced in a 
Faxitron X-ray cabinet at 5-10 Gy/min. or by means of single-cell laser microirradiation (see 
below). 
Antibodies  
 The mouse monoclonal γH2AX antibody was obtained from Millipore and the rabbit 
polyclonal c-Myc antibody (sc-789) from Santa Cruz Biotechnology. The rabbit polyclonal 
FLAG antibody and the anti-FLAG M2 affinity gel, used for co-immunoprecipitation, were 
purchased from Sigma. Rabbit polyclonal Mdc1(889) and sheep polyclonal Mdc1(3835) 
antibodies were raised against Mdc1-FHA–GST as described previously 5. The phosphospecific 
antibody Mdc1 'pT4' was raised in rabbit against the phosphopeptide MEDT(P)QAIDWDVC and 
affinity puried using the phosphorylated and non-phosphorylated peptide (Eurogentec). Rabbit 
polyclonal ATM antiserum for ATM immunoprecipitation was a kind gift from Graeme Smith 
(KuDOS Pharmaceuticals, Cambridge, UK). 
Biochemical analysis 
Hela nuclear extract was purchased from Cilbiotech (Mons, Belgium). Mdc1-GST 
fragments were affinity purified on glutathione-Sepharose (GE Healthcare Biosciences) as 
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described previously 15. For peptide pull down analysis, the C-terminally biotinylated 
phosphopeptide MED[pT]QAIDWDAE[KBtn] (Sigma) was used. Where indicated, 25 nmol of 
the peptide were pre-incubated with 100 U ? phosphatase (New England BioLabs) at 30°C for 
20 min. Peptide pull down analysis was done as described 8. 
For in vitro ATM kinase assays, ATM was immunoprecipitated with a rabbit polyclonal 
ATM antiserum 16 from HeLa nuclear extract (Cilbiotech) in IP buffer (25 mM HEPES pH 7.4, 
250 mM KCl, 2 mM MgCl2, 10% glycerol, 0.1% NP-40, 0.5 mM EDTA, 1 mM NaF, 1 mM β-
glycerophosphate). The immunocomplex was subsequently bound to Protein A-Sepharose beads 
(GE Healthcare). The kinase assay was performed by adding 1 µg GST-Mdc1 (aa 1-154) to the 
beads in ATM-kinase buffer (50 mM HEPES pH 7.4, 150 mM NaCl), 4 mM MnCl2, 6 mM 
MgCl2, 10% glycerol, 1 mM DTT, 1 mM NaF, 1 mM β-glycerophosphate, 0.5 mM ATP and 10 
µCi γ-[32P]ATP) and incubating for 30 min at 30°C. Gels were analyzed by autoradiography and 
GelCode (Pierce) or Coomassie blue staining. ATM inhibitor KPL0064 and DNA-PK inhibitor 
NU7026 were a kind gift from Graeme Smith (KuDOS Pharmaceuticals, Cambridge, UK) and 
were used at 10 µM and 20 µM, respectively. 
Expressed protein ligation 
Purified Mdc1 1-158 was digested with trypsin (Promega) at a ratio of 1:250 w/w 
enzyme:substrate to yield a 112 residue fragment (26-138) containing the FHA domain and part 
of the preceding linker with Cys-26 at its N-terminus. Synthesis of a C-terminally protected 
pThr-4 peptide (MEDpTQAIDWDVEEEEETEQSSESLR-SBn) and in vitro ligation to the Mdc1 
26-138 fragment were carried in 200 mM phosphate buffer pH 8.0, 150 mM NaCl, 10mM TCEP, 
2% w/v 2-mercaptoethanesulphonic acid overnight at room temperature. 
SEC-MALLS 
Samples were applied at a concentration of 80-100 µM to a Superdex 75 10/300 GL 
column mounted on a Jasco HPLC and equilibrated in 20 mM Tris-HCl pH 8.3, 150 mM NaCl 3 
mM DTT at a flow rate of 0.5 ml/min. Scattered light intensities of the column eluate were 
recorded at sixteen angles using a DAWN-HELEOS laser photometer (Wyatt Technology Corp., 
Santa Barbara, CA) and protein concentration of the eluted peak fractions were determined from 
the refractive index change (dn/dc = 0.186) using an OPTILAB-rEX differential refractometer 
equipped with a temperature-regulated flow cell at 25°C. The weight-averaged molecular weights 
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of proteins and complexes within the elution peaks were determined using the ASTRA software 
version 5.1 (Wyatt Technology Corp., Santa Barbara, CA).  
Isothermal titration calorimetry 
ITC was carried out using a VP-ITC calorimeter (MicroCal, USA). Protein and peptides were 
equilibrated with a buffer containing 20 mM Tris-HCl pH 8.3, 150 mM NaCl, 0.5 mM TCEP. 
Typically, 10 µl aliquots of peptide at a syringe concentration of 0.5 mM were titrated over 30 
injections into Mdc1 FHA domain samples at a concentration in the ITC cell of 50 µM. Data 
were corrected for heats of dilution and analysed using the Origin 5.0 software. Phosphopeptides 
were synthesized by Dr. W. Mawby (University of Bristol, UK). 
Co-immunoprecipitation  
HEK 293T cells were transiently co-transfected with pcDNA3.1-Mdc1(800)-FLAG and 
pcDNA3.1-Mdc1(800)-Myc or the T4A, R58A, T4A/R58A mutants respectively using calcium 
phosphate. 48 h later, cells were mock- or IR-treated with 10 Gy. After 45 min, cells were lysed 
in NP-40 buffer (50 mM HEPES-KOH pH 7.9, 100 mM NaCl, 1mM EDTA, 1mM DTT, 0.5 % 
NP-40, 20% glycerol, PMSF, Leupeptin, Pepstatin A, Bestatin, 10 mM β-glycerophosphate and 1 
mM NaF) for 15 min at 4°C and subsequently centrifuged at 14 000 rpm for 30 min at 4°C. 
Proteins in the supernatant were immunoprecipitated with anti-FLAG affinity gel (Sigma) in IP-
buffer (see NP-40 buffer, but use of 40 mM HEPES-KOH pH 7.4, 0.05 % NP-40, no glycerol, no 
DTT) for 4h at 4°C. Immunocomplexes were washed three times in IP-buffer, boiled in SDS 
sample buffer and loaded on an SDS-polyacrylamide gel. Protein analysis was performed with 
standard immunoblot methods as described above. 
Micro-irradiation and single-cell analysis 
 In order to generate DSBs in defined nuclear volumes laser microirradiation was performed 
with a MMI CELLCUT system containing a 355 nm UVA laser (55 Hz, Molecular Machines & 
Industries, Switzerland) coupled to an Olympus IX71 microscope station and focused through an 
LUCPLFLN 40X objective. The MMICELLTOOLS software with MMIUVCUT plug-in assisted 
the laser operation using an energy output of 55% (unless stated otherwise). Prior to laser 
irradiation, cells were grown on coverslips in cell culture dishes in the presence of 10 ?M BrdU 
(Bromodeoxyuridine; Sigma) for 24 h. Expression of EYFP-MDC-FHA constructs in U2OS-
TetOn cells was induced for 0.5 – 2 h with 1µg/ml Doxocycline. Coverslips were then transferred 
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into LabTek chamber slides (Nunc) and mounted on the microscope stage for irradiation. After 
irradiation, cells were placed back in the incubator for 30-60 min before fixation.  
 In case of live cell imaging, EYFP-Mdc1-expressing cells were directly grown on LabTek 
chamber slides in the presence of 10 ?M BrdU for 24 h. Laser irradiation was performed with a 
337 nm PALM microlaser workstation (30 Hz, Palm MicroBeam, Carl Zeiss Microimaging Inc.) 
mounted on an Axiovert 200 microscope (Zeiss) and focused through a LD 40x, NA 0.6 Zeiss 
Achroplan objective. The microlaser procedure was assisted by the PALMRobo-Software. 
Images were immediately recorded after laser treatment. 
For immunofluorescence analysis, cells grown on coverslips were fixed in 4 % 
paraformaldehyde for 20 min and permeabilized in 0.25 Triton X-100 in PBS for 15 min. After 
blocking in 10% FCS/PBS, cells were incubated in 5% FCS/PBS with the indicated primary 
antibodies for 1 h and secondary antibodies Alexa Fluor 568 (Molecular Probes) or Texas Red 
(Jackson Immuno Research) for 30 min. Finally, the coverslips were mounted with DAPI-
containing Vectashield (Vector Laboratories). Confocal image acquisition was performed on a 
Leica SP2 microscope with a 40 x (NA 1.25) oil immersion objective or on an LSM-510 (Carl 
Zeiss Imaging) microscope with a 40 x Plan-Apochromat (NA 1.3) oil immersion objective. 
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Figure Legends 
Figure 1 - ATM targets Mdc1 on a conserved threonine residue at its N-terminus.  
(a) In vitro ATM kinase assay of recombinant Mdc1 fragments. Top: Schematic representation of 
Mdc1’s domain architecture and of the GST-fusion fragments derived from its cDNA. Bottom: 
Upper panel: Coomassie blue stained polyacrylamide gel of the purified GST-fusion fragments. 
Bottom panel: Autoradiography of in vitro phosphorylated Mdc1 fragments 
(b) A conserved motif at the very N-terminus of Mdc1 is phosphorylated by ATM in vitro. Top: 
Sequence alignment of the Mdc1 N-terminus. The highly conserved Thr residue at position 4 
(T4) is highlighted by an arrowhead. Bottom: ATM-phosphorylation of fragment M-1 and the 
mutant T4A. AR: Autoradiograph; CB: Coomassie blue; IB: immunoblot; PS: Ponceau red 
(c) Left panel: Dose titration using the pThr-4 phosphospecific antibody (pT4). Right panel: 
Kinetics experiment using the pT4 antibody. The band corresponding to Mdc1 is highlighted by 
an arrowhead. 
(d) Mdc1+/+, Mdc1–/– MEFs were irradiated with various doses of IR. Extracts were probed with 
the pT4 antibody. 
(e) Mdc1 Thr-4 phosphorylation in response to IR is ATM-dependent. U2OS cells were pre-
treated with ATM inhibitor, DNA-PKcs inhibitor or a combination of both inhibitors. Cell 
extracts were probed with the phosphospecific pT4 antibody. 
 
Figure 2 - The phosphorylated Mdc1 N-terminus constitutes a recognition motif for 
the Mdc1 FHA domain. 
(a) The N-terminal Mdc1 pThr-4 sequence closely resembles the optimal binding motif derived 
previously 20 by oriented peptide library selection. Circled residues highlight exact matches. 
(b) Immunoblot analysis indicates that endogenous Mdc1 is efficiently pulled down by the pThr-
4 phosphopeptide. 
(c) Coomassie blue-stained PAGE of a pThr-4 phosphopeptide pull-down experiment using 
purified M-1 GST-fragment (containing the FHA domain) and purified M-8 GST-fragment 
(containing the BRCT domains). 
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(d) ITC binding isotherm for interaction of a synthetic pThr-4 peptide with recombinant Mdc1 
FHA domain. Data were analysed assuming one or two site binding which consistently favoured 
the latter model, showing tight, stoichiometric (1:1) binding to similar but non-identical sites. 
 
Figure 3 - Mdc1 FHA domain dimerization 
 
(a) Stereo view of a segment of omit electron density map (1.25σ) at the periphery of the FHA-
FHA interface from the 1.8Å resolution peptide complex. Protein residues are shown as stick 
representation and water molecules are shown as red spheres. 
(b) Ribbons representation of the dimeric arrangement observed in the peptide-free Mdc1 FHA 
crystal structure. The position of the local 2-fold symmetry axis is indicated. All structural 
representations were generated using PyMOL (http://pymol.sourceforge.net/). 
(c) FHA-FHA interactions are predominantly mediated by a conserved cluster of five 
hydrophobic residues from each protomer. 
(d) Interface residues are highly conserved in all available sequences of Mdc1 orthologues. The 
locations of β-strands observed in the structure are indicated in the lower panel, along with the 
positions of the four residues most highly conserved in the FHA domain family (circles). 
(e) SEC-MALLS analysis of the wild-type Mdc1 FHA (27-138) and a mutant form in which two 
residues that form the core of the observed dimer interface have been substituted with glutamate. 
The observed weight-averaged molecular weight of the mutant is substantially less than the wild-
type protein. The shorter retention time for the mutant may reflect a more extended shape for 
monomeric forms, or differential electrostatic effects on interaction with the column matrix. 
 
Figure 4 - Head-to-tail dimerization is stabilised by pThr-4  
(a) Structure of the Mdc1/pThr-4 peptide complex is shown as a Cα plot/surface representation 
with the peptide shown as sticks, viewed along the local 2-fold symmetry axis. 
(b) The phosphopeptide interacts with conserved FHA domain residues mainly through pThr-4 
and main-chain atoms from pT+1 and +3 residues. The Trp-9 indole nestles in a cleft formed at 
the interface between the two FHA domains in the dimer. 
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(c) SEC-MALLS analysis shows that a substantial stabilization of the Mdc1 FHA dimer by the 
pThr-4 peptide is greatly reduced by substitution of Trp-9 with alanine (W9A). 
(d) The sequence C-terminal to the pThr-4 motif (yellow) contains a highly conserved stretch of 
acidic residues highlighted in blue (top panel). These would be predicted to interact with arginine 
and lysine residues that are also conserved and form a basic patch adjacent to the binding site for 
the peptide C-terminus of the bound peptide (bottom). 
(e) Cartoon showing the three most likely effects of Thr-4 phosphorylation 
(f) Ligation of an extended pThr-4 peptide to trypsin-cleaved Mdc1 FHA (left) produces a 
stoichiometrically and specifically phosphorylated protein encompassing the entire N-terminal 
region that forms a tight dimer by SEC-MALLS analysis (right). Mo- observed molecular weight, 
Mc - calculated molecular weight. 
 
Figure 5 - Dimerization of the Mdc1 N-terminal region in vivo 
(a) The interaction between differentially tagged Mdc1 N-terminal fragments is dependent upon 
the intact FHA domain and Thr4 phosphorylation. 293T cells were transiently transfected with 
Flag-tagged Mdc1(1-800aa) and Myc-tagged Mdc1(1-800aa) wildtype and the indicated mutants, 
respectively. Protein complexes were immunoprecipitated with monoclonal anti-Flag agarose and 
immunoblotted with polyclonal anti-Myc and polyclonal anti-Flag antibodies. 
(b) The Mdc1 FHA domain is recruited to damaged chromatin regions. U2OS expressing a 
tetracycline-inducible EYFP-FHA(WT)TetOn fusion protein were treated with doxocyclin for 1 
hour and subjected to laser irradiation. Cells were fixed 30 min after irradiation and 
immunostained for γH2AX.   
(c) Kinetics of Mdc1 FHA domain recruitment. U2OS FHA(WT)-EYFPTetOn cells were incubated 
with doxocycline for 1h and subjected to laser irradiation. Time-lapse live cell microscopy was 
performed and images were taken at the indicated times. Note that for technical reasons, 0 min 
time point was taken about 20 sec after micro-irradiation. 
(d) Recruitment of Mdc1 FHA domain is dependent on endogenous Mdc1. U2OS 
FHA(WT)EYFPTetOn cells were either treated with control siRNA or siRNA against endogenous 
Mdc1. Cells were induced with doxocycline for 1h, subjected to laser irradiation and images were 
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taken 30 min thereafter. Cells were subsequently fixed and immunostained for γH2AX.  
(e) Recruitment of Mdc1 FHA domain is dependent on phospho-specific interaction between 
Thr4 and the FHA domain as well as on an intact hydrophobic interface between FHA 
monomers. U2OS FHA-EYFPTetOn cells expressing the wild type and indicated mutants were 
induced with doxocycline for 1h, subjected to laser irradiation and images were taken 30 min 
thereafter. Cells were subsequently fixed and immunostained for γH2AX.  
 
Figure 6 – Regulation of Mdc1 interactions through phospho-dependent and 
phospho-independent FHA domain surfaces by dimerization. 
 (a) Binding of Thr-phosphorylated partners such as Chk2 (gold) can occur through the canonical 
phospho-dependent surface on the Mdc1 FHA (green patch) that is subsequently occluded 
following Thr-4 phosphorylation and tight head-to-tail dimerization. 
(b) Interaction of phospho-independent binding partners (red) with some or all of the Mdc1 
dimerization interface residues (yellow) competes with weak FHA-FHA interactions in un-
phosphorylated Mdc1, but is occluded in the pThr-4 dimer. 
(c) Tight Mdc1 dimerization might create a contiguous phospho-independent binding surface 
(cyan) spanning the two FHA domains. 
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Table 1 - Crystallographic Statistics 
 
 Mdc1/pThr-4 (Se SAD) Mdc1 
Data Collection   
   Space group P212121 P212121 
   Cell dimensions (Å)   
    a, b, c (Å) 58.5, 59.9, 72.1 35.3, 54.7, 98.1 
 Peak  
   Wavelength (Å) 0.9790  
   Resolution (Å) 15.0 – 1.8 (1.86-1.80) 20.0 – 2.3 (2.40-2.30) 
   Rmerge (%) 3.7 (31.5) 8.4 (40.4) 
   < I/? (I) > 27.5 (2.1) 11.7 (2.8) 
   Completeness (%) 93.4 (55.3) 93.7 (90.2) 
   Redundancy  3.2 (2.1) 3.0 (2.9) 
   
Refinement   
   Resolution (Å) 15 – 1.8 15.0 - 2.3 
   No. reflections 21805 8461 
   Rwork/Rfree (%)b 21.3/24.0 23.8/27.1 
No. atoms   
   Protein 1741 1693 
   Peptide 134 - 
   Water 200 106 
B-factors (Å2)   
   Protein 24.5 48.6 
   Peptide 38.7 - 
   Water 36.6 53.4 
R.m.s deviations   
   Bond lengths (Å) 0.008 0.009 
   Bond angles (°) 1.2 1.3 
 
*Values in parentheses are for highest-resolution shell 
 
 
Refere 
 
66
67
68
69
70
71
72
Supplementary information 
 
The molecular basis of ATM-dependent dimerization of the MDC1 DNA-
damage checkpoint mediator 
 
 
 
 
 
Supplementary Figure 1 – Autoradiography of in vitro-phosphorylated N-terminal MDC1 
fragment comprising the FHA domain. In this fragment, two ATM/ATR consensus sites (TQ) 
are present (T4 and T98). However, only T4 is phosphorylated by ATM in vitro since M1 
(ΔN) lacking the N-terminal T4 is not phosphorylated.  
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Supplementary Figure 2 – The MDC1 pT4 antibody specifically recognized phosphorylated 
T4 but not the phosphorylated TQXF cluster. In vitro ATM kinase assay of recombinant 
fragments M1 (containing Thr-4), mutant M1-T4A and M4 (containing the MDC1 TQXF 
cluster).  
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Supplementary Figure 3 - Silver-stained SDS PAGE gel of proteins pulled down by the Thr-
4 phosphopeptide and its unphosphorylated derivative. The major bands present only in the 
phosphopeptide pull-down are highlighted by arrowheads.  
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Supplementary Figure 4 - Comparison of the Mdc1 FHA structure with that of human Chk2 
(PDB ID: 1GXC) reveals a similar, characteristic core FHA domain β-sandwich architecture. 
76
  
Supplementary Figure 5 - Least-squares superposition of the Mdc1 FHA domain dimer in 
the peptide-free (black) and pThr-4 peptide-bound (gold) structures, shown as Cα plots. The 
bound phosphopeptide is shown in stick representation. 
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Supplementary Figure 6 - Topology diagram (left panel) and surface representation (right 
panel) show that hydrophobic residues that form the conserved Mdc1 FHA-FHA interface 
(red circles) overlap with a putative self-interacting surface (blue) previously identified by 
sequence analysis (Lee et. al 2003).  
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Supplementary Figure 7 - Electrostatic surface representation of the Mdc1 FHA dimer 
viewed along the non-crystallographic 2-fold axis. Regions of positive potential are shown in 
blue and acidic regions in red. Association of the two FHA domains produces a continuous 
region of negative charge that extends across the dimer. 
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Adivalent FHA/BRCT-bindingmechanism couples the
MRE11–RAD50–NBS1 complex to damaged chromatin
Flurina J. Hari*, Christoph Spycher*, Stephanie Jungmichel, Lucijana Pavic & Manuel Stucki+
Institute of Veterinary Biochemistry and Molecular Biology, University of Zurich, Zurich, Switzerland
The MRE11–RAD50–NBS1 (MRN) complex accumulates at sites
of DNA double-strand breaks in large chromatin domains flanking
the lesion site. The mechanism of MRN accumulation involves
direct binding of the Nijmegen breakage syndrome 1 (NBS1)
subunit to phosphorylated mediator of the DNA damage check-
point 1 (MDC1), a large nuclear adaptor protein that interacts
directly with phosphorylated H2AX. NBS1 contains an FHA
domain and two BRCT domains at its amino terminus. Here, we
show that both of these domains participate in the interaction
with phosphorylated MDC1. Point mutations in key amino acid
residues of either the FHA or the BRCT domains compromise the
interaction with MDC1 and lead to defects in MRN accumulation
at sites of DNA damage. Surprisingly, only mutation in the FHA
domain, but not in the BRCT domains, yields a G2/M checkpoint
defect, indicating that MDC1-dependent chromatin accumulation
of the MRN complex at sites of DNA breaks is not required for
G2/M checkpoint activation.
Keywords: DNA double-strand breaks; chromatin; NBS1; MDC1;
G2/M checkpoint
EMBO reports advance online publication 12 March 2010; doi:10.1038/embor.2010.30
INTRODUCTION
Nijmegen breakage syndrome (NBS) is a rare autosomal genetic
disorder. NBS patients suffer from growth retardation, microcephaly,
dismorphal features, immunodeficiency and predisposition to cancer,
mainly lymphomas. Cells derived from NBS patients are radio-
sensitive, show chromosomal instability and cell-cycle checkpoint,
as well as apoptotic defects (van der Burgt et al, 1996).
The NBS gene codes for a 754-amino-acid protein named
NBS1 (p95; nibrin). It exists exclusively in a complex with two
enzymes: MRE11, a structure-specific nuclease, and RAD50, an
ATPase/adenylate kinase. Together, these three proteins form the
MRE11–RAD50–NBS1 (MRN) complex, a conserved and essential
DNA-damage response (DDR) factor that functions in many
cellular processes involving DNA double-strand breaks (DSBs),
including DSB repair, checkpoint signalling, DNA replication,
meiotic recombination and induction of apoptosis (Stracker et al,
2004; Difilippantonio & Nussenzweig, 2007).
The MRN complex accumulates at sites of DSBs in large
microscopically discernible subnuclear structures, usually referred
to as DNA-damage foci. The functional implication of this massive
accumulation at sites of DSBs is not yet fully understood. We and
others showed recently that focus formation by the MRN complex
is mediated by a direct interaction between NBS1 and phos-
phorylated mediator of the DNA damage checkpoint 1 (MDC1),
which is a large nuclear adaptor protein that specifically
recognises phosphorylated H2AX (gH2AX; Chapman & Jackson,
2008; Melander et al, 2008; Spycher et al, 2008; Wu et al, 2008).
The interaction between NBS1 and MDC1 is dependent on the
amino-terminal portion of NBS1 that contains the FHA domain
and interacts directly with a constitutively phosphorylated acidic
repeat region in MDC1, the SDT repeat (Chapman & Jackson,
2008; Melander et al, 2008; Spycher et al, 2008). The SDT repeat
region is characterized by conserved patches of 8–10 amino acids
comprising serine and threonine residues typically separated by an
aspartate and embedded further in an acidic sequence environ-
ment. This SDT region (referred to as the SDTD region in some
papers) interacts with the MRN complex in a phosphorylation-
dependent manner. In human MDC1, six SDT motifs were
identified and deletion of at least five of them leads to complete
abrogation of MRN foci formation (Melander et al, 2008; Spycher
et al, 2008). Analysis of NBS1 recruitment to sites of DSBs showed
that on expression of an MDC1 version lacking the SDT regions,
NBS1 only accumulates in micro-foci and is not found in the
broader chromatin compartments usually covered by gH2AX and
MDC1 (Chapman & Jackson, 2008). This indicates that the MRN
complex is recruited to DSBs in an MDC1-independent manner,
but its sustained interaction with the DSB-flanking chromatin
requires MDC1.
Interestingly, MDC1 and MRN exist in a complex even in
undamaged cells. This interaction is dependent on the activity of
the acidophilic casein kinase 2 (CK2), for which the SDT motifs
form consensus phosphorylation sites (Spycher et al, 2008; Wu
et al, 2008). Both serine and threonine residues in each SDT motif
are phosphorylated by CK2 in vivo and only doubly phosphory-
lated pSDpT motifs are able to mediate the interaction with NBS1
(Melander et al, 2008; Spycher et al, 2008).
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No structural information of full-length NSB1 is yet available,
but recent nuclear magnetic resonance (NMR) structural data
suggested that besides the FHA domain, NBS1 might also feature a
tandem BRCT domain at its N terminus (Xu et al, 2008). Similarly
to FHA domains, tandem BRCT domains have been shown to
act as phospho-specific protein–protein interaction modules
(Glover et al, 2004).
Here, we present evidence that both the NBS1 FHA domain
and the tandem BRCT domain interact specifically with phos-
phorylated MDC1. We show that single point mutations in key
residues in both the FHA and the tandem BRCT domain of NBS1
disrupt the interaction with MDC1 and abrogate the accumulation
and retention of the MRN complex at sites of DSBs. Surprisingly,
only a mutation in the FHA domain induces a significant G2/M
DNA-damage checkpoint defect, whereas mutation in the tandem
BRCT domain does not. Thus, our findings indicate that MDC1-
mediated accumulation of the MRN complex at sites of DSBs is
not required for G2/M checkpoint activation and strongly suggest
that the FHA domain of NBS1 might have additional, as yet
unidentified, interaction partners that mediate G2/M checkpoint
activation in response to DSBs.
RESULTS AND DISCUSSION
Both FHA and BRCT domains of NBS1 interact with MDC1
Until recently, sequence comparison and structure predication
algorithms indicated that the N-terminal region of NBS1 contained
an FHA domain and one single BRCT domain (reviewed in
D’Amours & Jackson, 2002). Three years ago, a second putative
BRCT domain at the N terminus of NBS1 was discovered by
means of a refined bioinformatic analysis (Becker et al, 2006). The
existence of two BRCT domains downstream from the FHA
domain at the NBS1 N terminus was partly confirmed by a
recently published NMR structure of the second BRCT domain
(Xu et al, 2008). Interestingly, there seems to be no spacer
between the FHA domain and the putative tandem BRCT domain,
indicating that these domains might form one single compact
globular structure (Fig 1A). Moreover, conservation of key
phospho-binding amino-acid residues in the BRCT tandem
domain suggests that like the FHA domain, it might act as a
phospho-specific protein–protein interaction module.
We and others have shown recently that the FHA domain of
NBS1 associates directly with a constitutively phosphorylated
region in MDC1, the SDT repeat region (Chapman & Jackson,
2008; Melander et al, 2008; Spycher et al, 2008). Mammalian
MDC1 contains a total of six SDT motifs, and at least three of these
are required for efficient MRN accumulation at sites of DSBs
(Spycher et al, 2008). This might indicate that more than one
binding site with affinity to the phosphorylated SDT region might
exist in NBS1. Thus, we tested whether the intact NBS1 BRCT
tandem domain was required for efficient association of NBS1
with the full-length phosphorylated SDT region. We phospho-
rylated (or mock-treated) the human glutathione-S-transferase
(GST)-tagged MDC1 SDT fragment and assessed its ability to
interact with in vitro-translated full-length NBS1 protein that
carried point mutations in key residues in its phospho-binding
FHA and BRCT tandem domains, respectively. As shown before,
full-length wild-type NBS1 interacted efficiently with the phos-
phorylated SDT region of MDC1 (Fig 1B; Melander et al, 2008;
Spycher et al, 2008). Interestingly, FHA domain single mutant
(R28A) and a BRCT tandem domain single mutant (K160M)
also showed residual SDT-binding activity. However, a double
phosphopeptide-binding mutant (R28A/K160M) failed to bind to
the phosphorylated SDT region (Fig 1B). This indicates that
both the FHA domain and the BRCT tandem domain are able to
interact with the phosphorylated MDC1 SDT region in vitro.
NBS1 does not exist on its own in the nuclei of mammalian
cells, as it is always associated with MRE11 and RAD50. Thus, our
assay conditions with the in vitro-translated NBS1 do not
accurately reflect a physiological situation where NBS1 is part
of a heterotrimeric complex. Therefore, we co-expressed all three
subunits of the MRN complex in insect cells and tested their
binding affinity to the phosphorylated SDT region of MDC1. Also
in the context of the intact MRN complex, wild-type NBS1 bound
efficiently to the phosphorylated SDT region (Fig 1C). Surprisingly,
neither the FHA mutant (R28A) nor the BRCT tandem domain
mutant (K160M) was able to associate with the phosphorylated
SDT region (Fig 1C). This indicates that when NBS1 exists in a
heterotrimeric complex with MRE11 and RAD50, both the intact
FHA domain and the BRCT tandem domain of NBS1 are essential
for efficient association with phosphorylated MDC1. It is not clear
why the NBS1 single mutants interacted with the phosphorylated
SDT region when translated in vitro but did not in the context of
the heterotrimeric MRN complex. However, it is possible that
when NBS1 is an integral part of the MRN complex, its N-terminal
phosphopeptide-binding region might be sterically less accessible
so that efficient association with the SDT region is only possible
when both the FHA domain and BRCT tandem domain are
contributing to the interaction.
As an intact NBS1 FHA domain and a BRCT tandem domain
seem to be essential for interaction with the MDC1 SDT region,
we next asked if both of these domains were also involved in
complex formation with MDC1 in mammalian cell extracts. We
co-expressed a Flag-tagged 800-amino-acid N-terminal fragment
of MDC1 (containing the SDT region) with Myc-tagged full-length
NBS1 wild type and a mutant derivative, respectively, and tested
their association by co-immunoprecipitation. Significantly, only
wild-type NBS1 interacted with the MDC1 fragment in extracts
prepared from the transfected cells, whereas neither the FHA and
the BRCT tandem domain single-mutants (R28A; K160M) nor the
double mutant (R28A/K160M) showed any significant binding
activity towards MDC1 (Fig 1D).
The BRCT domains of NBS1 are required for MRN foci
Next, we investigated whether the K160M mutation in the BRCT
tandem domain would also compromise the accumulation of the
MRN complex at sites of DSBs, as observed earlier for the FHA
domain mutant R28A (Cerosaletti & Concannon, 2003; Lukas
et al, 2004). We generated NBS-iLB1 fibroblast cell lines stably
transduced with wild-type and mutant NBS1 (supplementary
Fig S1A online). Then, we assessed nuclear foci formation
of NBS1 in these cell lines by immunofluorescence microscopy.
In NBS-iLB1 parental fibroblasts, no NBS1 staining was observed
(Fig 2A, top row). However, 81% of the cells stably transduced
with wild-type NBS1 showed focal accumulation of NBS1 1 h
after irradiation at 5Gy. By contrast, only 20% of cells
stably transduced with R28A NBS1 and 13% of cells stably
transduced with K160M NBS1, had a focal NBS1 staining
pattern (Fig 2A), thus indicating that sustained interaction of
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MRN complex with damaged chromatin requires the phospho-
peptide-binding capacity of both the FHA and tandem BRCT
domains of NBS1.
To develop these findings further, we used UV-laser micro-
irradiation to induce DSBs in subnuclear volumes (Lukas et al,
2004). Under these conditions, wild-type NBS1 accumulated
throughout the micro-irradiated nuclear compartments (Fig 2B).
However, both the R28A and K160M mutation prevented
binding of NBS1 to the gH2AX-coated areas, except for a
small fraction of the protein scattered along the irradiated path
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Fig 1 | Both the FHA domain and the tandem BRCT domain of NBS1 are required for the interaction with the phosphorylated SDT region of MDC1
in vitro. (A) Schematic representation of full-length human NBS1 and its domain composition. The enlarged area shows a sequence alignment of
the FHA and BRCT domains of human, mouse and Xenopus NBS1. The putative secondary structure of the first (amino-terminal) BRCT domain is
indicated by pale colours. The secondary structure of the second (carboxy-terminal) BRCT domain (indicated by bright colours) was derived from
Xu et al (2008). Phospho-interacting amino acids are highlighted in yellow. (B) Purified MDC1 GST-SDT fragment was preincubated with CK2 and
ATP. The fragment was then incubated with in vitro-translated 35S-labelled NBS1 wild type or mutants for 1 h, washed and resolved by SDS–PAGE
and autoradiography. (C) Purified MDC1 GST-SDT fragment was preincubated with CK2 and ATP. The fragment was then incubated with purified
MRN complex where the NBS1 subunit was either wild type or contained a point mutation in the FHA domain (R28A) or in the BRCT tandem domain
(K160M). Bound proteins were separated by SDS–PAGE followed by immunoblotting. The blots were probed with a polyclonal antibody against
NBS1. (D) Human embryonic kidney 293T cells were transiently transfected with Flag-tagged MDC1(800) fragment and Myc-tagged NBS1 wild type
and mutants, as indicated. Flag antibodies were used for co-immunoprecipitation and Myc antibodies for western blot analysis. CK2, casein kinase 2;
GST, glutathione-S-transferase; IP, immunoprecipitation; MDC1, mediator of the DNA damage checkpoint 1; MRN, MRE11–RAD50–NBS1 complex;
NBS1, Nijmegen breakage syndrome 1; SDS–PAGE, sodium dodecyl sulphate–polyacrylamide gel electrophoresis; wt, wild-type.
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(Fig 2B, enlarged areas). This indicates that phospho-specific
binding of both the NBS1 FHA domain and the BRCT tandem
domain to the MDC1 SDT region is essential for efficient
accumulation and retention of the MRN complex in damaged
nuclear areas.
G2/M checkpoint does not require BRCT domains of NBS1
We proposed previously that MDC1-mediated accumulation of
the MRN complex in chromatin regions flanking DSBs was
required for efficient activation of the G2/M DNA-damage
checkpoint. This was on the basis of the observation that point
mutations in the FHA domain that disrupt its phospho-specific
binding show partial G2/M checkpoint defects both in human and
mouse cells (Difilippantonio et al, 2005, 2007; Spycher et al,
2008). If this interpretation was correct, we would predict that the
K160M mutation in the NBS1 BRCT tandem domain also leads to
a G2/M checkpoint defect similar to the R28A FHA mutation,
because MDC1-binding and chromatin accumulation are as
severely compromised in the K160M mutant as they are in the
R28A mutant (see above). Surprisingly, however, we found that
several independent clones of NBS fibroblasts stably transduced
with K160M NBS1 activated the G2/M checkpoint almost as
efficiently as wild-type NBS1 (Fig 3; supplementary Fig S1B
online). This indicates that MDC1-binding and MDC1-mediated
accumulation of the MRN complex at sites of DSBs are not
required for activation of the G2/M checkpoint.
MRN foci formation is not required for the G2/M checkpoint
To verify the aforementioned conclusion, we exploited an earlier
observation that overexpression of a C-terminal fragment of
MDC1 comprising its gH2AX-binding C-terminal BRCT domains
yielded a strong dominant-negative effect on the accumulation
and retention of the DDR proteins at sites of DSBs (Stucki et al,
2005). We reasoned that if our conclusion was correct, we should
not observe a G2/M checkpoint defect on overexpression of the
MDC1 BRCT domains. To test this, we used a U2OS cell line
carrying a stably integrated, tetracycline-regulated, expression
cassette directing the expression of the MDC1 tandem BRCT
domain fused to yellow fluorescent protein (YFP). As observed
previously (Stucki et al, 2005), induction of YFP-BRCT expression
by the tetracycline analogue doxocycline (DOX) completely
abrogated MRN accumulation at sites of DSBs, as reflected by
both NBS1 foci formation (Fig 4A) and UV-laser micro-irradiation
(Fig 4B). However, induction of YFP-BRCT expression did not
trigger a measurable G2/M checkpoint defect after 1 and 3Gy of
irradiation, respectively (Fig 4C). Significantly, however, down-
regulation of endogenous MDC1 in this cell line still yielded a
significant G2/M checkpoint defect, irrespective of whether YFP-
BRCT expression was induced or not, thus supporting the previous
observation that MDC1 is required for G2/M checkpoint activa-
tion (Lou et al, 2003, 2006; Stewart et al, 2003). These data thus
support our conclusion that MDC1-mediated accumulation and
retention of the MRN complex at sites of DSBs is not required for
activation or maintenance of the G2/M checkpoint response.
Speculation
Here, we present a unique divalent FHA/BRCT-binding mechan-
ism that couples the MRN complex to gH2AX-enriched chromatin
regions that mark sites of DSBs, and we show for the first time to
our knowledge that phospho-binding activities of both the NBS1
FHA domain and the BRCT tandem domain are essential for focal
accumulation of the MRN complex at sites of DSBs in vivo. It is
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Fig 2 | The BRCT tandem domain of NBS1 is required for focal
accumulation of the MRN complex at sites of DSBs in vivo. (A) NBS-iLB1
fibroblasts and NBS-iLB1 fibroblasts stably transduced with wild-type,
R28A or K160M mutant NBS1, respectively, were irradiated at 5Gy. The
irradiated cells were incubated for 1 h, fixed with methanol and probed
with the indicated antibodies. Cells were then analysed by confocal
microscopy and nuclear foci-positive cells were counted for statistical
evaluation. (B) NBS-iLB1 fibroblasts stably transduced with wild-type, R28A
or K160M mutant NBS1, respectively, were micro-irradiated as described in
Methods. The irradiated cells were incubated for 1h, fixed with methanol
and probed with the indicated antibodies. Cells were then analysed by
confocal microscopy. DAPI, 40,6-diamidino-2-phenylindole; MRN,
MRE11–RAD50–NBS1 complex; NBS1, Nijmegen breakage syndrome 1.
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unknown why such a divalent binding mechanism has evolved,
but it is interesting to note that mutation in the NBS1 FHA domain
triggers a G2/M checkpoint defect, whereas mutation in the BRCT
tandem domain does not. This suggests that besides phosphory-
lated MDC1, the NBS1 FHA domain might have an additional, as
yet unidentified, binding partner that mediates G2/M checkpoint
activation in response to DSBs. While this paper was under
revision, it was shown that Schizosaccharomyces pombe Ctp1,
a protein that is involved in the resection of DSBs in the S and G2
phases of the cell cycle, interacts directly with the yeast Nbs1 FHA
domain in a mechanism that involves CK2-dependent phospho-
rylation of SDT-like motifs in Ctp1 (Lloyd et al, 2009; Williams
et al, 2009). Thus, CtIP, the human orthologue of Ctp1, might be a
promising candidate for an additional NBS1 interaction partner.
CtIP was shown previously to be required for efficient induction of
the G2/M DNA-damage checkpoint (Yu & Chen, 2004). Further-
more, human CtIP also contains a region that comprises several
conserved CK2 consensus sites; indeed, this region is phospho-
rylated efficiently by CK2 in vitro (F.H. & M.S., unpublished
observation). However, whether or not these putative CK2
sites in CtIP interact with human NBS1 to mediate the G2/M
DNA-damage checkpoint remains to be established.
METHODS
Cell lines and plasmids. NBS-iLB1 cells stably expressing
wild-type and K160M mutant NBS1 were generated by retroviral
transduction. The YFP-BRCT-expressing U2OS cell line was
described by Stucki et al (2005). The human MDC1 GST-SDT
construct was described by Spycher et al (2008). The MDC1(800)
fragment was cloned into a modified pcDNA3.1-Flag mammalian
expression vector (Invitrogen, Eugene, OR, USA). Myc-NBS1
was subcloned into a pFastBac transfer vector (Invitrogen) to
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Fig 4 | Experimental uncoupling of the MRN complex from damaged
chromatin does not trigger a G2/M checkpoint defect. (A) Nuclear foci
formation of NBS1 in inducible U2OS YFP-BRCT-overexpressing cells
after irradiation at 5Gy. Non-induced cells (top) and YFP-BRCT-expressing
cells (bottom). (B) Microlaser-induced DNA-damage recruitment analysis
of NBS1 in inducible U2OS YFP-BRCT-overexpressing cells. Non-induced
cells (top) and YFP-BRCT-expressing cells (bottom). (C) Overexpression
of the MDC1 BRCT domains does not trigger a G2/M checkpoint defect.
Expression of YFP-BRCT fusion protein was induced 8 h before
irradiation (þDOX). Mock-induced cells acted as the control (DOX).
Depletion of endogenous MDC1 by siRNA (siM) partly abrogated the
G2/M checkpoint regardless of whether or not MDC1 is proficient for
gH2AX binding. The error bars represent the standard deviation. DAPI,
40,6-diamidino-2-phenylindole; DOX, doxocyclin; MDC1, mediator of
the DNA damage checkpoint 1; MRN, MRE11–RAD50–NBS1 complex;
NBS1, Nijmegen breakage syndrome 1; siRNA, small interfering RNA;
YFP, yellow fluorescent protein.
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Fig 3 | Mutation in the tandem BRCT domain of NBS1 does not yield
a G2/M DNA-damage checkpoint defect. NBS-iLB1 fibroblasts and
NBS-iLB1 fibroblasts stably transduced with wild-type, R28A or K160
mutant NBS1, respectively, were left untreated or irradiated at 1 and
10Gy. Cells were harvested 1 h after irradiation, fixed with methanol
and stained with an antibody against phosphorylated H3 (P-H3)
and propidium iodide. The percentage of P-H3-positive cells was
determined by fluorescence-activated cell sorting analysis. In this
graph, three independent experiments (each performed in triplicate)
are summarized. The error bars represent the standard deviation.
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generate recombinant NBS1 baculoviruses and into pLPCX
(Clontech, Mountain View, CA, USA) to generate retroviral
particles, respectively. Point mutations were introduced by
using the QuickChange site-directed mutagenesis kit (Stratagene,
Cedar Creek, TX, USA).
Single-cell analysis. DSBs in defined nuclear volumes were
induced by laser micro-irradiation using an MMI CELLCUT system
containing a 355 nm UVA laser (55Hz; Molecular Machines
& Industries, Glattbrugg, Switzerland). Cells were stained with
antibodies against human Nbs1 (Novus, Littleton, CO, USA) and
gH2AX (Upstate, Temecula, CA, USA). Images were captured by
using a Leica SP2 confocal microscope (Leica Microsystems,
Wetzlar, Germany) with a 40 (oil immersion, NA 1.25)
objective.
Biochemical analysis. GST pulldown assays were performed by
mixing 5 mg of GST-fusion proteins with a standard TNT reaction
and 5 mg of purified MRN, respectively. For co-immunoprecipita-
tion, human embryonic kidney 293T cells were co-transfected
with a Flag-tagged fragment of MDC1 (1–800 amino acids) and
Myc-tagged Nbs1 constructs. Anti-Flag(M2)-beads (Sigma-Aldrich,
St Louis, MO, USA) were used to immunoprecipitate proteins from
total cell extract. All samples were analysed by sodium dodecyl
sulphate–polyacrylamide gel electrophoresis and immunoblotting.
G2/M checkpoint analysis. G2/M checkpoint analysis of NBS
fibroblasts was performed as described by Spycher et al (2008).
See the supplementary information online for details.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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SUPPLEMENTARY MATERIALS 
 
A divalent FHA/BRCT-binding mechanism couples the MRE11/RAD50/NBS1 
complex to damaged chromatin 
 
 
METHODS 
 
Cell extraction and protein purification 
Hela nuclear extract was purchased from Cilbiotech (Mons, Belgium). MDC1-GST-
SDT fragment was affinity purified on Glutathione-Sepharose (GE Healthcare 
Biosciences). Recombinant MRN purification from Sf9 cells was described (Spycher 
et al, 2008). For in vitro-translation of full-length NBS1, the TNT system (Promega) 
was used. 
 
Microirradiation and single-cell analysis 
In order to generate DSBs in defined nuclear volumes laser microirradiation was 
performed with a MMI CELLCUT system containing a 355 nm UVA laser (55 Hz, 
Molecular Machines & Industries, Switzerland) coupled to an Olympus IX71 
microscope station and focused through an LUCPLFLN 40X objective. The 
MMICELLTOOLS software with MMIUVCUT plug-in assisted the laser operation 
using an energy output of 50%. Prior to laser irradiation, cells were grown on 
coverslips in cell culture dishes in the presence of 10 µM BrdU (Bromodeoxyuridine; 
Sigma) for 24 h. Coverslips were transferred into LabTek chamber slides (Nunc) and 
mounted on the microscope stage for irradiation. After irradiation, cells were placed 
back in the incubator for 30-60 min before fixation.  
 
Biochemical analysis 
For GST pull down assays, purified GST-fusion proteins (5 µg) were mixed with 1/5 
volume of a standard TNT reaction and 5 µg of purified MRN, respectively. Where 
indicated, GST fusion proteins were pre-treated with 100 U of CK2 (New England 
BioLabs). The mixture was incubated at 4°C for 30 min to allow binding. Glutathione 
sepharose beads were added and the suspension was incubated for further 60 min. The 
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beads were washed with buffer (50mM Tris pH 7.5, 120 mM NaCl, 1 mM DTT, 0.2% 
NP-40) and resuspended in SDS loading buffer. 
For co-immunoprecipitation, HEK 293T cells were co-transfected with a Flag-tagged 
fragment of MDC1 (1-800 aa) and Myc-tagged Nbs1 constructs. Cells were lysed in 
lysis buffer (25 mM Tris pH 7.5, 40 mM NaCl, 2 mM MgCl2, 0.5 % NP-40, protease 
and phosphatase inhibitors, 25 U/ml benzonase (Novagen)) and incubated for 30 min 
at 4 °C. The concentration of NaCl was increased to 450 mM and incubated for 
another 30 min at 4 °C. After centrifugation, extracts were diluted to 100 mM NaCl, 
added to pre-blocked anti-flag(M2)-beads (Sigma) and incubated for 3 h at 4 °C. The 
beads were washed with IP-buffer (25 mM Tris pH 7.5, 100 mM NaCl, 10 % 
glycerol, 2 mM EDTA, 1 mM DTT, 0.5 % NP-40, protease and phosphatase 
inhibitors) and resuspended in SDS loading buffer. All samples were analyzed by 
SDS PAGE and immunoblotting.  
 
 
Checkpoint analysis 
Cells were irradiated with a Faxitron X-ray cabinet at the indicated doses during the 
exponential growth phase. 1h later, cells were harvested, fixed with 70% ethanol/PBS 
and incubated over night at -20°C. After permeabilization with 0.25% Triton/PBS, 
cells were stained with anti-phospho-histone H3 (Upstate), followed by secondary 
anti-FITC (Jackson) or Alexa 700 (Invitrogen) antibodies and propidium iodide. Data 
were acquired with a Becton Dickinson flow cytometer (NSB fibroblasts) or a 
Beckham Coulter CyAn ADP 9 Color flow cytometer (U2OS YFP-BRCT cell line).  
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Supplementary Figure S1 
(A) NBS1 expression profile of NBS-iLB1 fibroblasts stably transduced with wild 
type NBS1, R28A NBS1 and K160M NBS1.  
(B) Two independent clones of NBS-iLB1 fibroblasts stably transduced with wild 
K160M mutant NBS1 were left untreated or irradiated with 1 Gy and 10 Gy. Cells 
were harvested 1 hour after irradiation, fixed with methanol and stained with an 
antibody against phosphorylated H3 (P-H3) and propidium iodine. The percentage of 
P-H3 positive cells was determined by FACS analysis. NBS-iLB1 parental cells and 
NBS1-iLB1 cells stably transduced with wild type NBS1 served as negative and 
positive controls, respectively. Error bars represent standard deviation. 
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RESULTS 
 
5.3 Unpublished data on DNA damage-induced MDC1 
dimerization 
5.3.1 Extended analysis of MDC1 pT4 phosphorylation and DNA 
damage-induced dimerization  
 
We previously identified an N-terminal MDC1 fragment (amino acids 1-124) to 
be phosphorylated in vitro by the ATM kinase, and the highly conserved Thr4 as the 
residue to be modified (Figure 1A and 1B in Jungmichel et al, 2010). Upon this 
finding, an antibody was generated against a short N-terminal MDC1 phospho-
peptide (pThr4). The specificity of this antibody was confirmed in vitro using the 
original peptide in a dot blot assay, where the antibody detected only the 
phosphorylated but not the unphosphorylated peptide (Figure 5.1A). Moreover, the 
antibody recognized a recombinant MDC1 protein fragment upon phosphorylation by 
immunopurified ATM and showed only little cross-reaction with the non-
phosphorylated fragment or a fragment containing a T4A mutation (Figure 1B in 
Jungmichel et al, 2010). We further described in vivo phosphorylation of endogenous 
MDC1 at Thr4 in U2OS cells in a time- and dose-dependent manner in response to IR 
and in dependency of active ATM since a specific ATM inhibitor strongly reduced 
the T4-phosphorylation signal of MDC1 (Figure 1C and 1E in Jungmichel et al, 2010 
and Figure 5.1B). For further proof of ATM to be acting as the major kinase for 
MDC1 Thr4 phosphorylation, we set out to analyze cells derived from AT patients 
that are defective in expressing functionally active ATM. In comparison to U2OS 
cells treated with 10 Gy of IR, we could not detect a positive signal for phospho-Thr4 
in irradiated human AT fibroblasts (Figure 5.1C), indicating that ATM is the 
responsible kinase for MDC1 Thr4-phosphorylation in response to IR. In addition to 
IR-induced DNA damage, Thr4 phosphorylation in U2OS cells also occured in 
response to treatment with 100 J/m2 of UV radiation, that is known to produce SSBs 
that might be converted into DSBs during replication (Figure 5.1D). 
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Figure 5.1 MDC1 phosphorylation at Thr4 is dependent on ATM. (A) Unphosphorylated 
(T4) or phosphorylated (pT4) peptides were dotted in different concentrations on a Nitro-
cellulose membrane and incubated with α-MDC1 pT4 antibody. γH2AX peptide incubated 
with α-γH2AX antibody was used as a positive control. (B) U2OS cells were incubated with 
10µM ATM inhibitor for 30min and then treated with 10Gy of IR. Cell extracts were prepared 
30min after IR and analyzed with α-MDC1 pT4 and α-MDC1 (889) antibodies. (C, D) U2OS 
cells or human AT fibroblasts were treated with 10Gy of IR or UV radiation and cell extracts 
were analyzed with α-MDC1 pT4 antibody. ( * indicates pT4-phosphorylated MDC1) 
  
 
Previously, an oriented phosphopeptide library screen identified the optimal 
sequence for binding to certain classes of FHA domains (Durocher et al, 2000). 
Interestingly, phosphopeptide sequences with high similarity to the phosphorylated N-
terminus of MDC1 (M-E-D-pT-Q-A-I) selectively bound to the FHA domain of 
MDC1. These data showed a strong preference for isoleucine at the +3 position 
following the phosphorylated threonine. Based on this information, we performed a 
series of interaction studies that would support the emerging idea of an interaction 
between the Thr4-phosphorylated MDC1 N-terminus with the MDC1 FHA domain. 
Indeed, peptide pulldowns revealed an interaction of the T4-phosphopeptide but not 
its unphosphorylated form with the purified recombinant MDC1 FHA domain as well 
as with endogenous MDC1. In addition, several known interactions partners of MDC1 
were retrieved from HeLa nuclear extract, namely NBS1, MRE11 and RAD50, 
(Figure 2B in Jungmichel et al, 2010). In order to demonstrate a DNA damage-
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dependent interaction between two different MDC1 molecules in vivo, we transiently 
expressed differently tagged MDC1 fragments (amino acids 1-800) in 293T cells that 
had either been treated with IR or left untreated and subsequently performed co-
immunoprecipitation experiments. C-terminally truncated fragments of MDC1 
lacking the BRCT domain were used since it has generally been difficult to strip full-
length MDC1 from chromatin. As expected, wild-type sequences of Myc-tagged and 
FLAG-tagged MDC1 were immunoprecipitated in irradiated cell extracts with the aid 
of an anti-FLAG affinity gel, whereas a Myc-tagged mutant fragment (T4A) showed 
almost no interaction (Figure 5A in Jungmichel et al, 2010). In another experiment, 
the immunoprecipitated samples were blotted with the MDC1 pT4 antibody to test its 
reactivity against ectopically expressed wild-type or T4A mutant MDC1 protein in a 
DNA damage-dependent manner, this time using CPT as DSB-causing agent (Figure 
5.2A). The antibody specifically detected the enriched wild-type MDC1 fragments in 
the immunoprecipitate, but not the T4A mutant proteins. Thr4 phosphorylation 
seemed to occur in cells that had not been exposed to DNA damage. We suspect that 
the phosphorylation may arise as a consequence of the calcium phosphate transfection 
procedure, which has been described to elicit a stress response possibly leading to 
activation of DNA damage signaling (Rodriguez and Flemington, 1999; Nickoloff, 
1998). We therefore analyzed U2OS cells that stably express the wild-type FHA 
domain or a T4A mutant (amino acids 1-154) upon induction with Doxocycline so 
that potential activation of the DNA damage response during calcium phosphate 
transfection can be avoided (Figure 5.2B). Thus, it appeared that the antibody 
recognized the pT4 of the wild-type FHA domain in a damage-dependent manner, 
although the antibody showed some unspecific reactivity against unphosphorylated 
FHA domains (as already observed in Figure 1B in Jungmichel et al, 2010), which 
could be circumvented by lower exposures of the blot. The phosphorylation of MDC1 
in response to transfection strain might also account for the observed interaction 
between differently tagged MDC1 fragments in non-irradiated cell extracts (Figure 
5A in Jungmichel et al, 2010 and Figure 5.2A). Former attempts to immunoprecipitate 
MDC1 fragments with a FLAG antibody subsequently coupled to G-sepharose beads, 
mostly failed to retrieve sufficient protein from the extract to be detected in Western 
blot. However, in some cases, the amount of protein loaded was adequate to detect a 
clear increase in interaction between Myc- and FLAG-tagged MDC1 in irradiated as 
compared to non-irradiated cell extracts (Figure 5.2C). In conclusion, the above 
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experiments strongly support the interpretation that phosphorylation of MDC1 at Thr4 
occurs in vivo in response to exogenous DNA damage and that this leads to a 
multimerisation of the protein. 
 
 
 
Figure 5.2 DNA damage-dependent Thr4 phosphorylation and dimerization of MDC1 (A) 293T cells 
were transfected with plasmids expressing wild-type or T4A mutant MDC1 (amino acids 1-800) 
carrying a C-terminal FLAG or Myc tag. After 48h, cells were treated with 10 µM Camptothecin for 
1h, washed and replaced with fresh medium for further incubation of 2.5h. Protein complexes were 
immunoprecipitated with monoclonal α-FLAG agarose and immunoblotted with α-Myc, α-MDC1 
pT4, α-FLAG and α-MDC1 (889) antibodies. (B) U2OS TetOn-FHA cells (wild-type and T4A 
mutant) were induced with 1µg/ml Doxocyclin for 12h and treated with 10Gy of IR. Cell extracts were 
analyzed with α-MDC1 pT4 and α-MDC1 (3835) antibodies. (C) 293T cells were transfected with 
plasmids expressing wild-type MDC1 (amino acids 1-800) carrying a C-terminal FLAG or Myc tag. 
After 48h, cells were treated with 10Gy of IR. After 30 min protein complexes were 
immunoprecipitated with monoclonal α-FLAG antibody and immunoblotted with α-Myc and α-FLAG 
antibodies. 
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5.3.2 Functional characterization of the MDC1 FHA domain in an 
overexpression system 
 
In order to understand the role of the MDC1 FHA domain in the context of the 
proposed MDC1 dimerization mechanism during the DNA damage response we 
sought to analyze the effects of overexpression of an N-terminal MDC1 fragment 
containing the FHA domain in human cells. We applied a system that allows tight 
control of mammalian gene expression via tetracycline-responsive promoters and 
offers the additional advantage of using isogenic cell lines in assays evaluating 
responses to DNA damage: U2OS cells stably expressing the tetracycline repressor 
were transfected with plasmids encoding a fusion protein of EYFP and the wild-type 
or mutant MDC1 FHA domain (amino acids 1-154) and selected with G418 for stable 
integrants. Clones of comparable expression were isolated after induction with the 
tetracycline-analogue Doxocycline. As depicted in Figure 5.3A, the increase of 
protein levels for the wild-type FHA domain and the T4A mutant reached a maximum 
8 h after induction with 1 µg/ml Doxocycline and was maintained for at least 24 h.  
 
 
Figure 5.3 Overexpression 
of the FHA domain 
abrogates MDC1 foci 
formation. (A) U2OS 
TetOn cells stably 
expressing a tetracycline-
inducible EYFP-FHA(WT 
or T4A) fusion protein were 
induced with 1µg/ml 
Doxocyclin for the 
indicated times. Protein 
expression was analyzed 
with α-MDC1 (3835) and 
α-tubulin antibodies. (B) 
U2OS TetOn EYFP-
FHA(WT) or -FHAΔN 
cells were induced with 
1µg/ml Doxocyclin for 12h, 
subjected to 10Gy of IR, 1h 
later fixed in PFA and 
immunostained for MDC1 
(3838) and γH2AX. 
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Previous studies demonstrated that overexpression of the FHA domain exerts a 
dominant-negative effect on MDC1 and MRN foci formation, similar to what has 
been observed for the overexpressed BRCT domain (Goldberg et al, 2003; Stucki et 
al, 2005). Hence, in some of the following experiments BRCT overexpressing U2OS 
cells were used as a control. We could confirm that the induced overexpression of the 
wild-type FHA domain impaired endogenous MDC1 foci formation, but not γH2AX 
foci (Figure 5.3B). Overexpression of the FHA domain lacking the Thr4-containing 
N-terminus had a similar effect on MDC1 and γH2AX foci as the wild-type.  
To further substantiate the dominant negative effect of the FHA domain on 
MDC1 chromatin retention we examined release of endogenous MDC1 from 
chromatin in a biochemical fractionation assay. In non-irradiated cells MDC1 was 
mainly found in the nuclear chromatin pellet and only salt concentrations of higher 
than 210 mM NaCl led to a substantial release of MDC1 into the nuclear soluble 
fraction (Figure 5.4A). However, a small fraction of MDC1 was already released at 
125 mM NaCl, which was not observed upon treatment with 3 Gy of IR, indicating 
that induction of DNA damage causes a stronger retention of MDC1 at chromatin. As 
expected, overexpression of the FHA domain promoted release of endogenous MDC1 
from chromatin already at 125 mM after irradiation, an effect that could similarly be 
observed for the overexpressed BRCT domain (Figure 5.4A). Concomitantly, the 
nuclear chromatin pellet showed a slightly decreased MDC1 protein level in case of 
the FHA domain, though this effect seems to be even enhanced for the BRCT domain. 
These data corroborate the dominant negative effect of the MDC1 FHA domain 
overexpression on chromatin retention of MDC1 and presumably other DDR factors. 
With regards to the above-mentioned cellular effects of the overexpressed FHA 
domain, we wondered whether an excess of the purified recombinant FHA domain 
would also displace HNE-derived MDC1 from binding to a γH2AX-peptide in vitro 
and whether the T4A mutation would reverse this effect (Figure 5.4B). It has been 
shown before that an excess of the MDC1 BRCT domain competed for binding to the 
γH2AX-peptide and led to an almost complete release of endogenous MDC1 (Stucki 
et al, 2005). However, we did not observe a change in binding of MDC1 to the 
γH2AX-peptide (lane 5 and 7) in the presence of an excess of purified FHA domain. 
This may be caused by the fact that we used cell extract from undamaged cells, and 
FHA domain purified from bacteria, thus lacking posttranslational modification.  
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Figure 5.4 Effects of the overexpressed FHA domain on MDC1 chromatin retention and 
H2AX phosphorylation (A) U2OS TetOn EYFP-FHA(WT) or EYFP-BRCT cells were 
induced with 1µg/ml Doxocycline for 12h or mock-treated. Cells were irradiated with 
3Gy of IR and 1h later subjected to chromatin fractionation (C = cytosol, NF1 = soluble 
nuclear fraction with 125 mM, NF2 = soluble nuclear fraction with 210 mM NaCl, NP = 
nuclear pellet). Different fractions were analyzed for presence of endogenous MDC1 
with α-MDC1 (889) antibody. Fractionation was controlled with α-PARP1 antibody. 
(B) γH2AX pulldown. HeLa nuclear extract was supplemented with ATP for in vitro 
kinase activation and purified recombinant FHA domains (WT or T4A) and subjected to 
a pulldown with H2AX or γH2AX peptides.  Protein analysis was performed with α-
MDC1 (889) antibody. (C) U2OS TetOn cells expressing EYFP fused to BRCT, FHA 
WT, FHAΔN or FHA-R58A domains were induced with 1µg/ml Doxocycline for 24h. 
Cell extracts were prepared 1 h after treatment with 10 Gy of IR and proteins analyzed 
with α-MDC1 (3835), α-MDC1 (3838), α-γH2AX and α-H2A antibodies. 
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Therefore, we supplemented HeLa nuclear extract with ATP and specific buffer 
reagents that are required for activation of ATM in vitro (Kozlov et al, 2003). We 
expected that this would facilitate phosphorylation of pT4 in the MDC1 FHA domain 
and promote an interaction with full length MDC1. Surprisingly, the presence of ATP 
alone in the extracts led to almost complete dissociation of MDC1 from the γH2AX-
peptide (lane 5 and 6), which rendered the further interpretation of effects of the 
purified FHA domain impossible.  
Consistent with earlier observations (Stucki et al, 2005) overexpression of the 
BRCT domain led to H2AX phosphorylation even in non-irradiated cells, whereas 
simple overexpression of the FHA domain or of either of its mutants did not change 
the γH2AX phosphorylation status (Figure 5.3B and Figure 5.4C). In response to 
ionizing radiation, γH2AX was hyperphosphorylated upon induction of the BRCT 
domain as compared to non-induced cells that showed a similar γH2AX level as non-
irradiated BRCT overexpressing cells. However, overexpression of the FHA domain 
did not seem to change γH2AX levels upon treatment with IR. In summary, we 
conclude that overexpression of the FHA domain does not influence the 
phosphorylation status of γH2AX.  
Previously, Goldberg et al. (2003) reported an RDS phenotype in transiently 
transfected HeLa cells overexpressing MDC1 FHA-GFP and to a lesser extent for an 
R58A mutant. The Arg58 has been suggested to be an essential residue in the 
phosphopeptide-binding site of the MDC1 FHA domain. Unfortunately, we could not 
reproduce these results using our inducible U2OS-TetOn system, since no difference 
in the reduction of 3H-Thymidine incorporation could be observed between non-
induced or induced cells. This was the case for FHA wild-type, T4A or L120E/L127E 
mutants upon 15 Gy of IR (Figure 5.5A). We therefore suspected that overexpression 
of the FHA domain might induce a defect in G2/M checkpoint activation. 
Unexpectedly, we could also not detect a pronounced G2/M checkpoint defect in 
FHA-overexpressing cells treated with different doses of IR. As a positive control 
cells were analysed with siRNA-mediated downregulation of endogenous MDC1, 
which have been described to be defective in G2/M checkpoint activation (Figure 
5.5C and Stewart, 2003). An extended analysis of cells overexpressing either wild-
type or R58A mutant FHA domain at different doses of irradiation did not reveal any 
disturbance of G2/M checkpoint activation (Figure 5.5B). Interestingly, 
overexpression of the BRCT domain did neither exhibit a G2/M checkpoint defect 
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(Figure 4C in Hari et al, 2010) nor an intra-S-phase checkpoint defect, whereas a 
strong defect in random plasmid integration was observed (Stucki et al, 2005), 
indicating that MDC1 accumulation and retention at sites of DNA damage is not 
required for the G2/M checkpoint response but might rather be involved in DSB 
repair.  
 
 
 
Figure 5.5 Overexpression of the MDC1 FHA domain does not elicit defects in activation 
of intra-S-phase and G2/M checkpoints. (A) RDS assay. U2OS TetOn EYFP-FHA WT, 
T4A or L120/127E were induced with 1µg/ml Doxocycline for 12h and subsequently 
treated with 15Gy of IR. Inhibition DNA synthesis was analyzed by measuring [3H]-
thymidine incorporation standardized to [14C]-thymidine incorporation. (B) G2/M 
checkpoint assay. U2OS TetOn EYFP-FHA WT or R58A were induced with 1µg/ml 
Doxocycline for 12h. 1h after treatment with the indicated doses of IR, cells were fixed 
and stained with α-pH3 antibody and propidium iodide and analyzed by flow cytometry. 
(C) Left panel: G2/M checkpoint assay. U2OS TetOn EYFP-FHA WT were induced with 
1µg/ml Doxocycline for 24h or treated with siRNA against endogenous MDC1 (siM_R). 
1h after treatment with the indicated doses of IR cells were fixed and stained with α-pH3 
antibody and propidium iodide and analyzed by flow cytometry. Right panels: FACS 
profiles of cells used for the checkpoint assay induced or not for expression of the EYFP-
FHA fusion protein. The EYFP signal was detected in the FITC channel.  
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5.3.3 Towards the generation of a human MDC1 complementation 
system 
 
The previous data support the idea that MDC1 dimerizes in response to DNA 
damage in a mechanism that is mediated through DNA-damage induced pT4 
phosphorylation and the binding of pT4 to the FHA domain of MDC1. In order to 
analyze the functional implications of this dimerization e.g. in the regulation of DNA 
damage signaling and repair pathways, the establishment of an MDC1 
complementation system is required. In a first approach, we stably expressed full-
length MDC1 fused to GFP at the N-terminus and carrying an siRNA-resistant 
cassette at the C-terminus and transiently downregulated endogenous MDC1 with 
specific siRNAs in U2OS cells. Isolation of single clones, which had been selected 
with G418 for two weeks, yielded about 50% GFP-MDC1_WT and 20% GFP-
MDC1_T4A expressing cells with relatively equal protein expression levels as 
detected by immunofluorescence (data not shown). Enrichment of GFP-positive cells 
by FACS sorting did, however, not result in a constant increase of the cell population 
expressing GFP-MDC1. Rather, expression of recombinant MDC1 seemed to rapidly 
decrease over time in cells kept in culture, so that early passages had to be used for 
cellular analysis. Initial screens of different stable clones using siRNA (siM_C) 
against endogenous MDC1 proved siRNA-resistance of GFP-MDC1, since the GFP 
signal was not affected by siM_C (Figure 5.6A). As a control, a siRNA (siM_R) 
targeting a sequence in the MDC1 repeat region, efficiently downregulated both 
endogenous MDC1 and recombinant GFP-MDC1. Figure 5.6B further illustrates 
efficient knockdown of MDC1 in U2OS cells through siM_C, as IRIF formation was 
fully abrogated for MDC1 and strongly suppressed for its downstream effector 
53BP1. 
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Figure 5.6 Efficient knockdown of MDC1 by siRNAs. (A) Different clones of U2OS cells 
stably expressing siM_C-resistant GFP-MDC1 WT or T4A were treated with siRNA 
against the MDC1 C-terminus (C = siM_C) or the repeat region (R = siM_R). Cell extracts 
were analyzed with α-MDC1 (889) and α-GFP antibodies. (LC = loading control, 
unspecific bands of GFP antibody) (B) U2OS cells were treated with siRNA against MDC 
(siM_C). After 72h, cells were subjected to 4Gy of IR, fixed after 4h or 1h and 
immunostained with α-53BP1 and α-MDC1 (3835) antibodies, respectively. 
 
Immunofluorescence studies confirmed the capability of GFP-MDC1_WT to 
form nuclear foci upon treatment with IR or laser microirradiation (Figure 5.7 and 
Figure 5.8). Mutation of Thr4 did not measurably affect foci formation of GFP-
MDC1. Since MDC1 is known to be required for efficient accumulation and retention 
of 53BP1 at DSBs (Stewart et al, 2003), we tested whether GFP-MDC1_WT 
expressing cells would be proficient for 53BP1 foci formation in the absence of 
endogenous MDC1. Surprisingly, expression of GFP-MDC1_WT appeared to exert a 
dominant-negative effect on 53BP1 foci formation in the presence of endogenous 
MDC1 after 4 Gy of IR (Figure 5.7). Moreover, GFP-MDC1_WT could also not 
rescue 53BP1 foci formation after siRNA-mediated depletion of endogenous MDC1, 
even though some 53BP1 foci could still be detected in MDC1-depleted cells without 
a GFP-signal (Figure 5.7). The same effect was observed for GFP-MDC1-T4A 
expressing cells. Only cells with a very low expression level did not show abrogated 
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53BP1 foci, but the barely detectable GFP-signal complicated a reliable analysis of 
immunofluorescence samples. The dominant-negative effect exerted by GFP-MDC1 
on 53BP1 retention and the corresponding sensitivity to small changes in expression 
levels became even more apparent by means of laser microirradiation (Figure 5.8A). 
Interestingly, NBS1 localization in laser tracks of GFP-MDC1 expressing cells was 
not affected (Figure 5.8B). 
 
 
Figure 5.7 Mutation of Thr4 does not affect accumulation of GFP-MDC1 
in IRIF but GFP-MDC1 expression, in general, exerts a dominant 
negative effect on 53BP1 foci formation. U2OS cells stably expressing 
siM_C-resistant GFP-MDC1 WT or T4A were mock-treated or treated 
with siRNA (siM_C) against endogenous MDC1. Cells were fixed 4h 
after 4Gy of IR and immunostained with α-53BP1 antibody.  
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Figure 5.8 Stable expression of GFP-MDC1 causes dominant negative effect on 
relocalization of 53BP1 to sites of DNA damage but not of NBS1. U2OS cells stably 
expressing siM_C-resistant GFP-MDC1 WT or T4A were treated with siRNA 
(siM_C) against endogenous MDC1. Cells were fixed 1h after laser microirradiation 
and immunostained with (A) α-53BP1 and (B) α-NBS1 antibodies.  
 
Even though this apparent dominant-negative effect of GFP-MDC1 expression 
constitutes a major drawback for in vivo structure/function analysis, we nevertheless 
tested whether the GFP-MDC1_WT expressing cells would complement the G2/M 
checkpoint defect of MDC1-depleted cells (Stewart et al, 2003). Knockdown of the 
entire MDC1 pool in U2OS control and GFP-MDC1_WT expressing cells through 
siM_R as well as pre-treatment with an ATM inhibitor caused a rather mild 
checkpoint defect at 3 Gy detected as an increase in the mitotic index (pH3-positive 
cells) (Figure 5.9A). The same degree of checkpoint deficiency was reached in GFP-
MDC1_WT cells treated with siM_C to deplete endogenous MDC1. Hence, rescue of 
G2/M checkpoint activation could not be accomplished with our GFP-MDC1_WT 
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complemented cell lines. The results retrieved from this study led us to the conclusion 
that a complementation system employing human U2OS cells is not suitable to study 
the functional implications of MDC1 dimerization.  
 
 
 
Figure 5.9 Stable expression of GFP-MDC1 did not rescue the defect in G2/M checkpoint activation 
in the absence of endogenous MDC1. (A) G2/M checkpoint assay. U2OS cells or stable siM_C 
resistant GFP-MDC1 expressing cells were treated with siRNAs (siM_C or siM_R) 72h prior to IR or 
with ATM inhibitor 30 min prior to IR, as indicated. Cells were fixed 1h after 3 Gy of IR, stained 
with α-pH3 antibody and propidium iodide and analyzed by flow cytometry. (B, C) Control of 
siRNA-mediated downregulation of MDC1 with α-MDC1 (889) antibody for cells used in (A) and 
cells expressing fragment M(800)WT. 
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5.3.4 Towards the generation of a mouse MDC1 complementation 
system 
 
Since the human MDC1 complementation system failed to yield the required 
data, we aimed in a second approach at complementing transformed MEFs derived 
from MDC1-/- mice (untransformed MDC1-/- MEFs grow poorly in culture) (Lou et al, 
2006). When we received the MDC1-/- cells from the Chen/Scully/Peggo laboratories, 
we noticed a significant contamination of the cell population with cells apparently 
expressing normal levels of MDC1. This contamination was apparent in all the cell 
lines we received. Thus, we first had to isolate single cell clones to assure a clean 
MDC1-/- population (Figure 5.10A). Testing these cells in an initial G2/M checkpoint 
assay, we could confirm the previously described defect of MDC1-/- cells in G2/M 
checkpoint activation, particularly at low doses of irradiation (Figure 5.11)(Lou et al, 
2006). 
 
 
 
Figure 5.10 Expression of mMDC1-HA in MDC1-/- MEFs. (A) Irradiation of MDC1-/- and 
MDC1+/+ mouse embryonic fibroblasts with 4 Gy of IR and staining with polyclonal rabbit α-
mMDC1 antibody reveals contamination of MDC1-/- MEFs with MDC1-expressing cells, which 
subsequently required isolation of MDC1-/- single cell clones. (B) Transient transfection of 293T 
cells with wild-type or T4A mutant mMDC1-HA in MSIPuro retroviral expression vectors. 
Expression was analyzed with α-HA antibody. 
 
 
 
 
107
RESULTS 
 
Figure 5.11 Loss of MDC1 causes a 
defect in G2/M checkpoint activation. 
Transformed MDC1-/- and MDC1+/+ 
mouse embryonic fibroblasts were 
irradiated at the indicated doses, fixed 
and stained with α-phospho Histone 
H3 antibody to identify cells in 
mitosis. Cells were analyzed by flow 
cytometry. 
 
 
 
In the course of various attempts to stably express mouse MDC1 (mMDC1) in 
MDC1-/- cells we encountered several difficulties. MDC1-/- cells showed very low 
transfection efficiency (∼ 1%) when transfected with HA-tagged mMDC1 inserted 
into the pcDNA3.1 or pLPCX expression vector. Moreover, after selection with 
puromycin we could not isolate stable clones that positively stained for mMDC1-HA. 
In order to increase the chance to isolate positive clones, we subcloned mMDC1-HA 
in pIRESpuro vector containing an internal ribosomal entry site for expression of the 
puromycin resistance gene on the same mRNA as the transgene. However, again no 
stable clone expressing full-length mMDC1-HA could be isolated. Therefore, we 
sought to isolate stable transfectants by retroviral transduction employing pCL-Eco or 
pCL-Ampho vectors for retroviral packaging. Following co-transfection of 293T cells 
with mMDC1-HA in pLPCX retroviral expression vectors and transduction of  
MDC1-/- MEFs, puromycin resistant clones were isolated. However, immuno-
fluorescent screenings revealed no expression of mMDC1-HA. The use of an 
alternative mMDC1-HA retroviral expression vector that additionally contained an 
internal ribosomal entry site for expression of the puromycin resistance gene on the 
same mRNA as the transgene (MSIPuro) yielded similar results despite efficient 
transfection in 293T cells (Figure 5.10B). We suspect that the lack of stable 
integration of mMDC1 in MDC1-/- MEFs might be attributed to inefficient packaging 
of the mMDC1 mRNA (5.1 kb) in retrovirus particles and further, to defects of 
MDC1-deficient cells in random plasmid integration and HR (Lou et al, 2004; Xie et 
al, 2007). 
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6 DISCUSSION 
 
 The main body of this thesis describes the molecular mechanism of DNA 
damage-induced MDC1 dimerization. We showed that the N-terminally located and 
highly conserved Thr4 residue of MDC1 is phosphorylated by ATM in vitro and in 
vivo upon induction of DSBs. The phosphorylated Thr4 engages in a highly specific 
and phosphorylation-dependent interaction with the FHA domain of MDC1. X-ray 
structure analysis revealed that this interaction occurs in trans, i.e. the pThr4 of one 
MDC1 molecule interacts with the FHA domain of another MDC1 molecule. Binding 
of pThr4 to the FHA domain leads to an enhanced interaction between weakly 
associated MDC1 FHA domains, resulting in the formation of a tight dimer. The 
pThr4-dependent self-association of MDC1 molecules was confirmed to occur in 
vivo. Finally, in vivo dimerization mediates the accumulation of the FHA domain at 
sites of DNA damage in dependency of the phosphorylated Thr4 residue and the 
presence of endogenous MDC1. 
What could be the possible physiological roles of MDC1 dimerization? Unlike 
the mediator proteins 53BP1 and Crb2, whose oligomerization seems not to be 
regulated by post-translational modifications, dimer formation of MDC1 is dependent 
on DNA damage-induced phosphorylation as has been observed for Rad9p, 
suggesting a regulatory role of this mechanism in the DNA damage response. Yet in 
contrast to Rad9p and Crb2, disruption of oligomerization seems not to affect 
chromatin retention of MDC1 in IRIF (Figure 5.7). However, abolished 
oligomerization of Rad9p and Crb2 additionally leads to a defect in checkpoint-
dependent cell cycle arrest (Kilkenny et al, 2008; Usui et al, 2009). Interestingly, 
deletion of the MDC1 FHA domain was shown to also cause a defect in G2/M 
checkpoint activation indicating that MDC1 dimerization might be involved 
checkpoint activation (Lou et al, 2006). In line of this interpretation, overexpression 
of the FHA domain has also been reported to elicit an intra-S-phase checkpoint defect 
upon transient transfection of HeLa cells with FHA expressing plasmids (Goldberg et 
al, 2003). However, in this work, we could not observe any effect of the 
overexpressed MDC1 FHA domain on the activation of the intra-S-phase or G2/M 
checkpoint (Figure 5.5). This may be attributed to the expression level of the stably 
integrated FHA domain, which may not be sufficient to cause a pronounced 
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checkpoint defect, or to the EYFP tag being at the N-terminus instead of the C-
terminus of the FHA domain expression construct, which may interfere with 
dimerization. Another indication for a possible involvement of FHA domain-mediated 
dimerization in checkpoint activation arises from the fact that only a very mild G2/M 
checkpoint defect at very low doses of irradiation has been reported for H2AX 
deficient cells in contrast to a more pronounced intra-S-phase and G2/M checkpoint 
defects of MDC1-depleted cells (Celeste et al, 2002; Fernandez-Capetillo et al, 2002; 
Goldberg et al, 2003; Lou et al, 2006; Stewart et al, 2003). Even more specifically, 
the interaction between the MDC1 BRCT domain and γH2AX was not required for 
intra-S-phase and G2/M checkpoint activation, indicating that another region in 
MDC1, possibly the FHA domain, could participate in these functions (Stucki et al, 
2005). Alternatively, MDC1 dimerization may not be involved in checkpoint 
activation but rather in its maintenance. This appears to be the case for yeast proteins 
Rad9p and Crb2 (Kilkenny et al, 2008; Usui et al, 2009).  
On the molecular level, MDC1 dimerization might regulate the interaction of the 
FHA domain with other proteins, from which three different possibilities emerge. 
First of all, pThr4-mediated dimer formation could preclude the availability of the 
FHA phospho-binding surface for another protein with a suitable pThr-containing 
motif. This might be a feasible mechanism for the regulation of the checkpoint kinase 
CHK2. It was shown that CHK2 dimerizes upon ATM-dependent phosphorylation of 
Thr68 in a manner similar to MDC1. Dimerization is mediated by intermolecular 
binding of the FHA domain to phosphorylated Thr68 and is required to bring the 
kinase domains in close proximity for efficient trans-autophosphorylation. Following 
complete activation, CHK2 dissociates into active monomers (Ahn et al, 2002; Ahn et 
al, 2000; Li et al, 2008). Previously, pThr68 of CHK2 was demonstrated to directly 
bind the FHA domain of MDC1 in vitro and an enhanced interaction between these 
proteins was observed in vivo after treatment with IR (Lou et al, 2003). However, 
activated CHK2 is not retained at DSBs and its localization remains rather diffuse 
after induction of DNA damage. Still though, CHK2 requires the relocalization to 
sites of DNA damage in order to become efficiently activated (Lukas et al, 2003). 
MDC1 might therefore act as an adaptor to initially couple CHK2 to the DSB to 
facilitate its complete activation via ATM-dependent phosphorylation, but it might 
also regulate its subsequent release from the chromatin via MDC1 self-association in 
order to spread the CHK2-dependent DNA damage checkpoint signal throughout the 
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nucleus. A second possibility for how MDC1 dimerization modulates protein 
interactions would be that the MDC1 FHA domain provides a phospho-independent 
interaction surface for another protein, which is occluded upon DNA-damage induced 
dimerization, thus resulting in the release of the former interaction partner. Such a 
scenario has been previously described for the FHA domain-containing protein 
Rv1827 from Mycobacterium tuberculosis (Nott et al, 2009). In a third option, 
dimerization would create a new phospho-independent interaction surface spanning 
both FHA domains. 
To date, several interaction partners have been suggested for the MDC1 FHA 
domain. Besides CHK2, the ATM kinase was proposed to directly bind the MDC1 
FHA domain, although it remains unclear if this interaction is DNA damage-
dependent (Lou et al, 2006). Moreover, the MDC1 FHA domain was recently shown 
to interact with RAD51 in a phosphorylation- and DNA damage-independent manner 
(Zhang et al, 2005). Unfortunately, these publications lack the description of the 
sequences of their FHA constructs used for the interaction studies with CHK2, ATM 
and RAD51 (Lou et al, 2006; Lou et al, 2003; Zhang et al, 2005). It is thus unclear 
whether the sequences of the FHA domain comprised the N-terminal Thr4, whose 
DNA damage-dependent phosphorylation may be important to modulate the 
interaction with other proteins and substantially influence the regulation of the DDR. 
However, the proposed interactions with ATM and/or RAD51 support the notion that 
MDC1 dimerization might be involved in DNA repair processes. In fact, MDC1 
mutants lacking the FHA domain were shown to be defective in efficient DSB repair 
through HR (Xie et al, 2007; Zhang et al, 2005). 
The analysis of the biological function of MDC1 dimerization mutants in a 
MDC1 null background requires the establishment of an efficient complementation 
system in order to perform bulk cellular assays such as checkpoint activation or 
maintenance, DSB repair and cell survival assays. Stable integration of siRNA-
resistant GFP-tagged recombinant MDC1 into human U2OS cells with the aim to 
downregulate endogenous MDC1 via siRNA transfection was not successful, as 
recombinant MDC1 expression appeared to disturb downstream effects of MDC1 
signaling (e.g. defective in 53BP1 foci formation). This indicates that the cell might 
need to carefully balance the protein levels of MDC1 and 53BP1 in order to 
adequately respond to DNA damage. In support of this notion, overexpression of the 
MDC1 FHA domain triggers a dominant-negative effect upon 53BP1 accumulation in 
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dysfunctional telomere-induced foci in normal human fibroblasts (Dimitrova & de 
Lange, 2006). In a different complementation attempt, we did not succeed to isolate 
stable clones efficiently expressing the MDC1 gene in transformed MDC1-/- mouse 
embryonic fibroblasts after transfection or viral transduction. This might be attributed 
to the low transfection efficiency of transformed MDC1-/- MEFs and the random 
plasmid integration defect observed in MDC1-depleted cells (Lou et al, 2004). 
An elegant approach for the identification of specific interaction partners for the 
MDC1 FHA domain involving phosphorylation of Thr4 would be SILAC (Stable 
Isotope Labeling by Amino acids in Cell culture). This is a mass spectrometry-based 
technique, which analyzes cell populations that have metabolically incorporated the 
light or heavy nitrogen isotope form of an amino acid (usually Arg and Lys). 
Subsequent analysis by quantitative MS can distinguish between the different stable 
isotopes, and comparison of the peak intensities allows the quantification of the 
relative abundance of the proteins. Thus, this method allows the efficient detection of 
differences in cell signaling, protein expression or protein-protein interactions. In 
order to analyze dimerization-dependent protein-protein interactions, cells would be 
grown in medium supplemented with differentially labeled amino acids and 
simultaneously be transfected with the wild-type or T4A mutant MDC1-FHA domain 
fused to a suitable tag for protein purification. After treatment (e.g. IR) cell 
populations would be combined to equal amounts and the subsequently prepared cell 
extract subjected to affinity purification or immunoprecipitation. Proteins would then 
be analyzed by MS. In this way, specific binding partners of non-phosphorylated and 
Thr4-phosphorylated FHA domains could be identified in non-irradiated and 
irradiated cell extracts, respectively. Moreover, protein interactions could be analyzed 
at different time points after induction of DNA damage. Hence, the application of this 
method has a great potential to unravel specific in vivo interaction partners that may 
be regulated through MDC1 dimerization. 
Dimerization/oligomerization seems to be a common theme for mediator proteins 
participating in the DDR. Homo-dimerization has recently been described for the 
mediators PALB2, TopBP1 and MCPH1 (Liu et al, 2006; Sy et al, 2009; Yang et al, 
2008) and has been extensively studied for the yeast proteins Rad9p in S. cerevisae 
and Crb2 in S. pombe, and for the metazoan protein 53BP1 (Kilkenny et al, 2008; 
Soulier & Lowndes, 1999; Zgheib et al, 2009). 
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Even though there does not seem to exist a clear MDC1 or 53BP1 orthologue in 
yeast, similar domain organizations and functions in DNA damage signaling and 
repair have been reported for oligomerizing mediator proteins. Rad9p, Crb2 and 
53BP1 comprise a tandem Tudor domain, which has been suggested to mediate 
chromatin binding at sites of DSBs, although the mode of chromatin recognition 
slightly differs between the proteins. Their Tudor domains were shown to bind 
methylated histones H3 and/or H4, but in case of Rad9p and 53BP1, they have also 
been implicated in the direct sensing of DNA breaks (Botuyan et al, 2006; Grenon et 
al, 2007; Huyen et al, 2004; Lancelot et al, 2007; Sanders et al, 2004). Moreover, all 
four proteins, Rad9p, Crb2, 53BP1 and MDC1, do share a tandem BRCT domain at 
their C-terminus. This tandem BRCT fold mediates the common function of binding 
to γH2AX for MDC1, and γH2A for Rad9p and Crb2, respectively, whereas for 
53BP, it mediates binding to p53 in a phosphorylation-independent manner. 
(Derbyshire et al, 2002; Hammet et al, 2007; Javaheri et al, 2006; Joo et al, 2002; 
Stucki et al, 2005). However, there are clearly differences in the mechanism of 
dimerization and also how the individual domains, in particular the dimerization 
motifs, contribute to the physiological function of these proteins. 
In the case of Crb2, the tandem BRCT domain is responsible for both 
phosphopeptide binding and dimerization, which was shown to be essential for a 
proper checkpoint function (Du et al, 2004). The crystal structure of the BRCT 
domains of Crb2 revealed that residues in the inter-BRCT linker segment (C663, 
S666) form the interface for the head-to-tail dimer, whereas the γH2A peptide is 
bound in a cleft at the junction of the two BRCT domains (R616, K617, K619) 
(Kilkenny et al, 2008). Interestingly, mutations that disrupt dimerization of the BRCT 
domains do not affect phosphopeptide binding and vice versa. Consequently, 
mutations that distinguish between these two functions lead to different physiological 
outcomes. Dimerization-defective Crb2 (S666R) is not recruited to IRIF, and cells 
harboring this mutant are compromised in Chk1 phosphorylation, which causes a 
defect in cell cycle checkpoint arrest, but it had only little effect on activation of DNA 
repair. On the other hand, the K619E mutation, which disrupts binding to γH2A, did 
not affect IR-induced Crb2 foci formation or checkpoint responses, but reduced DNA 
repair kinetics, subsequently leading to the extension of the DNA damage checkpoint 
(Kilkenny et al, 2008). However, the precise mechanism of the Crb2 dimer formation, 
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especially whether or not the interaction occurs constitutively or is regulated by DNA 
damage remains unclear. 
DNA damage-induced dimerization was also shown to be essential for the 
biological function of Rad9p (Soulier & Lowndes, 1999; Usui et al, 2009). The earlier 
of these studies demonstrated that purified Rad9p BRCT domains interacted with 
each other in vitro. The authors further showed that the Rad9p BRCT domain 
preferentially interacts with hyperphosphorylated Rad9p from UV-irradiated cell 
extracts and that BRCT mutations disrupting the homodimerization of Rad9p 
molecules also affect DNA damage checkpoint activation and cell survival (Soulier & 
Lowndes, 1999). The more recent study refined the model for the molecular 
mechanism of Rad9p oligomerization by showing that, instead of the Rad9p BRCT 
domain itself, the phosphorylated SQ/TQ cluster domain (SCD) of Rad9p forms the 
binding substrate for the Rad9p BRCT domain with the phosphorylated T427 as the 
main residue contributing to this interaction (Usui et al, 2009). The SCD-BRCT 
mediated Rad9p oligomerization appears to be dispensable for initial Rad53 
activation and for relocalization of Rad9p to sites of DNA damage. However, Rad9p 
oligomerization is required for the maintenance of Rad53 activation and checkpoint-
dependent cell cycle arrest. Interestingly, Rad53-dependent phosphorylation of the 
Rad9p BRCT domain seems to attenuate the SCD-BRCT mediated Rad9p 
oligomerization, thereby providing a feedback loop of Rad53 activation (Usui et al, 
2009). 
Furthermore, homo-oligomerization of 53BP1 was found to occur in a DNA 
damage-independent and BRCT-independent manner (Adams et al, 2005; Ward et al, 
2006). The Tudor domain, which is essential for accumulation of 53BP1 in IRIF 
(Huyen et al, 2004), is also not required for 53BP1 oligomerization. However, a 
region upstream of the Tudor domain was identified to be responsible for 53BP1 
oligomerization (Adams et al, 2005). In addition to the Tudor domain, this 
independently folding oligomerization domain and a C-terminal extension of the 
Tudor domain were recently shown to be required for efficient 53BP1 focus 
formation (Zgheib et al, 2009). However, the exact role of oligomerization in 53BP1 
foci formation is not yet understood. Interestingly, there seems to exist two 
independent mechanisms that regulate the relocalization of 53BP1 to IRIF. Initial 
53BP1 recruitment rapidly occurs in an H2AX-independent manner but accumulation 
and maintenance of 53BP1 at sites of DNA damage requires phosphorylation of 
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H2AX (Celeste et al, 2003). This process is regulated by phosphorylation of MDC1, 
which binds to γH2AX and in turn recruits the E3 ligase RNF8, thus leading to 
ubiquitination of histones H2A and H2AX, which facilitates the efficient assembly of 
53BP in IRIF (Huen et al, 2007; Kolas et al, 2007; Mailand et al, 2007). It remains to 
be established to what extent 53BP1 oligomerization is involved in these processes. 
Importantly, an oligomerization-defective mutant caused residual γH2AX foci 27h 
after IR, suggesting a role of this mechanism in DSB repair (Ward et al, 2006). In 
contrast to Rad9p and Crb2, 53BP1 has only limited checkpoint functions. Depletion 
of 53BP1 causes a modest G2/M checkpoint defect at only low doses of IR and a 
partial intra-S-phase checkpoint defect in mammalian cells (Wang et al, 2002), which 
is also true for depletion of MDC1. 
While one mediator protein (Rad9p or Crb2) has been implicated in the PIKK-
mediated phosphorylation of effector kinases in yeast, the much more complex 
signaling network in metazoans might explain the need of several mediator proteins 
such as 53BP1, MDC1 and BRCA1. It had been suggested that 53BP1, MDC1 and 
BRCA1 may function redundantly. However, the phenotype of 53BP1/MDC1 double 
knockout mice does not significantly add to the DDR defects observed in the single 
knockouts, which indicates that both proteins act in same pathway, e.g., MDC1 acting 
as the upstream regulator of 53BP1 (Minter-Dykhouse et al, 2008). Nevertheless, 
53BP1 plays a prominent role during NHEJ, V(D)J recombination and CSR, whereas 
MDC1 seems to be primarily involved in HR, although it may also participate in 
NHEJ of dysfunctional telomeres and in CSR by controlling 53BP1 retention at sites 
of DSBs (Difilippantonio et al, 2008; Dimitrova & de Lange, 2006; Lou et al, 2006; 
Manis et al, 2004; Ward et al, 2004; Xie et al, 2007). 
Additional DDR mediators were recently described to homo-oligomerize and this 
mechanism was also proven to be important for cellular responses to DNA damage. 
The scaffold protein PALB2 has been suggested to be responsible for the 
relocalization the BRCA2•RAD51 complex to DSBs in order to facilitate DNA repair 
through HR (Xia et al, 2006). Recently, oligomerization of PALB2 was shown to be 
induced upon treatment with IR (Sy et al, 2009). It was further demonstrated that an 
N-terminal coiled-coil domain mediates homo-oligomerization and is required for 
accumulation of PALB2 in nuclear foci. Deletion of this domain impedes the function 
of PALB2 in HR (Sy et al, 2009). However, the precise mechanism of PALB2 
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recruitment to DNA lesions remains to be elucidated. In another example, Akt-
mediated phosphorylation of TopBP1 (topoisomerase II-binding protein 1) was shown 
to induce oligomerization through its seventh and eighth BRCT domain. This leads to 
an increased interaction with the transcriptional regulator E2F1, thereby inhibiting 
E2F1-mediated apoptosis. Thus, TopBP1 oligomerization likely influences 
transcriptional regulation under normal physiological conditions. However, whether 
oligomerization of TopBP1 also plays a role in the DDR remains to be determined 
(Liu et al, 2006). A similar BRCT-dependent oligomerization mechanism seems to 
exist for MCPH1, which also induces binding to E2F1 and subsequently influences 
the transcriptional regulation of genes involved in DNA repair, DNA damage 
checkpoints and apoptosis (Yang et al, 2008). This raises the idea that oligomerization 
of DDR mediator proteins in general might regulate the transcription of target genes 
involved in DNA damage checkpoint, DNA repair and apoptosis. 
In conclusion, dimerization/oligomerization as a common theme for DDR 
mediator proteins strongly implies that DNA-damage induced MDC1 dimerization 
may similarly contribute to the regulation of some aspect of the DDR in higher 
eukaryotes. Future analysis of the physiological implication of MDC1 dimerization 
will shed more light on its specific role in the DDR. 
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7 MATERIALS AND METHODS 
Cell lines and transfections 
293T, U2OS, MDC1-/- MEFs, MDC1+/+ MEFs and human AT cells were cultured in 
Dulbecco’s modiefied Eagle’s Medium (Invitrogen) supplemented with 10% fetal calf 
serum (Gibco) and penicillin/streptomycin (100 U/ml, Gibco). MDC1-/- cells were 
retrieved from Junjie Chen and Ralph Scully, the according MDC1+/+ from Penny 
Jeggo. U2OS-TetOn cells stably expressing the EYF-BRCT fusion protein were 
generated as described (Stucki et al, 2005). Transfection of plasmids was performed 
either with calcium phosphate, FuGene 6 (Roche) or Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. SiRNA duplexes were purchased from 
Dharmacon. The coding strand for siRNA against the MDC1 C-terminus (siMDC1-C) 
was 5’-GUCUCCCAGAAGACAGUGAdTdT-3’ and for siRNA against the MDC1 
repeat region (siMDC1-R) was 5’-ACAGUUGUCCCCACAGCCCdTdT-3’. SiRNA 
transfections were performed with RNAiMAX (Invitrogen). For this, 4 µl of 
RNAiMAX and 4 µl of 10 µM siRNA duplexes were separately added to 250 µl 
OptiMEM (Gibco). Both solutions were mixed by carefully pipetting up and down. 
After 20 min incubation at room temperature, the transfection mix was added to the 
cells (50% confluency) on ∅6cm dishes containing 2 ml medium. Cellular analysis 
was performed 72 h after transfection. For retroviral transduction, 293T cells were 
transfected with pCL-Ampho vector and the according retroviral vectors expressing 
mMDC1-HA using the calcium phosphate method. Alternatively, 293T Phoenix-Eco 
cells stably expressing the genes of the pCL-Eco packaging vector were used directly 
for transfection of the retroviral expression vectors. Fresh medium was added 24 h 
after transfection. Another 24 h later, the supernatant containing the virus particles 
was either transferred directly to MDC1-/- cells in ∅6cm dishes or concentrated with 
the Lenti-X Concentrator (Clontech, #631231) prior to that. For efficient infection, 
6µg/ml Polybrene was added to the medium. After 48-72 h, the transduced cells were 
splitted to ∅10cm dishes and selected with Puromycin for at least one week. Stable 
clones were analyzed for expression of the gene of interest by immunofluorescence. 
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Plasmids 
The pcDNA3.1 expression plasmid for wild-type GFP-MDC1 was kindly provided by 
Ross Chapman. The construct carries a siMDC1-C-resistant sequence containing 6 
silent wobble base mutations (5’-GTCTCGCAAAAAACGGTCATC-3’). The T4A 
mutation was inserted with primers using standard cloning procedures. The retroviral 
expression construct for MSIPuro-Myc-mMDC1 and the empty vector control were 
obtained from Ralph Scully. The Myc-mMDC1 sequence was cut out and replaced 
with either wild-type or T4A mutant mMDC1 carrying a C-terminal HA-tag in a two-
step cloning procedure. The pIRESpur2 vector for insertion of mMDC1-HA was 
kindly provided by Dennis Castor.  
 
Antibodies  
The rabbit polyclonal PARP1 antibody was provided by Michael O. Hottiger. The 
mouse monoclonal β-tubulin antibody was purchased from Sigma, polyclonal rabbit 
H2A antibody from Upstate, polyclonal rabbit NBS1 antibody from Novus and 
polyclonal rabbit 53BP1 antibody from Santa Cruz (sc-22760). 
 
Chromatin fractionation 
U2OS cells were trypsinized, washed with PBS and resuspended in buffer A (10 mM 
HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10 % glycerol, 1 mM 
DTT, 1 mM PMSF (Sigma), 1 µg/ml Leupeptin/ Bestatin/ Pepstatin A). Triton X-100 
(0.1 %) was added to the solution and incubated for 5 min on ice. Following 
centrifugation (4 min at 1300g, 4°C), the supernatant containing the cytosolic fraction 
was collected (S) and the pellet containing the nuclear fraction was washed once in 
buffer A and then lysed in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 1 
mM PMSF, 1 µg/ml Leupeptin/ Bestatin/ Pepstatin) containing 125 mM NaCl. After 
centrifugation (4 min at 1700g, 4°C), the supernatant containing the soluble nuclear 
fraction was collected and the remaining pellet again dissolved in buffer B under 
more stringent conditions (210 mM NaCl) to remove stronger adhering proteins from 
the chromatin. Centrifugation was repeated, the supernatant collected and the 
resulting insoluble chromatin pellet resuspended in Laemmli buffer and sonicated for 
15 s. Protein concentration was determined with the Lowry Method and the samples 
analyzed by SDS-PAGE and Western Blot. 
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G2/M checkpoint assay 
U2OS cells grown in ∅6cm dishes were irradiated with a Faxitron X-ray cabinet at 
the indicated doses in the exponential growth phase (50% confluency). Following an 
incubation at 37°C for 30-45 min, cells were carefully washed in PBS, trypsinized, 
resuspended in growth medium and subsequently transferred from the cell culture 
dish into 5 ml tubes suitable for flow cytometry analysis. Cells were centrifuged 
(1500g at 4°C for 5 min), washed once in 5 ml PBS, resuspended in 600 µl PBS and 
fixed by dropwise adding 1.4 ml of 100% icecold ethanol (to achieve a final 
concentration of 70% ethanol) while vortexing gently. After incubation at – 20°C for 
at least 1 h or overnight, the ethanol-fixed cells were again centrifuged (1500g at 4°C 
for 5 min), washed twice with PBS and permeabilized with 1 ml of 0.25% Triton X-
100/PBS for 10 min on ice. After centrifugation at 1800g for 5 min, the supernatant 
was aspirated and 100 µl of rabbit anti-pH3 antibody (Millipore) in 1% BSA/PBS 
added to a final concentration of 7.5 µg/ml and incubated with the cells at room 
temperature for 3 h. Thereafter, cells were washed with 4 ml 1% BSA/PBS (2500g for 
5 min) and stained with 50 µl of either anti-FITC (Jackson ImmunoResearch) 1:30 or 
Alexa700 (Invitrogen) 1:30 in 1% BSA/PBS at room temperature for 30 min. 
Following two additional wash steps with PBS, cells were finally resuspended in 500 
µl PBS containing 0.25 µg/ml of Propidium Iodide (Sigma) and 0.1 mg/ml RNase A 
(Roche).  Analysis was performed with a flow cytometer (Becton Dickinson FC500 or 
Beckham Coulter CyAn ADP 9 Color). 
 
RDS assay 
U2OS cells grown on 6-well plates were pre-labeled with 20 nCi/ml [14C]-thymidine 
(Amersham, CFA219) for 24 h, which was then replaced with fresh medium. After 
another 24 h, cells were irradiated and incubated for 45 min, before 2.5 µCi/ml [3H]-
thymidine (Amersham, TRK120) was added for 15 min. Subsequently, cells were 
washed in PBS, trypsinized and resuspended in warm growth medium. Following two 
additional washes in 5 ml of cold 1% FCS/PBS, cells were resuspended in 280 µl PBS 
and fixed by adding 720 µl icecold methanol dropwise while vortexing gently. For 
proper fixation, cells were kept at least 30 min at 4°C. The cell suspension was then 
filtered through GF/C filters (WhatmanA, 25 mm circles), washed twice with 70% 
methanol and once with 95% methanol. Dried filters were put in scintillation tubes 
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and 2.5 ml Emulsifier-Safe (PerkinElmer) was added. Inhibition of DNA synthesis 
was measured with a MicroBeta TriLux 1450 liquid scintillation counter. 
 
 
Additional information on Materials and Methods is provided in Jungmichel et al, 
2010.  
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